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Abstract 
The rational design of antimalarial therapies has historically been compromised 
by a paucity of pharmacodynamic data. Many antimalarials have been deployed 
at suboptimal doses contributing to the spread and development of resistance. 
Borrowing from antimicrobial experience, focus is now turning to methods to 
optimise dosing and combination therapy. The findings of the studies presented 
in this thesis demonstrate a modified P. berghei murine malaria model for 
collecting detailed in vivo pharmacodynamic data and a novel in silico 
mathematical model which enables optimisation of doses and combination 
therapy. These models provide an important contribution to preclinical 
knowledge, and the potential to assist in the development of methods to 
optimise clinical treatment. 
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CHAPTER ONE 
 
1.  Literature review 
1.1 Introduction 
Malaria is one of the most severe public health problems world wide and is likely 
to have killed more humans than any other disease [280]. It is a leading cause of 
death in many developing countries. Of the ten leading causes of death in the 
developing world, malaria is the only one with a real prospect for eradication 
[228]. The World Heath Organization’s World Malaria Report 2013 [434] 
estimated that 3.4 billion people in 104 countries live in areas at risk of malaria 
transmission. In 2012 this report estimated 627,000 deaths from 216 million 
clinical episodes. Ninety percent of the deaths were in the African region, 6% in 
the South-East Asian Region and 3% in the Eastern Mediterranean Region. 
Seventy seven percent of global deaths in 2012 were children [434]. Children 
and groups with low or little immunity, such as pregnant women, travellers, 
migrants or sufferers of autoimmune deficiency syndrome are most at risk of 
death or serious health consequences [132, 240]. 
 
Malaria is a curable disease. It is not an inevitable burden. Disease eradication 
is not a simple proposition at a global level. Global eradication requires a 
multifaceted, sustained strategy with funding and significant infrastructure as 
well as organisational support. Global malaria eradication is an achievable goal 
[55, 125, 149]. However, despite technological and increased understanding of 
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the disease, malaria is returning to areas where it had previously been 
eradicated, and population growth is increasing the number of human hosts in 
endemic areas [154, 296]. Eradication is a long term goal with elimination 
feasible in the short term [149]. 
 
Malaria inflicts a serious social and economic toll in endemic areas. Costs to 
individuals and small communities include purchase of drugs, preventative 
measures, travel to clinics, lost days of work and absence from school [331]. 
This often occurs in populations that are least able to cope with these additional 
costs of living. Costs to governments include health facilities, purchase of drugs 
and medical supplies, public health intervention programs and lost productivity 
due to lost days of work. Analysis of the Gross Domestic Product (GDP) of 
countries before and after malaria eradication demonstrates measurable 
benefits to GDP in all cases including Greece, Italy, Spain, Portugal, Jamaica 
and Western Europe [134]. Direct costs due to malaria including illness, 
treatment and death have been estimated at US $12 billion per year. Lost 
economic growth and development far exceed this, representing a serious 
socioeconomic burden resulting in a multitude of indirect generational 
opportunity costs. In 2008 the Gates Foundation with Roll Back Malaria 
published combined estimates for global malaria control and eradication of $6 
billion US annually, falling to US $1.5 billion over three decades [238]. 
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1.2 Malaria 
1.2.1 Discovering malaria 
The term malaria derives from the Italian mal’aria or “bad air” and records of 
malaria-like symptoms appear in records dating back to 2700 BC in Chinese 
medical writings [57] and Hippocrates in the 4th century BC noted the principal 
symptoms [51]. A number of Roman writers linked malaria to swamps. Despite 
many observations, the source of the disease or malaise was thought to be bad 
air or water up until the late 1800s.  As well as symptoms, treatments were also 
observed and recorded. 
 
In 1880, Alphonse Laveran, a French army surgeon in Constantine, Algeria 
discovered parasites in the blood of patients suffering from malaria [51, 56]. Six 
years later Camillo Golgi, an Italian neurophysiologist, established that there 
were at least two forms of the disease with differing fever periodicity. He also 
observed the fever coincided with the release of merozoites into the blood 
stream [57, 78, 342]. 
 
In 1897 Ronald Ross, a British officer in the Indian Medical Service 
demonstrated that malaria parasites could be transmitted from infected patients 
to mosquitoes [323]. This solved malaria transmission. In 1899 transmission of 
human malaria parasites was demonstrated by an Italian group led by Giovanni 
Grassi [98]. Mosquitoes were fed on malarial patients in Rome and the 
mosquitoes sent to London to feed on healthy volunteers, who developed 
malaria. The complete sporogenic cycle of Plasmodium falciparum, P. vivax and 
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P. malariae was demonstrated [57, 78, 342]. After thousands of years of 
suffering to malaria, humanity was now armed with the basic understanding of 
the disease and its vector, to enable the beginning of the war between 
Plasmodium and humans that is still in the balance today. There is still a great 
deal that needs to be elucidated and accomplished before malaria can be 
considered to be globally controlled, let alone eradicated.  
1.2.2 Geographical distribution 
Understanding the geographical distribution of malaria is important when 
implementing any global strategies to control the disease. Knowledge of disease 
distribution, as well as population distributions, urbanisation maps, climate maps 
and altitude maps have been used to identify populations at risk from malaria. 
Studies by Guerra et al in 2006 identified over 3 billion of the planet’s population 
as being at risk from malaria [155-157]. Seventy five percent of those at risk are 
from 10 countries. Globally these top ten malaria endemic countries in order of 
highest population at risk are India, China, Indonesia, Bangladesh, Pakistan, 
Nigeria, Vietnam, Thailand, the Democratic Peoples Republic of the Congo and 
the Philippines [157]. The World Health Organization (WHO) estimates that 
more than 90% of the over 0.6 million deaths attributed to malaria annually 
occur in Africa [434]. 
 
Malaria transmission occurs predominantly in sub tropical regions in sub-
Saharan Africa, Central and South America, the Middle East, the Indian 
Subcontinent, South-East Asia and Oceania (Figure 1.1 [137]). In malaria 
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endemic areas there is large variation in the intensity of transmission and risk of 
infection. Areas higher than 1500m and areas with less than 1000mm annual 
rainfall typically have less malaria [434]. Urban areas are also usually lower risk, 
although uncontrolled population growth can increase urban transmission [205]. 
There is growing concern over the possible influence of climate change on 
infectious disease distribution [282]. Malaria is the disease of greatest public 
concern and seems most likely to be sensitive to climatic change. Malaria is 
often seasonal around weather and research in India has demonstrated a link 
between extreme climatic events and malaria epidemics [49]. Recent studies 
indicate that malaria epidemic risk increases five-fold the year after an El Nino 
weather event [49]. 
 
1.2.3 Malaria species 
There are over 550 species in the order of Haemosporidia, of which the genus 
Plasmodium constitutes almost half of these species [336]. Species are entirely 
parasitic with part of the lifecycle spent in a vertebrate host, and part in an 
invertebrate host, which is generally a mosquito. Vertebrate hosts include 
mammals, birds and reptiles. Five Plasmodium species have been identified that 
can infect humans, Plasmodium falciparum (P. falciparum), P. vivax, P. ovalae, 
P. malariae and P. knowlesi [21, 96, 192, 293]. A comparison of the 
characteristics of the five malaria species that infect humans is shown in Table 
1.1 
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Figure 1.1 – 2010 global distribution of P. falciparum malaria as published by the 
Malaria Atlas Project [137]. 
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. 
Table 1.1 – Characteristics of human malaria species (adapted from [111, 136, 193, 243, 
319, 351, 388, 436]) 
 P. falciparum P. malariae P. ovalae P. vivax P. 
knowlesi 
Distribution (% of 
cases per region) 
80-90% Africa 
40-50% SE Asia 
4-30% S Asia, S 
America 
2-3% Africa 
Sporadic Asia, S 
America 
8% parts of Africa 
Sporadic Asia 
70-90% Asia, S 
America 
50-60% SE Asia 
1-10% Africa 
Reported in 
SE Asia up 
to 70% 
Erythrocytic Life 
Cycle (hrs) 
48 72 48 48 24 
Merozoites per 
erythrocyte 
Schizont 
8-24 6-12 6-14 12-24 10-16 
Exoerythrocytic 
Cycle (days) 
6 13 9 8 9 
Merozoites per 
tissue Schizont 
40000 2000 15000 >10000 ? 
Erythrocytic 
preference 
All Mature 
erythrocytes 
Reticulocytes Reticulocytes ? 
Complications Cerebral renal - - - 
Fever Pattern Tertian, sub 
tertian 
Quartan Tertian Tertian Quotidian 
Severe Malaria Up to 24% rare rare Up to 22% 6-10% 
Anaemia ++++ ++ + ++ ? 
Drug resistance Yes No No Yes No 
1.2.4 Life cycle of the malaria parasite 
The life cycle of the malaria parasite consists of two distinct species phases. 
Sporogony is the phase occurring in the female Anopheles mosquito while 
schizogony is the exoerythrocytic and erythrocytic stages occurring in human 
hosts [348]. After feeding on a malaria infected host, Anopheles mosquito have  
gametocytes introduced into the stomach. Fertilisation of the female 
gametocytes occurs in the stomach. The zygote develops into a mobile ookinete 
within 24 h and moves to the stomach wall where it develops into an oocyst. 
Oocyst mature over one to two weeks and rupture to release up to 10,000 
sporozoites which migrate to the mosquito salivary glands [304].  
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Humans may be infected with malaria while being fed on by carrier Anopheles 
mosquitoes. The process of withdrawing blood introduces mosquito saliva into 
the host’s bloodstream, including malaria sporozoites if the mosquito is infected. 
Sporozoites are taken up by hepatocytes where they develop over a week. 
Upon maturation, the hepatic schizonts rupture releasing more than 10,000 
merozoites into the host’s bloodstream. In P. vivax and P. ovalae infections 
some sporozoites become dormant, as hypnozoites, which can remain in the 
hepatocytes for months or years until they cause a relapsed malaria infection 
[294, 296]. Merozoites quickly invade healthy erythrocytes beginning the 
erythrocytic life cycle. 
 
The erythrocytic life cycle ranges from 24-72 h depending on the species of 
parasite (Table 1.1) with the P. falciparum cycle taking approximately 48 h. In P. 
falciparum infections, merozoites develop over a 24 h period into early 
trophozoites (rings) then into mature trophozoites by 26-38 h and then schizonts 
(Figure 1.2). As the trophozoites develop, the vacuole which gives them a 
characteristic ring profile expands and haemozoin accumulates in the vacuole 
as the parasite digests the erythrocyte’s haemoglobin. Infected erythrocytes 
finally rupture releasing 8-24 merozoites that go on to infect healthy erythrocytes 
and continue the infection. The destruction of erythrocytes causes anaemia and 
also releases pyrogenic material which is responsible for the symptoms of fever 
[294, 296]. 
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A small number of merozoites will develop as gametocytes which infect feeding 
Anopheles mosquitoes. In P. falciparum infections, as opposed to other strains, 
mature trophozoite and schizont stage infected erythrocytes do not remain in the 
peripheral circulation but instead sequester in the microvasculature of organs by 
inserting adhesion molecules into the erythrocyte’s cell membrane. Sequestered 
parasites adhering to brain microvasculature result in cerebral malaria. There 
are a number of morphological differences between the human malaria species 
as shown in Figure 1.3 [248]. 
 
Figure 1.2 – Diagram of P. falciparum malaria life cycle [304]. 
 
  28 
 
P. falciparum is characterised by rings and the absence of older stages which 
sequester. The rings tend to be smaller but more numerous than in other 
species. Erythrocytes infected by more than one merozoite are more common 
and the gametocytes of P. falciparum are distinctively crescent shaped [248]. P. 
vivax is characterised by enlarged infected erythrocytes and “Schuffner’ dots” 
which have the appearance of granules. P. ovale is similar to P. vivax with 
enlarged infected erythrocytes and “Schuffner’ dots” however it forms elongated 
erythrocytes and has fewer merozoites. P. malariae displays band form 
 
Figure 1.3 – Morphological Differences between Human Plasmodium Species [248]. 
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trophozoites which stretch across erythrocytes and merozoites often appear in a 
rosette pattern with a clump of pigment in the centre [248]. The morphology of P. 
knowlesi is similar to that of P. falciparum in the early stages, however late 
trophozoite, schizonts and gametocytes appear indistinguishable from P. 
malariae [220]. 
1.2.5 Clinical features of malaria 
P. falciparum is the most widespread and severe form of malaria responsible for 
most malarial mortality. P. vivax is almost as widespread as P. falciparum 
(Figure 1.1) but rarely results in death to the host [75]. The signs and symptoms 
of uncomplicated malaria are relatively similar between the different forms 
except for variations in fever periodicity [129]. The classic symptom of malaria is 
intermittent high fever, caused by rupture of red blood cells during merozoite 
release. This fever has a typical 48 h periodicity in relatively synchronous vivax 
infections, while fever becomes more continuous in other malaria infections. 
Fever is preceded by a range of non-specific symptoms including malaise, 
fatigue, headache, myalgia, anorexia, dyspepsia, nausea, vomiting and 
diarrhoea [129]. 
 
Anaemia (erythrocyte count <3x106 per L), thrombocytopaenia (platelets 
<150x109 per L), splenomegaly and hepatomegaly are also commonly seen 
especially in P. falciparum and P. vivax infections [130]. Renal impairment is 
common though typically mild. The most serious complication of falciparum 
infection is cerebral malaria caused by sequestration of late stage trophozoite 
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and schizont infected erythrocytes in cerebral microvasculature. Symptoms of 
cerebral malaria include seizures and coma, prior to which patients become 
delirious and psychotic [130]. 
1.2.6 Malaria immunity 
Malaria is a disease that mainly affects immune naïve individuals, particularly 
children under 5 years of age [240] and pregnant women [132]. In regions of 
high transmission intensity, the immunity to uncomplicated malaria develops 
slowly and chronic infection seems to be necessary for maintaining a protective 
immunity [59]. Low immunogenicity and high heterogeneity of malaria antigens 
allowing parasites to evade humoral immunity may be the explanation for this 
slow immune protection [266]. Alternatively, parasites could induce immune 
dysregulation inhibiting the development of  protective cellular immunity [122]. 
Antibody responses against specific antigens are short-lived and dependent on 
the presence of circulating parasites [58, 77, 95], suggesting that memory 
formation and longevity of either B and T cell responses or both are perturbed. 
 
Immunity to severe malaria develops after a number of infections, indicating the 
existence of antigenic homogeneity in parasites causing severe disease [159]. 
As well as this acquired or adaptive immunity gained through repeated exposure 
to infection, innate immunity plays an important role in endemic areas. 
 
Innate immunity involves scavenging cells such as dendritic cells, natural killer 
(NK) cells, natural killer T cells and T cells. Dendritic cells are important for the 
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activation of immune responses and link innate and adaptive immunity. They 
reside in almost all tissues and screen their environment by pinocytosis and 
phagocytosis of protein and cellular debris. When they encounter foreign 
antigens, dendritic cells are activated and leave the tissue via the lymph or blood 
and migrate to the draining lymph node and the spleen. During migration, 
dendritic cells mature and interact with T cells secreting cytokines, which are 
important for activation of other leucocytes, such as NK cells, 
monocytes/macrophages, and B cells [28]. For a more in depth review of innate 
immunity see “Early interactions between blood-stage Plasmodium parasites 
and the immune system” [398]. 
 
P. falciparum differs from other human malaria species as it can achieve much 
higher parasitaemia and the mature forms of the erythrocytic stages sequester 
in micro vasculature. Sequestration ensures that at least a proportion of the 
infected erythrocytes mature without passage through the spleen where they 
can be removed by cordal macrophages due to reduced deformability and 
opsonisation [19, 85, 86]. Sequestration of infected erythrocytes is mediated by 
P. falciparum erythrocyte membrane protein (PfEMP1), which is inserted into the 
membrane of infected cells approximately 18 h after invasion and  is encoded by 
59 var genes, providing the antigenic variation to evade the  host humoral 
immune response [210].  PfEMP1 mediates not only adhesion of endothelial 
cells in microvasculature, but also red blood cells and leucocytes.  
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1.2.7 Diagnosis 
Early and accurate diagnosis of malaria is essential for effective disease 
management and malaria surveillance [434]. Misdiagnosis can result in 
significant morbidity and mortality as well as inappropriate drug use, which can 
lead to resistance. The WHO recommends prompt malaria diagnosis by either 
microscopy or malaria rapid diagnostic test in all patients with suspected malaria 
before treatment is administered [434]. 
 
The long time standard for definitive diagnosis in nearly all settings is direct 
microscopic examination of intracellular parasites on Giemsa stained blood 
films, and microscopy is still considered the “gold standard” by some experts 
[259, 333]. Microscopy allows differentiation between species, quantification of 
parasite density and elucidation of parasite stages including distinguishing 
asexual forms from gametocytes. The method is simple and requires little 
expensive equipment [45, 174, 437]. However, the technique is time consuming 
and microscopists need to be trained to ensure reliability [45], especially at low 
parasitaemia [411].  
 
There are several alternative diagnostic tests available besides direct light 
microscopy (Table 1.2). Various rapid diagnostic tests exist which do not 
quantify parasitaemia but can identify species or differentiate between species. 
These antigen detection or dipstick tests require no electricity or special 
equipment, are fast, require little training and can be stored at ambient 
temperatures. These tests can however remain positive after parasite clearance 
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[259]. Molecular tests identifying parasite genetic material through polymerase-
chain reaction techniques are also available. These methods effectively 
distinguish between parasite species and identify resistance and mixed 
infections. They are however costly, require electricity, special equipment and 
require a high degree of operator training. Fluorescent microscopy provides 
faster results than light microscopy techniques however have poor sensitivity at 
low parasite densities. Electricity and specialised equipment and consumables 
are also required for fluorescent diagnosis. It should be noted that a requirement 
for reliable electricity, which is assumed in first world settings, is often lacking in 
areas where malaria diagnosis is of greatest importance, such as many areas in 
Africa.  
 
The diagnostic performance of microscopic methods has been shown to be 
equivalent in clinical settings in both sensitivity and specificity to other diagnostic 
methods, although this may be over estimated. Ochola et al. [275] found that 
HRP2-based techniques are better than standard microscopy for monitoring P. 
falciparum infections in clinical cases in endemic areas, and that  microscopy is 
still important for  the diagnosis of mixed infections and parasite quantification. 
The role of microscopy as the gold standard for malaria diagnosis has been 
questioned due to false negative results at lows levels of infection, due to the 
limit of detection and errors in species identification in mixed infections [94, 275]. 
 
  
  34 
Table 1.2 – Techniques currently available for detecting malaria parasites in the human 
host – table adapted from Bloland 2001 [45, 198, 259, 275, 308, 345, 353, 365, 439]. 
 
Another common diagnostic technique is clinical or presumptive diagnosis. 
Reliable diagnosis cannot be made on the basis of symptoms because of their 
non specific nature; however clinical diagnosis is common in many portions of 
the malaria-endemic world. In these areas resources and trained staff are so 
scarce that clinical diagnosis is the only practical option. This method is fast, 
simple and low cost, consisting of diagnosis being largely made on the basis of 
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fever symptoms. This approach can identify most patients who do need 
antimalarial treatment but is also likely to lead to considerable over diagnosis 
and over treatment [45]. 
1.2.8 Enumeration of malaria parasites 
Since 1910, when Ross and Thomson proposed a method for enumeration of 
parasite density [326], it has been accepted that parasite density is highly 
correlated to the severity of the disease, and an important aspect of diagnosis 
and disease treatment. Clinical practice has since developed and conventional 
thick and thin films stained with Giemsa, Wright’s or Field’s stain are the long 
time standards for diagnosis and enumeration [411]. 
 
Blood for films can be acquired clinically by pricking a finger or earlobe or by 
venepuncture collected in an anticoagulant tube. Blood from a finger or earlobe 
is ideal as the density of trophozoites and schizonts is greater in blood from a 
capillary rich area. Additionally, blood collected via venipuncture should be used 
quickly after being drawn to minimise alteration of the morphology of white blood 
cells and parasites [259]. Thin films are prepared by spreading approximately 
1L of whole blood along a microscope slide to produce a uniform monolayer of 
blood cells [140]. The films are then fixed with methanol prior to staining. Thick 
films are prepared by spreading approximately 3L of whole blood in a circular 
pattern to produce a uniform layer of blood approximately 10mm in diameter. 
The films are stained unfixed, which causes lysis of red blood cells [140, 259]. 
Thick films provide a much greater degree of sensitivity than thin films for 
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detection of low levels of parasitaemia. Thin films provide a greater specificity 
than thick films and allow simpler morphological identification. The thin film is 
often preferred for routine estimation of parasitaemia as organisms are easier to 
see and count. Examination of sequential films enables response to therapy to 
be easily monitored.  
 
The sensitivity that can be achieved by an experienced microscopist using thick 
films is approximately 50 parasites per L of blood, assuming 5×106 red blood 
cells per L. This is equivalent to 0.001% infection. The routinely achievable 
sensitivity is closer to 0.01% or 500 parasites per L [254]. Compared with thick 
films, thin films are only one tenth as sensitive [411]. 
 
The most important aspect of reporting malaria enumeration is the estimation of 
the level of parasitaemia present on a blood film. Several methods have been 
described using either thin or thick films [431]. Using thick films the parasites 
present in 1L can be estimated using white blood cells (WBC) and assuming 
8000WBC/L. The microscopist counts the number of parasites until 200 WBC 
have been observed, then multiplies the number of parasites by 40 to estimate 
parasites/L. This type of estimation can be improved if an accurate WBC count 
is known. Using thin films the number of parasitised RBC observed in 10,000 
RBC is approximated by determining an approximate number of RBC per field of 
view. If a field of view contains approximately 250 RBC, 40 fields of view would 
need to have infected RBC counted. The number of parasitised cells is then 
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expressed as a percentage. From a percentage the number of parasites present 
in 1L of blood can be estimated by assuming that 1L of blood contains 5×106 
RBC. The accuracy of this method can be increased if the number of RBC/l is 
known accurately. 
 
It should be noted that parasite enumeration in endemic areas tends to be 
expressed as parasites/L, while in non endemic areas, where parasitaemia is 
usually low, percentage of infected erythrocytes is used [259]. Counting 
parasites in a limited number of fields (for example 10, rather than 40) is used 
when higher parasitaemia are observed in endemic areas. The methods outlined 
here for parasite enumeration are acceptable for the clinical management of 
malaria. However for accurate parasite enumeration thin films should be used to 
determine the percentage parasitaemia [151]. 
1.2.9 Parasite clearance 
Malaria parasites are cleared from the bloodstream by the reticuloendothelial 
system, and principally the spleen, where damaged or dead parasites are 
removed, and previously parasitised red blood cells are returned to the 
circulation [85]. Asplenic patients demonstrate a reduced capacity to remove 
parasites despite intense antimalarial therapy and even when parasites are 
determined to be non viable. This has led to the theory that splenic pitting may 
be the principal mechanism for removal of circulating parasites following 
antimalarial therapy [86, 219]. Other tissues, particularly the liver, are also 
believed to play a role in parasite clearance, although this has not been fully 
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elucidated. The deposition of haemozoin in macrophages and Kupffer cells 
during malaria infection indicates that the liver could take on some of the storage 
and extraction functions of the spleen [413]. This is also backed by the ability of 
the liver to remove bacteria, viruses and other organisms from the circulation 
[19]. 
 
Parasite clearance can be divided into several stages. The three basic phases 
are lag, clearance and patency (or “tail”). During the lag phase parasitaemia can 
continue to increase after treatment administration as the drugs are absorbed, 
distributed and act to destroy parasites. A lag phase is not seen in all cases 
[128]. The second phase is clearance, where the spleen and possibly the liver 
act to remove parasitised RBC or parasites from circulation. There is some 
suggestion that the rate of clearance is dependent on the drug treatment [104, 
128, 196, 232, 233, 428]. Late in a successful clearance phase parasitaemia will 
drop below the limit of detection (patency). At these very low levels accurate 
data of parasitaemia is difficult to obtain. It is thought that at these low levels the 
immune system is able to clear the remaining infection more effectively. 
 
Parasite clearance time (PCT) is the time from commencement of treatment to 
the first of at least two negative smears. The PCT is reliant on the frequency of 
smears, so the time to reach 50% of the original parasitaemia (PCT50) is often 
used as a measure of drug efficacy [425]. PCT is important as a potential 
indicator of treatment failure and parasite resistance to drug treatment. This is 
particularly critical for artemisinin based compounds where prolonged parasite 
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clearance is the only currently identified indicator of resistance [128]. Sowunmi 
et al  [361] proposed that P. falciparum clearance exceeding two days is 
associated with risk of treatment failure and resistance, and could be used as a 
criterion to change therapy in children. 
 
Several studies have investigated modelling of parasite clearance to provide a 
parasite clearance estimator (PCE). Modelling allows standardisation of parasite 
clearance estimates from parasite density time profiles and facilitates improved 
epidemiological investigations of resistance. This is accomplished by 
identification and exclusion of the lag (if it exists) and patency phases and 
calculation of the slope of the clearance phase. Parasite clearance follows a first 
order process and so the clearance rate is constant [105]. If parasitaemia at time 
t is given by )(0
kt
t PP

 where P0 is the initial parasitaemia, then the reduction in 
the parasite population in a unit time is ke1 . The clearance rate constant is 
equal to the minus slope of the loge parasitaemia-time profile. Several models 
have been proposed to identify the clearance phase and elucidate the PCE 
including log-linear, log-quadratic and log-cubic [104, 128].  Log-linear PCE 
models clinical data with little or no lag phase and little or no tail. Log-quadratic 
models a lag phase with little tail while a log-cubic models both lag and tail 
(Figure 1.4). In a comparison of quinine and ACT treatment data by Flegg et al 
[128] using the modelling described here, quinine data showed a greater lag 
phase and an extended lag phase compared with ACT data.  
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There are a number of examples of more advanced modelling of parasitaemia-
time data in humans [318, 334]. These are referred to as within-host models of 
individual infection or asexual blood stage models as distinct from 
epidemiological models of population infection and transmission. 
1.2.10 Mathematical models of malaria transmission 
Mathematical models of malaria transmission began with Ronald Ross, soon 
after his demonstration of transmission by mosquitoes. Ross himself explained 
[245] 
“To say that a disease depends upon certain factors is not to say much, until we 
can also form an estimate as to how largely each factor influences the whole 
result. And the mathematical method of treatment is really nothing but the 
application of careful reasoning to the problems at issue…from such reasoning 
alone we derive the very important practical conclusion that in order to 
      (A)                                               (B)                                     (C)    
 
 
Figure 1.4 – Typical (A) linear, (B) quadratic and (C) cubic shaped log parasitaemia 
time profiles in falciparum malaria [128]. Polynomial fits are shown in pink, black 
points represent data and green points represent censored values. 
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counteract malaria anywhere we need not banish Anopheles there entirely – we 
need only to reduce their number below a certain figure.”  
 
With the discovery of malaria parasites and the role of the mosquito vector, the 
fight against malaria was to begin in earnest, initially with modelling 
epidemiology. Ross believed that understanding malaria epidemiology would 
provide the answer to fighting the disease. In Ross’ epidemiological 
compartmental model of infectious disease, transmission of infectious agents in 
the host population is the basic process that requires description. Ross’ model 
(Table 1.3) showed that reduction of mosquito numbers below a “transmission 
threshold” was sufficient to counter malaria [324]. In the 1950s George 
Macdonald similarly concluded that “The aim of mathematical epidemiology is to 
integrate circumstantial data into one coherent whole” [236]. One of 
Macdonald’s most important contributions to malaria theory was his emphasis 
on defining and measuring parameters, such as the basic reproductive number 
and stability index, that were operationally relevant for eradication [84]. 
 
Macdonald integrated biological information of latency in the mosquito due to 
parasite development and identified the survival of adult female mosquitoes as 
the weakest element in the malaria cycle. Macdonald suggested that increasing 
the daily mortality of the vector from 5% to about 45% would be enough to solve 
the malaria problem, and this formed the basis for a DDT-focussed WHO 
coordinated campaign [236]. The campaign was hugely successful in full 
eradication of malaria from some 35-40 countries, however failed ultimately in 
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tropical areas with stable malaria [245]. The failure was due to an incomplete 
understanding of malaria, its biology and epidemiology, rather than a failure of 
the models and their concept. Macdonald’s original modelling did not include 
population dynamics, seasonal Anopheles population dynamics and elements of 
the malaria cycle that were at that time undiscovered [245]. Shortcomings of 
these models were used to improve understanding and improve epidemiological 
modelling, as demonstrated by Anderson and May by including latency in 
humans (Table 1.3). Since then, epidemiological modelling has progressed to 
include  vector characteristics, human immunity, parasite diversity, insecticide 
resistance dynamics, drug resistance dynamics, environmental and seasonal 
changes and spatial heterogeneity [26, 113, 117, 158, 206, 245].  
 
McKenzie made a number of astute comments in his article Why Model Malaria? 
in 2000 [245]. “The utility of a malaria model depends not so much on how well a 
mathematical job has been accomplished as on how well a particular biological 
question has been translated, how thoroughly each assumption and its 
consequences have been tested, how carefully the range of relevance has been 
bounded, how closely descriptions and predictions fit data and the broader 
purpose, and how much its development has suggested explanations and 
deepened biological understanding.” “Models are made to fit past and predict 
future data because these achievements improve hypotheses.” “A model is 
useful if it sharpens questions, points to what is missing in our data or in our 
conceptual grasp, and contributes to a larger process that will render it obsolete; 
a model that cannot be shown to be wrong is typically of little use.” 
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Table 1.3 – Basic malaria models where Sh, Ih, Eh and Sm, Im, Em are epidemiological 
compartments representing susceptible, infected and exposed human and mosquito 
populations. Table adapted from Mandal et al 2011 [239].  
 
1.2.11 Mathematical models of within host asexual dynamics 
Several groups have developed mathematical models of P. falciparum asexual 
parasitaemia or within host parasite dynamics [17, 175, 256]. This is a complex 
process involving the estimation of a large number of biological variables as 
described by Molineaux et al [256], including: 
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 total parasite density 
 basic parasite multiplication 
 density of parasite variants 
 probability that a parasitised RBC switches gene variant 
 variables describing the probability of a variant escaping innate 
immune responses 
This simplified list outlines the daunting task facing modelling of within host P. 
falciparum dynamics, particularly when considering there are 50 parasite 
variants per clone. There is also a paucity of untreated P. falciparum infection 
data in humans which serves as the basis for this modelling, due to ethical 
considerations in acquiring data. The data used in these studies is an untreated 
subset of 35 of 334 patients infected with either P. falciparum or P. vivax to treat 
neurosyphilis from the early 20th century [52, 53, 118, 121, 187, 188].  
 
Models of within host parasite dynamics have been studied to improve 
epidemiological modelling [191] and to assist in planning and evaluation of 
intervention trials and control programs [175-178, 256]. Since mathematical 
models of malaria are contingent on a detailed understanding of the parasite 
lifecycle, they have improved understanding of infection biology as modellers 
strive to provide ever more biologically realistic models. This includes 
understanding of merozoite and gametocyte dynamics [112] resulting  
synchronicity [395], immune interactions [395] and infection transmission [191].  
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1.2.12 The importance of mathematical models of malaria 
In 2010 the WHO published a progress and impact series report on 
“Mathematical Modeling to Support Malaria Control and Elimination” [84] for Roll 
Back Malaria. This report outlines the requirement for global malaria control and 
eradication to be based on conceptual and mathematical models that allow 
knowledge to be extrapolated and synthesised in a rational way, providing 
critical quantitative insights. The reliance on mathematical models is due to the 
diversity in the range of conditions, biological, environmental and socio-
economic that effect malaria. Responses cannot be based solely on evidence 
acquired through randomised trials in a number of settings [84]. The report also 
highlights that many questions cannot be answered by field trials as they may be 
too expensive or unethical. 
 
History is a testament that there are no simple solutions to global control and 
eradication of malaria. It has taught the lesson that mathematical modelling of 
biology and epidemiology are crucial to the fight against malaria [84].  
1.3 The fight against malaria 
Malaria eradication efforts in the Roman Campagna prior to 1889 were based on 
broad ideas of cleansing the water, air and land without really understanding the 
source of the malaria sickness [358]. Control programs tended to be successful 
in developed countries that already had the infrastructure and organisations in 
place to run large scale health programs.  
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The first successfully recorded malaria control program was executed from 
1905-1910 during the construction of the Panama Canal. Cases dropped from 
21,000 of 26,000 workers on the project in 1906 to 5,600 of over 50,000 
employees in 1912 through a program of insect and malaria control [78]. 
 
A major malaria epidemic during World War I affecting British, French and 
German armies provided the impetus for research into improved malaria 
treatment options. This spurred efforts to produce synthetic antimalarials. This 
era saw synthetic antimalarials provide a cheap, safe and very effective 
treatment for the malaria infected [78]. 
 
In 1939 Paul Müller in Switzerland discovered the insecticidal properties of 
Dichloro-diphenyl-trichloroethane (DDT). DDT was used for malaria control at 
the end of World War II after proving to be effective against malaria carrying 
mosquitoes. Following on from successful war time efforts to control Malaria in 
troop populations around troop training areas and military bases, the US began 
the National Malaria Eradication Program in 1947. From 15,000 cases of malaria 
annually in 1947, malaria was considered eradicated from the US by 1951 [78]. 
 
With the success of control programs and availability of DDT and synthetic 
antimalarials the WHO submitted a proposal for the eradication of malaria 
worldwide at the 1955 World Health Assembly [279]. Eradication efforts were 
based around house spraying, drug treatment and surveillance but excluded 
most of sub-Saharan Africa. Macdonald collected data to test Ross’ model for 
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malaria eradication and helped to explain that insecticides such as DDT worked 
because they greatly reduced the number of mosquitoes that survived 
sporogony and could transmit malaria [256]. The program was successful in 
nations with temperate climates and seasonal malaria transmission, but had 
negligible traction in countries such as Indonesia, Afghanistan and Nicaragua. 
The emergence of drug resistance, widespread resistance to insecticides, wars, 
population movements, sustained funding issues and lack of community 
participation meant the ultimate failure and abandonment of the program in 1978 
[78]. 
 
An easily overlooked consequence of the Global Malaria Eradication Program 
was the attrition to professional staff and research malariologists, which 
occurred due to the routine workload imposed during the program, war, 
economic crisis, inadequate funding and a lack of newly trained malaria 
professionals who would not be required in a world in which malaria was 
eradicated [265]. In the mid 1970s, WHO launched the Special Program for 
Research and Training in Tropical Diseases (TDR) in an effort to re-establish the 
role of research in malaria control which was lacking due to professional 
attrition, yet critically required to address problems with the Global Malaria 
Eradication Program [265]. Despite important successes by the TDR, there has 
existed a rift between malaria control programs and research bodies in which 
research projects have had little operational bearing on control programs, which 
themselves have lacked capacity to carry out and guide research [265]. 
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In the early 21st century a concerted effort by endemic countries, donors and 
global malaria partners has seen a resurgence of interest in combating malaria 
and a strengthening in malaria control [435]. The gains achieved in this time 
have no parallel since the Global Malaria Eradication Program [93, 277]. Cohen 
et al [93] have linked 91% of the 75 malaria resurgences since 1930 to 
weakening of control programmes. There is need to develop practical solutions 
to the financial and operational threats to sustaining successful malaria control.  
1.3.1 Antimalarial strategies 
The goal of antimalarial strategies, or malaria control, is to reduce the incidence 
of infections and deaths due to malarial parasites. Control can be simply divided 
into preventative actions, which generally target reducing disease transmission, 
or when this fails, treatment, which requires effective diagnostic tools and 
therapies. Antimalarial strategies are most effective when multiple strategies are 
employed simultaneously and include both preventative and treatment 
strategies. The ultimate end of control programs is to reduce disease 
transmission to the point where it is no longer a public health problem. Malaria 
control strategies include vector control, transmission control, prophylaxis, 
vaccination and treatment. 
 
Malaria chemotherapy can be broadly divided into vaccination, prophylaxis and 
treatment. Despite substantial effort towards vaccine development for P. 
falciparum, few candidates have shown significant efficacy in clinical trials [65]. 
Many problems exist in development of an effective vaccine, however the most 
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telling is the parasite’s sophisticated ability to avoid detection by the host 
immune system. Plasmodium express a large number of antigens, have high 
antigenic variation and antigen allelic polymorphism (or sequence diversity) [33]. 
Studies have also suggested that Plasmodium may immunomodulate by 
reducing dendritic cell function [142, 252, 253], but also by invading and 
replicating in dendritic cells [441, 442]. A lack of understanding of parasite host 
interactions is also a factor in effective vaccines not having been developed. 
 
Malarial chemoprophylaxis generally refers to the use of antimalarial drugs to 
prevent infection. Mass chemoprophylaxis has been attempted to varying 
degrees of success and can range from blanket mass administration, as in 
chloroquine laced salt, to more specific target groups being children and/or 
pregnant women. An important concern with these types of mass drug 
administration campaigns is development of resistance. However, prophylactic 
administration of chloroquine to children in Ghana and Madagascar did not 
result in the emergence of resistance [307]. This was despite weekly 
administration to over 1 million children of chloroquine over a 12 year period in 
Madagascar [161]. Resistance to pyrimethamine after mass prophylaxis in 
children is well documented [25, 80]. There are also suggestions that 
chloroquinized salt may have been a major factor in the development of 
chloroquine resistant P. falciparum [284]. 
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1.3.2 Antimalarial treatment strategies 
Early diagnosis and prompt treatment is one of the key technical components of 
any effective malaria control program [5]. The effectiveness of this intervention is 
reliant upon antimalarial drugs which should be effective and safe, as well as 
available and affordable to the population at risk. The rational use of antimalarial 
drugs shortens the duration of illness and reduces chances of severe illness and 
death. It also reduces the chances and speed of the development of parasite 
resistance to antimalarial drugs. 
 
In its 2001 Antimalarial Drug Combination Therapy Report of a WHO Technical 
Consultation [46] the purpose in establishing a national antimalarial treatment 
policy is outlined to “enable the population at risk of malaria infection to have 
access to safe, good quality, effective, affordable and acceptable antimalarial 
drugs, in order to: 
 
 ensure a rapid and long lasting clinical cure for individual malaria patients 
 prevent progression of uncomplicated malaria to severe disease and 
death 
 shorten clinical episodes of malaria and reduce the occurrence of malar-
ia-associated anaemia in populations residing in areas of high malaria 
transmission 
 reduce consequences of placental malaria infection and maternal malar-
ia-associated anaemia through chemoprophylaxis or preventive 
intermittent treatment during pregnancy 
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 delay the development and spread of resistance to antimalarial drugs.” 
 
The report goes on to outline the need to balance two key principles; prompt 
treatment and ensuring that drugs have a maximum useful therapeutic life. The 
discovery of the antimalarial properties of chloroquine combined with its safety 
and low cost spurred malaria eradication efforts in the 1950s. Chloroquine 
development and distribution was one of the most significant public health 
interventions of the 20th century [414].  The emergence of resistance diminished 
its efficacy and led to the demise of these initial eradication efforts, largely due 
to treatment failure, which in turn led to a resurgence of the disease [416]. 
1.3.3 A brief history of antimalarial chemotherapy 
In 1820, Pierre Joseph Pelletier and Jean Bienaime Caventou announced the 
isolation of an alkaloid from the Cinchona bark with curative properties, which 
they named quinine [64]. Quinine quickly became routine for treatment of 
malaria and remained frontline treatment for malaria in many countries until the 
early 21st century. 
 
During the First World War Germany was unable to obtain quinine, and as a 
result many of its soldiers suffered from malaria in southern Europe. To prevent 
this occurring again, German chemists began working on synthetic alternatives. 
By the 1930s mepacrine, a simplified version of quinine, was being produced in 
Germany [357]. Similarly, during the Second World War American troops did not 
have access to either quinine or mepacrine and set about producing mepacrine 
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and also developed chloroquine, which proved to protect troops very effectively 
[321, 373]. 
 
Several drug discoveries produced during war efforts were used as prototypes 
for developing new antimalarials. Proguanil was developed by the British from 
efforts during the Second World War and led to the development of 
pyrimethamine. These two compounds began to be used in combination during 
the 1970s as Fansidar. Similarly, the Americans developed mefloquine and 
much later atovaquone from discoveries during the Second World War [321]. 
  
Post Second World War, armed with DDT and chloroquine, the WHO began its 
program to eradicate malaria, which was planned similarly to the successful 
smallpox eradication program. However, it proved impossible to drain all 
marshes in tropical regions, Anopheles developed resistance to DDT and 
chloroquine showed decreasing efficacy. Malarial resistance to chloroquine was 
emerging and during the 1970s chloroquine resistance spread. 
 
The US and Chinese during this time were both searching for new alternatives 
to chloroquine with different mechanisms of action to avoid the existing parasite 
resistance mechanisms. The US developed mefloquine to replace chloroquine, 
while the Chinese isolated artemisinin. At the end of the 1970s Western 
malariologists Nicholas White and David Warrell became aware of the claims 
about artemisinin as an antimalarial treatment in China, and in 1981 obtained a 
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sample of artemisinin to test the Chinese claims. It was confirmed that 
artemisinin was indeed an effective antimalarial [64]. 
 
With all other widely used antimalarials showing diminishing clinical 
effectiveness, spreading multidrug parasite resistance, and the failure of tropical 
malaria control programs, artemisinin presented itself as the only saviour. 
However, use of artemisinin was delayed as it was costly to produce, poorly 
water soluble making delivery to patients difficult, there were fears of parasite 
resistance developing to this new drug and it was required to undergo 
toxicological testing like other new pharmaceuticals in the Western world [64]. 
1.3.4 Classification of antimalarial chemotherapeutic agents 
Antimalarial drugs are generally classified according to their chemical structure, 
or family, responsible for their antimalarial properties or the stage in the 
parasites life cycle they primarily display their antimalarial properties. Chemical 
classification of antimalarials is based on their chemical classes, functions, or a 
combination of these. Classes include endoperoxides, 4- and 8-
aminoquinolines, sulfonamides, amino alcohols, antifolates, antibiotics and 
“others”. The antimalarial chemical classifications are represented in Figure 1.5 
taken from Delves et al 2012 [109]. 
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Antimalarials can also be classified depending on which parasite stage they 
target as blood schizontocides, tissue schizontocides, gametocytocides, 
 
Figure 1.5 – The main classes of antimalarials. The chemical structures of all the main 
classes of antimalarials and other therapeutic and control molecules are assembled 
according to either the chemical classes they belong to (endoperoxides, 4- and 8- 
AQs, amino-alcohols) or their function (antifolate, antibiotics), or both (e.g., sulfona-
mides, a chemical class of antibiotic used in combined antimalarial therapies) [109]. 
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hypnozoitocides and sporontocides. The stages and chemotherapies targeting 
these stages are outlined in Figure 1.6 taken from Delves et al 2012 [109].  
 
 Blood schizontocides act on the asexual erythrocytic forms of Plasmodium 
species. The majority of common antimalarials fall into this category including 
 
Figure 1.6 – Summary of the activity of the most widely used antimalarials throughout 
the life cycle of Plasmodium. The three main phases, i.e., liver stage, blood stage, and 
vector stage, of the life cycle of Plasmodium are shown. The two key entry points 
leading to transmission of the parasites from vector to host and from host to vector 
are indicated (green circles). Parasite forms specific to each stage are highlighted and 
drugs identified as inhibitors of development of these forms are listed in boxes and 
coloured as described in Figure 1.5. Stars highlight components of the main artemis-
inin combination therapies: green, coartem; red, pyramax; orange, eurartesim; blue, 
fixed dose artesunate+amodiaquine [109]. 
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quinine, chloroquine, mefloquine, sulfadoxine, tetracyclines and artemisinin 
derivatives [27, 180, 208]. Tissue schizontocides target tissue schizonts or latent 
hypnozoites and include primaquine, pyrimethamine and proguanil. They are 
used as prophylactics or to prevent relapse of P. vivax or P. ovalae [27, 180, 
208]. Gametocytocides kill sexual forms of Plasmodium and so prevent 
transmission to mosquitoes. Chloroquine and quinine have gametocytocidal 
activity against P. vivax and P. malariae but not against P. falciparum, for which 
primaquine is commonly used [27, 180, 208]. There is also some evidence that 
artemisinins have gametocytocidal activity against P. falciparum [167, 306]. 
Sporontocides, including primaquine, pyrimethamine and proguanil prevent 
development of malaria in mosquitoes via inhibition of oocyst and sporozoites 
[27, 180, 208]. 
1.3.5 Optimisation of antimalarial chemotherapy 
Many of the antimalarial drugs in current use were introduced at suboptimal 
doses [423]. Improved or optimised dosing should limit the emergence and 
spread of resistance and maximise cost benefit [382, 423]. However there is 
currently no clear or established method for assessing optimisation of 
antimalarial chemotherapy. White [423] suggests that investing in 
characterisation of drug pharmacokinetic and pharmacodynamic relationships 
will likely lead to improve antimalarial dose regimens. This would increase the 
chance of selecting optimum treatment regimens in the future and reduce 
suboptimal dosing.  
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1.4 Resistance 
The control of malaria relies heavily on drug therapies. The Global Malaria 
Eradication Program failed due to a broad range of reasons, although chief 
among these was reliance on and development of resistance to chloroquine, 
and subsequently other chemotherapeutic agents. Chloroquine (CQ) was first 
introduced into the clinical setting in 1945, and its effectiveness drove the effort 
to eradicate malaria. However by the late 1950s CQ resistant P. falciparum was 
reported in South East Asia and South America. Within 50 years CQ resistant P. 
falciparum was almost ubiquitous [438]. P. falciparum strains also developed 
resistance to all commonly used antimalarials including mefloquine and 
sulfadoxine-pyrimethamine. In the past 50 years resistance to new antimalarials 
has developed within a short number of years after their introduction (Table 1.4).  
Table 1.4 – Dates of Introduction and first reports of antimalarial drug resistance adapted 
from Wongsrichanalai et al 2002 [43, 234, 290, 417, 438, 440]. 
 
Dates of introduction and first reports of antimalarial drug resistance 
Antimalarial Drug Introduced First reported 
Resistance 
Difference 
(years) 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulfadoxine-
pyrimethamine 
1967 1967 0 
Mefloquine 1977 1982 5 
Atovaquone 1996 1996 0 
Artemisinins 1980 2008 28 
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Resistance is an operational rather than an absolute term, with large differences 
possible between in vitro and in vivo results although in general terms it is the 
“ability of a parasite to survive in the presence of concentrations of drug that 
normally destroy parasites of the same species or prevent their multiplication” 
[412].  For this reason the WHO developed an in vivo classification system of 
response to CQ in the 1970s (Table 1.5). This classification has subsequently 
been used for assessment of response to other drug treatments [32]. 
Table 1.5 – Classification of response to antimalarial drug treatment [32, 422]. 
Classification Response Criteria 
S Sensitive Marked reduction in asexual parasitaemia to less 
than 25% of the admission parasite count within 
48hrs of commencing drug treatment. Clearance of 
asexual parasitaemia with seven days and no 
recrudescence (radical cure). 
RI Low Grade Resistance Marked reduction in asexual parasitaemia to less 
than 25% of the admission parasite count within 
48hrs of commencing drug treatment. Clearance of 
asexual parasitaemia within seven days. Recru-
descence within 28 days of commencing drug 
treatment.
a,b 
RII High Grade Resistance Marked reduction in asexual parasitaemia to less 
than 25% of the admission parasite count within 
48hrs of commencing drug treatment. Parasitaemia 
is not cleared although parasites may be undetect-
able for a short period of time. Early 
recrudescence.
a 
RIII High Grade Resistance No significant reduction in asexual parasitaemia 
within 48hrs of commencing drug treatment. 
Parasitaemia is not cleared and may rise despite 
drug treatment. 
a
 Recrudescence may be difficult to differentiate from reinfection. For RI and RII classifications to 
be considered valid, patients must remain in a non-endemic area where the risk of reinfection is 
low. 
b
 The length of time for recrudescence may be substantially longer for drugs with exceptionally 
long elimination half-lives. 
1.4.1 A brief history of chemotherapy resistance 
P. falciparum drug resistance to quinine was first reported in 1910 [415, 419]. 
Treatment failure due to resistance was observed in the late 1940s [287]. A 
number of failures of the global malaria eradication program including funding, 
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administrative, organisational failings and insecticide resistance lead to a heavy 
dependence on drug treatment to maintain the program in many developing 
malarious regions. Subsequent over use and lack of controlled application of CQ 
coupled with the other failings of the eradication program led to the speedy 
development and spread of resistance. Treatment failure continued to be 
observed in the 1950s and 1960s to a variety of antimalarials [287]. By the 
1970s chloroquine was no longer effective in the majority of South-East Asia 
and by 1978 the first cases of resistance in east Africa were reported. By the 
early 1980s 75% and 82% of infections in Kenya and Malawi respectively were 
found to be CQ resistant [47]. As resistance spread morbidity and mortality due 
to malaria increased [391, 452]. Alternative front line treatments were employed 
and CQ was replaced with combinations of sulfonamides and pyrimethamine 
[110]. This replacement of front line drugs was however very slow in some 
areas, contributing to the worsening spread and development of resistance. 
Between 1978 and 1988 resistance to CQ was reported in all tropical African 
countries and by 1989 resistance was widespread in sub-Saharan Africa [438]. 
Despite these reports, chloroquine remained the first line treatment of malaria 
until after 2000 in most of these countries [390]. Resistance to sulfadoxine-
pyrimethamine was first observed on the Thai-Cambodian border in the mid 
1960s [43]. By 1982 both pyrimethamine-sulphadoxine and chloroquine were 
ineffective against P. falciparum in Thailand [419]. A decade later quinine was 
only 50% effective and only 7 years after its introduction, mefloquine was less 
than 50% effective [419]. The emergence of mefloquine resistance may have 
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been influenced by the heavy use of quinine, which is functionally similar, prior 
to the introduction of mefloquine. 
 
In 1971, Qinghao which was first documented as an antimalarial treatment in 
340AD was rediscovered, purified and the chemical structure of the active 
constituent identified and officially named artemisinin [152]. Early clinical studies 
of artemisinin demonstrated rapid and high initial cure rates and high 
recrudescence [107, 171]. By the 1980s several semi-synthetic derivatives of 
artemisinin including dihydroartemisinin, artesunate, artemether and arteether 
had been developed as more potent treatment options. Due to increasing 
resistance and a lack of other suitable new antimalarials, artemisinin compounds 
began to be used clinically. The high frequency of recrudescence due to the 
short half-life of this family of compounds meant that artemisinins were soon 
paired with other existing antimalarials with longer half-lives. The artemisinin 
combination treatments (ACTs) allowed faster cure, less recrudescence, slowed 
the emergence of resistance and allowed compounds that were no longer 
effective monotherapies to continue to be used. 
 
Until 2008, the artemisinin family of antimalarials remained the only group for 
which clinical resistance in P. falciparum had not been observed. In 2009 
Dondorp et al [114] reported a marked reduction in in vivo sensitivity of P. 
falciparum cases to artesunate in western Cambodia and north-western 
Thailand. This spurred an already building international momentum for a 
resistance containment plan in Cambodia in an attempt to prevent the 
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emergence and spread of true artemisinin resistance, which could potentially 
stall current efforts to eradicate malaria, as CQ resistance had 50 years before. 
1.4.2 Determinants of antimalarial resistance 
The development and spread of resistance to CQ is evidence that determinants 
of both development and spread need to be understood to avoid the 
catastrophic consequences of similar resistance to artemisinin combination 
therapies. The determinants of resistance can be grouped into drug, human, 
parasite and vector. 
 
Resistance to chemotherapy depends on certain drug factors. Resistance to 
drugs with short half-lives develops more slowly than drugs with long half-lives. 
Parasites are exposed to concentrations of short half-life drugs below the mean 
inhibitory concentration for shorter periods than for drugs with long elimination 
half-lives [415]. This is due to more frequent dosing and the shorter period after 
the last dose that parasites have exposure to less than mean inhibitory 
concerntrations. This is one of the major benefits of artemisinin compounds over 
longer half-life counterparts such as mefloquine, chloroquine and piperaquine. 
Drugs such as mefloquine may exert significant residual selection on new 
infections contracted after the treatment of the primary infection [438]. The 
maintenance of adequate drug concentrations for clearing the entire parasite 
population is important. Use of subtherapeutic doses in treatment, poor 
compliance and mass prophalactic drug administration risk killing susceptible 
parasites and selecting for those with greater fitness, leading to the emergence 
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and spread of resistance. Wide spread and intense use of drugs increases drug 
pressure and the probability of selection of resistant parasite populations. 
 
Human factors such as immune status play an important role in resistance. 
Introduction of resistant malaria into non-immune populations increases the 
opportunity for emergence and spread of resistance. Immune populations are 
more able to clear low level parasite infections than the non-immune, so 
parasites with low or moderate resistance are more likely to be cleared in semi-
immune populations. 
 
Parasite factors also influence the emergence and spread of resistance. 
Increased risk of resistance emerging has been proposed in areas of both low 
and high levels of transmission [165, 257]. The fact that resistance developed 
earlier in areas of lower transmission, such as Thailand, and is still more 
prevalent in these areas seems to support the low transmission hypothesis. 
Other parasite determinants relating to genes and gene mutations are also 
important in the development and spread of resistance. Vector and 
environmental factors may effect the proliferation of resistant parasites over non-
resistant strains.  
1.4.3 Combating antimalarial drug resistance 
The emergence and spread of drug resistant parasites is a major challenge in 
the fight against malaria. The efficacy of artemisinin based combination 
regimens must be maintained because no practical alternative exists. 
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Resistance and particularly multidrug resistance must be contained. Logically 
and out of necessity antimalarial combinations are required to limit spread and 
further emergence of antimalarial resistance. Unfortunately the use of effective 
combinations began too late to prevent or slow resistance and its spread. 
 
Ensuring continued efficacy of existing agents requires surveillance, early and 
rapid detection of resistance, and containment of its spread [87, 115, 153, 270, 
303, 346, 404]. This requires that resistance is detected while at a low level and 
low frequency, so well before it is an obvious clinical risk. The tools for this form 
of surveillance are molecular markers for resistance, in vitro susceptibility tests 
and therapeutic efficacy tests [251]. Each of these methods has distinct 
limitations and they struggle to detect the emergence of resistance early enough 
to allow effective containment [123, 251, 375, 404]. 
1.5 Malaria models 
The study of human malaria involves an array of methods from epidemiology to 
population genetics to clinical studies in the field or hospital settings to analyses 
of post-mortem biopsies. There are however limitations involving collection, use 
and access to human data and samples. Access to post-mortem tissues can be 
obstructed by religious and cultural objection. There is often a lack of proper 
controls [454]. In depth longitudinal research requires invasive analysis to 
monitor disease and pathological progression and invasive biological sampling 
is often not possible. Models provide a necessary tool for researchers over 
which they can impose varying degrees of control to explore scientific 
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hypotheses. There are many types of malaria models aside from 
epidemiological and within host dynamic models which have already been 
discussed. 
 
As with many biological systems and diseases, a significant proportion of human 
understanding of malaria has resulted from in vitro and in vivo models of the 
disease. These models allow study of specific aspects of the disease and 
facilitate varying degrees of control over variables be they biological, chemical, 
cultural, environmental and ethical that can confound purely clinical research. 
Clinical work and clinical research leading to improvement in patient care and 
effective treatment are the ultimate goals of any malaria research. There are 
however certain limitations to clinical research especially in the case of life 
threatening diseases. In humans infected with P. falciparum, it has been difficult 
to investigate the early kinetics of events leading to clinical manifestations, and 
the factors responsible for the onset of a variety of symptoms remain unclear. 
During the rare experimental inoculations performed in man, both the duration of 
the infection and the number of factors investigated were limited, due to the 
requirement for early treatment and other obvious ethical considerations [119, 
244]. 
1.5.1 In vitro models of malaria 
In vitro models of malaria have been used for some time predominantly in drug 
screening and parasite sensitivity studies using human [34, 35, 48, 71, 83, 271, 
397] and animal malarias [173, 186, 312]. More complex in vitro models also 
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exist. Lertyot et al in 2005 [393] reported an in vitro blood brain barrier model 
utilising cultures of porcine brain capillary endothelial cells to study blood brain 
barrier disruption by P. falciparum. This in vitro system was used as a model of 
cerebral malaria to detect decreases in the endothelial barrier function and 
disruption of tight junction complexes. 
 
The short coming of in vitro models is closely related to the advantages they 
provide. They enable a vast amount of experimental control however this comes 
at the expense of providing data that is relevant to the clinical setting. For this 
reason in vitro research is mostly useful for providing study of isolated 
mechanistic principles (such as in the case of Lertyot et al [393]) and elucidation 
of aspects of host-parasite biological involvement, which due to the simplification 
of the models may or may not be clinically relevant. 
 
Animal models provide an important link between in vitro and clinical research 
and attempt to balance control and simplification of the clinical scenario while 
providing greater clinical understanding. 
1.5.2 Animal models of malaria 
Investigation of such a complex disease as malaria, which involves host and 
parasite biological systems and their interaction with each other and on 
chemotherapy agents is arguably best suited to research in an animal model in 
combination with limited human-based research [119] to confirm the translation 
of findings from preclinical to clinical. In this setting the time courses, doses, 
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parasite strains, environment, nutrition, and many other variables including host 
and parasite genetics can be controlled by the investigator. Animal models also 
allow indepth collection of data usually unable to be collected clinically due to it 
being overly invasive in humans. The data is more relevant to the clinical setting 
as it is being collected from a complete, or almost complete biological system 
with all its complex interactions. In many cases animal models are the only 
solution for researchers to test new hypotheses, which often can not be 
attempted in humans [215]. 
1.5.3 Non-human primate models of malaria 
Early research into animal models of malaria focussed on infecting primates with 
human forms of malaria. There is a distinction between animal models of 
malaria, and animal models of human malaria, the later using human malaria 
such as P. falciparum in an animal model. Early models were animal models of 
human malaria. The traditional concept held at the time that susceptibility of an 
animal to human malaria depended upon it closeness to humans in evolutionary 
phylogeny. In 1893 Laveran made the first unsuccessful attempt to inoculate 
human malaria parasites into laboratory animals [190]. Arguably the first 
successful inoculation of parasites into animals is recorded by Mesnil and 
Rouband in 1917 with the successful infection of the black chimpanzee with P. 
vivax [190]. The infection in black chimpanzees lasted only 22 days, and some 
years later Mesnil and Roubaud dismissed their own initial claims of successful 
inoculation. While these early models were of limited clinical value, they paved 
the way for many more efforts to establish an animal model of malaria. From 
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1917 P. falciparum was used to inoculate bats, rhesus monkeys, Macca irus 
monkeys, black chimpanzees, pigs, guinea pigs, rats, mice, rabbits, dogs and 
golden hamsters [190]. 
 
There were several other reports of successful inoculations in black 
chimpanzees with P. vivax although these experiments required splenectomy of 
the animals in order for erythrocytic stages to be viable and parasitaemia to 
reach greater than one percent [190]. In 1966 Cadigan et al showed that the 
Thai gibbon, was susceptible to P. falciparum infection [67, 68, 146, 410]. The 
Thai gibbon was the closest animal model yet observed to human malaria, 
although the infection was not fatal, animals were splenectomised in order for 
parasitaemias to reach 8% and infected gibbons were not able to infect 
mosquito species with malaria. In the same year Young et al also successfully 
infected Aotus monkeys with P. vivax [449, 450]. The Aotus monkeys proved to 
be a very good model for human malaria, after several generations of infection 
monkeys were not required to be splenectomised and parasitaemias and 
symptoms were reported to be similar to the human disease. This discovery of 
Aotus monkeys as being more susceptible to human malaria than chimpanzees 
and gibbons also went against traditional concepts of human malaria 
susceptibility being associated with evolutionary links or similarities.   
 
Despite the promise of non-human primate models of malaria as a research tool 
for human malaria there are some largedisadvantages. There is a high and 
growing degree of public concern and opposition on moral and ethical grounds 
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for utilising primate animal experimental models. Additionally chimpanzees and 
gibbons are large animals that are relatively scarce. Aotus monkeys are smaller, 
however they are difficult to rear under experimental conditions [133, 215]. 
 
It is worth noting that there has been expressions from the research community 
in recent years to supply additional funding to the non-human primate malaria 
models as they provide excellent human malaria models and have been 
underutilised [133, 215]. They lack some of the advantages of other animal 
models in that the genomes of the primate malarias have not been sequenced 
and this could provide valuable data for gene expression studies. There is also 
concern that without funding and encouraging of young researchers to utilise 
non-human primate models of malaria, these research models could be lost 
[215]. 
1.5.4 In vivo models for drug screening 
The importance of in vitro systems for antimalarial drug screening has already 
been mentioned. This method is useful for identifying compounds with true 
plasmodicidal activity, however not compounds with plasmodistatic action such 
as proguanil, pyrimethamine and sulphonamides [381]. In W. Peters words “For 
screening of drugs against malaria one must eventually fall back on in vivo tests 
in laboratory models”. The evolution of in vivo models for drug screening can be 
divided into three periods. Between 1926-1935 tests for drug actions used P. 
relictum in canaries. During World War II a vast screening program developed 
based on the avian P. gallinaceum in domestic chicks. These models were 
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replaced shortly after the discovery of rodent Plasmodium species from 1948. 
The rodent malaria models soon became widely used and characterised for not 
only drug screening, but for studying many other aspects of malaria. Davey in 
1963 summed up the difficultly of the choice between malaria models at that 
time, giving an indication of why the rodent malaria models are now so wide 
spread. 
 
“Monkeys are expensive and awkward to handle: they will also consume a lot of 
drug because of their size. Canaries are not easy to get in large numbers, they 
are relatively expensive, and they are delicate creatures. Mice are common, 
cheap, easily houses and handled. Chicks are also cheap and easy to handle, 
but they require extra heating. Finally, pigeons require much space, turkey 
poults are expensive, and ducks smell!” [101] 
1.5.5 Murine models of malaria 
In 1948 Ignace Vincke reported Plasmodium species in African thicket rats 
[405]. It was subsequently discovered that these parasites, named Plasmodium 
berghei, were not only able to exist in their natural host, but also to infect 
laboratory rats, mice and hamsters [293]. Three other rodent-specific 
Plasmodium species were also isolated P. vinckei, P. yoelli and P. chabaudi 
[200, 211, 316]. Several other species of malaria parasites in rodents have been 
described although these have not been investigated in detail [201]. The rodent 
malaria species were found to be analogous to human malaria species in the 
most essential aspects of structure, physiology and the life cycle (Table 1.6) [74, 
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212]. The advantages of rodent-based models are that they are cheap, easy to 
develop and maintain, robust, and versatile relative to other animal models such 
as the non-human primate models [213]. Large scale invasive and interventional 
studies are possible in rodent models as opposed to simian and human models 
due largely to ethical and logistical considerations [379].  
Table 1.6  – Characteristics of the four murine malaria parasites compared with human 
parasites [74, 201, 212, 293]. 
 Human 
Parasites 
P. berghei P. vinckei P. yoelli P. chabaudi 
Merozoites per schizont 8-16 12-18 6-12 12-18 6-8 
Reticulocyte preference Yes/No Yes No Yes No 
Synchronous blood infection Yes/No No Yes No Yes 
Sporozoites in glands days 
after infection 
Temp 
dependent 
13-14 10-13 9-11 11-13 
Optimum Temp. for Mosqui-
to transmission (C) 
>26 19-26 24-26 23-26 24-26 
Duration of pre-erythrocytic 
cycle (h) 
6-15 days 48-52 60-72 35-50 50-58 
Duration of asexual blood 
stage (h) 
48-72 22-24 24 18 24 
Development time gameto-
cytes (h) 
48h – 
12days 
26-30 27 27 36 
 
As with results from any model, those from murine models of malaria must be 
applied carefully to the clinical setting. Unsurprisingly there are important 
differences between human and rodent physiology. Extrapolation of findings 
from murine experiments are often controversial and concerns exist about the 
translational utility of animal models in pathogenesis, immunity, vaccine 
development and drug discovery [99, 427]. The goal of preclinical research is to 
  71 
improve clinical understanding. This can only be accomplished with a good 
understanding of the strengths and weakness of a model, the basis of which is 
the similarities between the model and the clinical case. 
1.5.6  The value of murine malaria models 
Since their discovery, the murine models of malaria have been used extensively 
as screening tools for new antimalarial chemotherapy agents. They have also 
contributed to understanding of parasite morphology [11, 237, 349], genetics 
[72, 408, 409], protein function [249, 371, 372], immunity [216, 301, 368], 
vaccine development [116, 120, 172, 273, 300], drug development [260, 288, 
322], resistance [204, 309, 321, 335], cerebral malaria [169, 195, 267, 315] and 
almost all other aspect of malaria researched. As well as the study of disease 
mechanisms, rodent models allow simple maintenance of the entire parasite life 
cycle in controlled and optimised laboratory conditions. Use of transgenic 
animals and parasites allows detailed study of host-parasite interactions [131, 
144, 302, 314, 378, 455].  
 
Developments in preclinical imaging technologies are providing researchers with 
greater opportunities to explore and characterise malaria pathology in animal 
models and explore the similarities with the human pathology.  
1.5.7 P. berghei murine malaria 
Plasmodium berghei is the most comprehensively studied and manipulated of 
the four murine malarias. P. berghei infects 37 animal species including African 
fruit bats and new born rabbits, however laboratory species of albino rats and 
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mice are by far the most commonly used hosts [293]. Early characterisation of 
P. berghei in laboratory rodents provided information on the similarities between 
P. berghei and human malaria species. These demonstrated similarities 
between the primate and P. berghei life cycles [447], ability to be passaged 
through anophelines [214], and similarities in sensitivities of drugs to P. 
falciparum and P. berghei [286]. Characteristics of P. berghei infections in 
laboratory rodents include a preference for reticulocytes, asynchronous infection 
and infection is generally lethal in laboratory models, although this is influenced 
by species and ages of hosts [453]. Cerebral effects may also be observed in 
certain rodent species, although the mechanisms for this are considerably 
different to those in human cerebral malaria. The morphology of asexual P. 
berghei is similar to that of P. vivax as can be seen in Figure 1.7 compared with 
Figure 1.3. 
 
There are small differences between P. berghei parasites of different isolates 
and laboratory lines that influence the characteristics of infection. Variations are 
generally the result of variations in environmental factors, hosts and genetic 
differences between parasite isolates. These factors can influence the course 
and intensity of blood infections, gametocyte production, virulence and 
pathology [214]. 
 
P. berghei shows a pronounced preference for reticulocytes. There is little 
difference between isolates in terms of reticulocyte preference, however there 
are reports that the NK65 isolate has a greater preference for reticulocytes than 
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the ANKA isolate in Swiss mice [108]. The number of merozoites per 
erythrocytic schizont is greater in reticulocytes (~12-18 merozoites per RBC) 
than in more mature red blood cells (~6-12 merozoites) [212]. P. berghei 
schizonts preferentially sequester in the microvasculature of the spleen, lungs 
and adipose tissue. An exception to this is the ANKA isolate in BALB/c and 
C57BL/6 mouse strains which sequester in the brain [168]. 
 
 
Figure 1.7 – P. berghei erythrocytic stage morphology at time from RBC invasion [185]. 
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There are a large number of factors which influence the virulence and pathology 
of P. berghei including age, diet, host genetics, parasite genetics and route and 
magnitude of the infection [13, 79, 124, 255, 299, 328, 329]. In most laboratory 
rodents P. berghei causes rapidly progressing infections leading to death within 
1-3 weeks. This is not the case in older laboratory rats which are able to clear 
parasites without treatment  [74]. The Leiden Malaria Research Group divided 
the course of the ANKA P. berghei isolate infection in Swiss mice into 3 stages. 
 Stage 1 – during this early phase of infection parasite multiplication is on 
average 10-fold per 24 h (1 life cycle) up to a parasitaemia of ~1-3% 
[185]. 
 Stage 2 – above a parasitaemia of 3% due to the course of infection the 
pool of available healthy reticulocytes is reduced. As a result there is an 
increase in multiply infected reticulocytes which does not allow parasites 
to develop into mature schizonts. As a result the average parasite multi-
plication rate decreases below 10-fold in stage 2 [185]. 
 Stage 3 – the average parasite multiplication rate increases in stage 3 
due to either a wave of production of reticulocytes in the host, or invasion 
of older red blood calls by parasites. The course of infection in stage 3 is 
much less predicable and is highly dependent on host and parasite fac-
tors [185].   
 
Gametocyte production in P. berghei is influenced by environmental factors and 
genetic differences between isolates [184, 258]. Gametocyte infectivity to 
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mosquitoes generally decreases as infection progresses in laboratory rodents as 
numbers of oocysts decrease. This is influenced by some immune and non-
immune-related blood factors [42, 63]. The infection rate of liver cells by 
sporozoites is highly dependent on the host species and innate immune 
responses [74, 199]. 
 
The age and gender of laboratory rats and mice is important to P. berghei 
models. Swiss rats and mice are less susceptible to P. berghei infection as their 
age increases, due to immune development so adolescent rats and mice are 
predominantly used [453]. There is also the potential that the oestrus cycle in 
female rats and mice may lead to variations in experimental results from 4 
weeks of age depending upon strains and individual variation [429, 453].  
1.5.8 P. berghei antimalarial chemotherapeutic tests 
P. berghei antimalarial chemotherapeutic testing began in 1950 and was based 
on standard tests developed for surveying antimalarial drugs with P. gallinaceum 
as described by Curd et al and Tonkin and Hawking [100, 389]. With the 
discovery of murine malaria came the opportunity for drug testing in a 
mammalian model which was considered much more similar to the human 
disease than that in the avian model and was logistically easier. In this “Thurston 
Test” mice ranging from 15-20g were infected i.p. with 5-15 million parasites in 
0.2ml [386]. Drugs were administered orally for four days commencing three to 
four h post inoculation and doses were normalised to mouse weight. Thin films 
were collected and examined on days five and seven and the percentage of 
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infected erythrocytes determined. The minimum effective dose was determined 
as the minimum drug dose to keep parasitaemia below one percent on the fifth 
day [387]. June Thurston’s findings were [386] 
 
“P. berghei is half as sensitive to the action of quinine as P. gallinaceum. On the 
basis of the Quinine Equivalents, P. berghei is as sensitive as P. gallium to 
proguanil; it is less sensitive to pamaquin and slightly more sensitive to 
mepacrine and chloroqin; it is many times more sensitive than P. gallinaceum to 
sulphonamides. In its susceptibility to sulphadiazine, 4’-diaminodiphenyl 
sulphone and sulphanilamide, P. berghei resembles the malaria parasites of 
monkey and man more than it does the avian species. P-Aminobenzoic acid 
antagonised the activity of sulphadiazine. It is proposed to adopt the test against 
P. berghei in mice for routine screening experiments in this laboratory in place of 
the existing test against P. gallinaceum in chicks.” 
 
The minimum effective dose determination used by Thurston was modified in 
subsequent years. In 1952 Rollo [320] reported chemotherapy responses in the 
form of a standard effective dose. It was the dose required to reduce 
parasitaemia to 50% that of controls [320]. This later became reported as the 
effective dose 50 (ED50), and the effective dose to reduce parasitaemia to 90 
percent that of controls, or ED90 [286]. 
 
The “Thurston Test” which was termed a “suppressive” or “prophylactic” test by 
Peters was modified and termed a therapeutic test. As the name would indicate 
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the therapeutic test differed from the suppressive Thurston test in that P. berghei 
infection in mice was left untreated to progress to 10% parasitaemia prior to 
chemotherapy, which was only 4 h post inoculation in the suppression test [286]. 
 
The “Rane test” was used to test the bulk of some 300,000 compounds for 
antimalarial action by the Walter Reed Army Institute for Research [293]. In this 
test mice were inoculated intraperitoneally with 106 P. berghei infected RBCs. 
Test drugs are then administered on day three after inoculation at a dose range 
of 80, 160, 320 and 640mg/kg subcutaneously [293]. The animals are observed 
daily for death or survival. Survival of twice that of controls is evidence of activity 
and survival past 60 days is considered cure. The maximum tolerated dose was 
described as the dose that produces no more than 1 in 5 toxic deaths. The 
maximum tolerated dose was compared with the minimum effective dose to give 
an indication of the therapeutic index. Promising compounds are then continued 
to the “4-day test” for a more accurate examination of their activity [293]. 
 
The suppressive and therapeutic tests were further developed into the “Peters 4-
day test” which similarly comprises a 4-day suppressive test followed by a 4 day 
assessment of blood schizontocidal activity [289]. The 4-day suppressive test 
involves inoculating mice with 2x106 P. berghei parasites on day zero. Groups of 
mice then receive a 30mg/kg dose once daily on days 0, 1, 2 and 3 via either 
s.c. or oral administration. Thin films are then collected on day 4 to preliminarily 
assess the activity of chemotherapy agents. The 4-day blood schizontocidal test 
is similar to the suppression test except mice are inoculated with 106 P. berghei 
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parasites on day zero and receive a dose on days 0, 1, 2 and 3 via a chosen 
administration route and dose as determined from the preliminary suppressive 
test. The ED50 and ED90 are then determined from semi log time-density plots 
from parasite data thin films prepared on day 4. 
1.5.9 Humanised models of murine malaria 
In attempts to bridge the gap between murine models and the clinical setting, 
development has gone into murine models containing human parasites. 
Humanised mouse models use immune compromised mouse strains such as 
scid (severe combined immunodeficiency), and NSG (NOD Scid gamma), 
sometimes in combination with pharmacological agents, to suppress the host 
immune responses [20, 344]. Human erythrocytes are then grafted into the 
animals, for example via a course of i.p. or retro-orbital injections, along with 
human serum to improve human erythrocyte survival [18]. This is continued until 
human erythrocytes constitute sixty percent of the host erythrocytes where upon 
they are inoculated with human parasitised RBC. As well as addressing the 
erythrocytic cycle, humanised models are in development to investigate 
gametocyte production, sequestration and liver infection. Liver investigation in 
humanised models is based on injections that kill murine hepatocytes followed 
by transplantation of human hepatocytes [18]. 
 
There are obvious potential benefits to humanised murine models of malaria in 
providing a relatively low cost (compared with clinical trials), high throughput in 
vivo model for human malaria [380]. However, they still require development, 
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characterisation and validation. These models also have certain disadvantages 
over more established and conventional murine malaria models such as cost 
and experimental complexity. Additionally P. falciparum is the only human 
parasite that has a humanised model, and this model is still incomplete [18]. 
Nevertheless humanised murine models have the potential to provide a useful 
tool for drug discovery and testing therapeutic efficacy, once validated [18]. 
 
No animal model, even those humanised, are prefect models of the human 
condition and disease. These models however do provide a useful insight into 
many aspects of disease and its treatment. Extrapolation from murine models to 
clinical practice should be explored with caution, and supported with clinical 
experimental evidence.  
 
“A model is useful if it sharpens questions, points to what is missing in our data 
or in our conceptual grasp, and contributes to a larger process that will render it 
obsolete; a model that cannot be shown to be wrong is typically of little use.” 
[245] 
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1.6 Aims of this thesis 
The emergence and spread of clinical resistance to all antimalarial compounds, 
including the artemisinins more recently, highlights the need to improve and 
protect the use of existing chemotherapies. Antimalarial treatment strategies 
have been limited by the paucity of pharmacodynamic information for dosage 
regimen design. 
 
Although murine malaria models have primarily been used for in vivo screening 
of new antimalarials, there is potential for broader applications. It is postulated in 
this thesis that a murine model could be used for pre-clinical stages of drug 
development, especially in dose-response studies, rational dose regimen design 
and evaluation of combination therapies. Sufficiently characterised, this in vivo 
malaria model could be used to provide detailed pharmacodynamic data for 
development of a mathematical in silico model of murine malaria. Such an in 
vivo-in silico model of murine malaria could provide an inexpensive, readily 
achievable and efficient malaria model to assist in optimisation of new and 
existing antimalarial therapies.  
 
Whilst the overall aim of this thesis was to investigate and develop a P. berghei 
in vivo-in silico murine malaria model as a tool for the pharmacodynamic 
assessment of antimalarial drugs, the specific objectives included: 
  
  81 
1. To develop an in vivo P. berghei murine malaria model capable of 
producing detailed pharmacodynamic dose response data. 
The P. berghei infection was characterised to develop an in vivo P. 
berghei model of malaria. The pharmacodynamic properties of 
dihydroartemisinin were investigated through a sub-therapeutic single 
dose study. It was hypothesised that this would provide detailed parasite 
pharmacodynamic graded dose response data (Chapter 3; Paper I). 
 
2. To develop an in silico mathematical model of P. berghei murine 
malaria and single dose dihydroartemisinin treatment. 
The previous investigations detailed the characterisation of an in vivo P. 
berghei model of murine malaria and treatment with dihydroartemisinin. 
These data were used to develop a mathematical model of P. berghei 
infection and treatment. It was hypothesised that such a mathematical 
model could be used to simulate parasite dynamics of single dose 
treatment (Chapter 4; Paper I).  
 
3. To develop an in silico mathematical model of P. berghei murine 
malaria and multiple dose dihydroartemisinin treatment. 
It was hypothesised that the in vivo-in silico model could be further 
developed to predict parasite dynamics after multiple dose treatment with 
dihydroartemisinin and to allow prediction of an optimised multiple dose 
treatment regimen (Chapter 5).  
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4. To develop an in silico mathematical model of P. berghei murine 
malaria and combination treatment. 
It was hypothesised that the in vivo-in silico model could be extended to 
other drugs (chloroquine) and that a combination dihydroartemisinin-
chloroquine in silico model could be used to optimise and evaluate 
combination treatment (Chapter 6).  
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CHAPTER TWO 
 
2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and Materials 
Artesunate (ARTS), dihydroartemisinin (DHA) and artemisinin (QHS) reference 
standards were gifts from Colonel Brian Schuster (Walter Reed Army Institute of 
Research, Washington DC, USA). DHA was obtained from Dafra Pharma NV 
(Turnhout, Belgium). All general chemicals were of analytical grade and were 
obtained from Sigma Aldrich (St Louis, MO, USA), BDH Laboratory Supplies 
(Poole, England) or Merck Pty. Limited, Kilsth, Victoria, Australia. De-ionized 
water was used for preparation of all buffers and aqueous solutions. 
Pentobarbitone injection was sourced as Nembutal, 60mg/mL, Boehringer 
Ingelheim Pty Ltd, Artarmon, NSW and was diluted with saline to 12mg/mL. 
 
Sterile disposable syringes and needles were obtained from Becton-Dickinson 
Medical Products (Singapore) or Terumo Medical Corporation (Elkton, MD, 
USA). Millex 0.22m disposable sterilizing filters were obtained from Millipore 
Corporation (Bedford, MA, USA). Sodium fluoride and sodium citrate blood 
collection tubes (Vacutainer) were obtained from Becton-Dickinson Medical 
Products (Rutherford, NJ, USA). 
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2.1.2 Parasites 
P. berghei ANKA parasites (Australian Army Malaria Institute, Milpo, QLD, 
Australia) were used for all experimental work. P. berghei ANKA was used as it 
is a well established model for testing antimalarial drug efficacy. It is 
characterised with a high mortality in rodents and is sensitive to all current 
antimalarial drugs [291].  
2.1.3 Mice 
An initial series of studies were undertaken to determine the age, weight and 
sex of animals to be used in further studies. A series of pilot studies were carried 
out which compared 6-8 week old male Swiss mice with 5-6 week old male 
Swiss mice and 5-6 week old female with male Swiss mice. 5 week old male 
Swiss mice were determined to be the most suitable experimental host as 
infection was stable and reliably reached 5% after 72 h following intra peritoneal 
infection. Additionally,  male mice were selected because they are slightly larger 
than females of the same age and there can be physiological and biochemical 
complications with females due to hormone fluctuations [213]. 
 
Experimental work was performed using male out bred albino Swiss Arc:Arc(S) 
mice aged five weeks (Animal Resources Centre, Murdoch, Western Australia). 
Original breeding stock of Arc:Arc(S) mice was received from the Charles River 
Breeding Laboratories (Kingston, NY). The out bred Swiss model was selected 
as it provided an economical and robust model.  
 
  85 
P. berghei malaria infection was maintained in inbred albino male BALB/c Arc 
mice aged 8 weeks (Animal Resources Centre, Murdoch, Western Australia). 
The strain is well established for passage of P. berghei infection as the animals 
are easy to handle, provide a stable infection for weekly passage and minimal 
immunological complications. 
 
Male out bred albino Swiss Arc:Arc(S) mice aged five weeks (Animal Resources 
Centre, Murdoch, Western Australia) were used throughout the course of 
experimental work as sentinel mice. Sentinel mice were housed in separate 
cages on racks containing experimental mice cages. They received the same 
food, water and bedding as experimental mice. Sentinel mice were replaced 
every three months at which time their blood was harvested and sent for 
laboratory testing (Murine Virus Monitoring Service, Gilles Plains, South 
Australia) against a panel of known murine viral pathogens, including mouse 
hepatitis virus, mouse parvovirus and mouse pneumonia virus. Sentinel mice 
remained pathogen free for the duration of the research. 
2.1.4 Animal welfare 
All studies were conducted in accordance with the National Health and Medical 
Research Council (NHMRC) Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes (1990). The studies were approved by the 
Animal Ethics Committee of Curtin University of Technology. 
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2.1.5 Euthanasia 
Animals were monitored and weighed daily during experiments. Animals were 
euthanized using a 20mg/mL i.p. pentobarbitone injection if animals were 
observed to be suffering. Additionally infected mice were euthanized if 
peripheral parasitaemia exceeded 40% and/or body weight decline by >10% in a 
24 h period, both of which were found to be indicative of terminal deterioration in 
health of malaria-infected mice.  
2.1.6 Animal holding 
Mice were housed in the School of Pharmacy Animal Holding Facility (Curtin 
University of Technology, Bentley, Western Australia) at 22°C in a 12 h day/12 h 
night cycle with free access to sterilised commercial rodent food (Glen Forrest 
Stockfeeds, Perth, Western Australia) and sterilised water (pH 2.5). Non-porous, 
translucent plastic cages with stainless steel tops were used to house mice. 
Small and large cages were used with a maximum of 4 mice held in small cages 
and up to 12 in large cages. Drip dispenser plastic autoclavable drinking bottles 
with stainless steel tops and rubber o-rings were used to hold drinking water. 
 
ALPHA-dri (Shepherd Specialty Papers; Able scientific, Perth, Western 
Australia) was selected as bedding material. This cellulose product produces 
lower levels of dust and does not contain chemical or compounds that may 
affect animal physiology like some wood chip bedding products [194]. 
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Acidified drinking water was provided for mice to prevent bacterial 
contamination. The pH 2.5 water was prepared by adding 400L of 32% w/v 
hydrochloric acid to 1 L Schott bottles of de-ionised water. Prior to provision to 
mice, water was autoclaved for 20 minutes at 121C on a fluid cycle (School of 
Pharmacy, Curtin University, Perth, Western Australia). 
 
All cage components, feed and bedding were autoclaved prior to use at 121C 
for 15 minutes on a hard goods cycle (School of Pharmacy, Curtin University, 
Perth, Western Australia).  
2.2 Methods 
2.2.1 Initial P. berghei malaria infection 
To establish the infection a suspension of cryopreserved P. berghei parasites 
was thawed and 200L injected i.p. into two 8-week-old male Balb/c mice. Intra 
peritoneal injection was chosen as the route of administration because it was 
considered to be more versatile when considering formulation of different 
pharmaceuticals and reproducible when injecting large numbers of young mice 
than the i.v. route. Each day the mice were weighed and a blood sample 
obtained from the tail vein using a 26G needle and 100L heparinised micro-
haematocrit tube. 
 
Approximately 7 days after infection mice were anaesthetised with 150L of 
12mg/mL pentobarbitone sodium (Nembutal Injection, 60mg/mL, Boehringer 
Ingelheim Pty Ltd, Artarmon, NSW diluted with saline) and blood was removed 
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via cardiac puncture and placed into a sodium citrate blood collection tube 
(Vacutainer containing 0.5mL of 0.129M solution, Becton-Dickinson, NJ, USA). 
100L of blood was used to infect two healthy mice. 
2.2.2 Passage of the P. berghei malaria infection 
7 days after infection, at parasitaemia of approximately 20%, mice were 
anaesthetised with 150L of 12mg/mL pentobarbitone sodium. All available 
blood was removed through cardiac puncture using a 26G1/4” needle from the 
ventricle after a midline incision to the sternum and cutting of the diaphragm. 
Blood was placed in a sodium citrate blood collection tube (Vacutainer 
containing 0.5mL of 0.129M solution, Becton-Dickinson, NJ, USA). 40L of 
blood was diluted in 8mL Red Cell Diluent (1% of 40% formaldehyde in 109mM 
Trisodium Citrate, Appendix A2.4) and gently mixed. 10L of this solution was 
then placed into an improved Neubauer counting chamber and the number of 
erythrocytes in 10 squares on the grid was counted. The number of erythrocytes 
per L was determined using Equation 2.1. 
Erythrocyte Count (per L) =  
(No. of cells counted in 10 squares)/Volume x Dilution Factor 
Where Volume = 0.04 and dilution factor = 200 
Equation 2.1 
The volume of blood containing 10×107 infected erythrocytes was then removed 
from the citrate collection tube and diluted to 1mL using citrate-phosphate-
dextrose solution (pH 6.9; Appendix A2.3). 100L of this solution was then 
passaged by i.p. injection into healthy mice. 
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2.2.3 Cryopreservation of P. berghei malaria 
Periodic samples of infected erythrocytes were cryopreserved to ensure access 
to viable P. berghei should the weekly infection maintained in BALB/c mice fail. 
Blood remaining in the citrate blood collection tube after passage was 
centrifuged at 3000g for 10 minutes to collect the erythrocytes. The supernatant 
was removed and the red cell pellet resuspended in saline (0.9M NaCl), and 
centrifuged at 3000g for 10 minutes. The red cells were washed twice in this 
way and then resuspended in 1mL 10% glycerol in Alsever’s Solution (Appendix 
A2.5) then placed in a 1.5mL eppendorf tube and stored at -80°C. 
2.2.4 Preparation and staining of blood films 
Peripheral thin blood films were prepared using blood collected from the tail vein 
of mice. Single drops of heparinised blood from micro haematocrit tubes were 
placed at the base of clean glass slides (1.0-1.2mm thick 76×25mm rounded 
glass slides with frosted end; Rowe Scientific, WA, Australia). The edge of 
another slide held at 45 degree was drawn back into the blood drop and spread 
up the slide with a smooth, uninterrupted movement producing a section of 
blood smear with a uniform monolayer of cells. Slides were dried in air at 22°C 
prior to staining. The thin film was fixed in methanol for 1 min, stained in freshly 
prepared Giemsa stain solution for 20 min, rinsed with distilled water and dried 
in air. The Giemsa stain solution was prepared by diluting Giemsa stock 10% in 
Sorenson’s phosphate buffer (pH 7.0; Appendix A2.9). Once dried, slides were 
cover slipped using DePex mounting medium and 22×60mm glass cover slips. 
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2.2.5 Parasite enumeration and staging 
The peripheral parasitaemia was determined as a percentage of the total 
erythrocytes by microscopic examination using 100 × magnification of thin films 
under oil immersion with ×10 eye pieces. One of the eye pieces contained a 
square 10×10 graticule to facilitate parasite enumeration by providing a set field 
of view with overlayed grid. Parasite densities <0.5%, 0.5-5% and >5% were 
determined by counting 100, 30 and 10 fields of view respectively which 
provided an acceptable error as indicated in Table 2.1. In general, one field of 
view contained approximately 200 erythrocytes. 
 
The errors indicated in Table 2.1 represent the minimum variability without 
account for technical or observational errors. The confidence intervals were 
approximated using the formula p(z.SE(p)) when SE(p) is the standard error of 
p and z is 1.96 for 95% confidence intervals. SE(p) was calculated as [p(1-
p)/n]1/2 where p is the percentage parasitaemia and n is the total number of cells 
counted. 
Table 2.1 – rationale for number of field of views examined to accurately determine the 
percentage parasitaemia. 
Parasitaemia (%) 0.02 0.1 1 4 10 
No. FOV 100 100 30 30 10 
No. Red Cells 20,000 20,000 6,000 6,000 1,000 
No. Infected Cells 4 20 60 240 100 
95% Confidence Interval 0.02  0.04 0.25 0.49 1.86 
Upper 95% CI 0.04 0.14 1.25 4.49 11.86 
Lower 95% CI 0.0004 0.06 0.75 3.51 8.14 
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Some parasite films had the parasitised erythrocytes classified into the parasite 
life cycle stages. A morphological chart (Figure 2.1) was constructed and used 
to classify parasites as rings, early trophozoites, late trophozoites and 
schizonts).  
 
Ring stage parasites (B) were defined as having a defined nucleus with a 
crescent shaped edge to the vacuole. Early stage trophozoites (C) have a larger 
and partly filled vacuole while late stage trophozoites were defined as those with 
half to completely filled vacuoles (D). Schizonts were characterised by the 
presence of multiple nuclei, and no clear separation between nucleus and 
vacuole (E). 
2.2.6 Formulation of dihydroartemisinin 
In pilot studies 20% ethanol in propylene glycol was used as a vehicle for DHA 
in mice studies since it had been used in previous studies involving Wistar rats 
[40]. The solubility of DHA in ethanol however was not sufficient to allow 
injection of doses of DHA above ~75mg/kg without causing visible ethanol side 
effects to mice and compromising the experiments. With the intention of 
performing multiple dose studies requiring up to 5 doses of the vehicle, it was 
determined that ethanol was not a suitable vehicle in the mouse model. The 
LD50 for ethanol in Swiss mice is 8.1g/kg which equates to ~300µL per 30g 
 
Figure 2.1 – P. berghei morphological chart (A) uninfected erythrocyte, (B) ring stages, 
(C) early trophozoites, (D) late trophozoites, (E) schizonts and (F) merozoites. 
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mouse [394]. It was determined in future studies the vehicle dose would be too 
close to the LD50.  
 
A series of basic solubility studies were conducted to determine a suitable 
vehicle for DHA formulation to be administered i.p.. The vehicle was required to 
reliably carry 50mg/mL of DHA, so that a single dose of 100mg/kg could be 
administered to mice in 100L. Dimethyl sulfoxide (DMSO) was selected as it 
met the solubility requirements and also low toxicity of greater than 15g/kg in 
mice [183]. DMSO was mixed with polysorbate 80 (LD50 i.p. mice of 7600mg/kg) 
to further reduce the LD50 of the vehicle [327, 401]. For single 100L i.p. doses 
the proportion of the LD50 of the two components of the vehicle was ~15% of the 
DMSO LD50 and ~18% of the polysorbate 80 LD50. 
 
The vehicle toxicology was tested. Four groups of four 5 week old male Swiss 
mice were injected with 100, 200, 300 or 400L of 60% DMSO in polysorbate 
80. No ill effects were observed in any mice. 400L represents 60% of the 
DMSO LD50 and 72% of the polysorbate 80 LD50. 
2.2.7 Dihydroartemisinin treatment methodology 
DHA was formulated in 60% v/v DMSO in Polysorbate 80, with a final injection 
volume of 100μL. The vehicle dose was less than 25% of the LD50 for both 
DMSO and Polysorbate 80 in mice.  
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Groups (generally n=8) of five week-old male Swiss mice received either single 
or multiple i.p. treatment starting 72 h after inoculation with 107 parasites, with 
either 0, 1, 3, 10, 30 or 100mg/kg DHA. Parasitaemia was monitored as 
described above until mice were euthanized according to pre-determined 
guidelines (2.1.5). 
2.2.8 Modelling and statistical analysis 
All modelling was performed using SAAM II Simulation, Analysis and Modelling 
Software for Kinetic Analysis (University of Washington Seattle, USA). All 
statistical analysis was performed using SAAM II, SigmaStat 2004 (SPSS Inc., 
Chicago) and Microsoft Excel for Windows. Statistical Data was plotted using 
the statistical program SigmaPlot 2004 (SPSS Inc., Chicago). 
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CHAPTER THREE 
 
3. Establishing a murine malaria infection model 
3.1 Introduction 
Parts of the work in this Chapter have been published [39, 138]. Refer to 
APPENDIX 1 – Development of a pharmacodynamic model or murine malaria 
and treatment with dihydroartemisinin (pg 286). 
3.1.1 Development of antimalarial treatment regimens 
Antimalarial treatment regimens have traditionally been based on in vitro and 
clinical studies of drugs given alone or in combination, with particular focus on 
efficacy against P. falciparum. Although in vitro studies are valuable for 
screening antimalarial candidates and sensitivity testing [66, 160], they provide 
only limited pharmacodynamic information for dosage regimen design. Zaloumis 
et al [451] commented when assessing the utility of an antimalarial 
pharmacokinetic-pharmacodynamic (PK-PD) model for aiding clinical drug 
development that “the PD effect predicted from in vitro growth inhibition assays 
does not accord well with the PD effect of the antimalarial observed within the 
patient.”. 
 
 By comparison, well conducted clinical trials aim to assess parasite clearance 
and do not generate dose-response relationships that can be used in developing 
rational dosage strategies [222]. Novel pharmacodynamic models have been 
developed for a range of drugs [341], but there is a paucity of graded dose-
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response data from clinical studies of falciparum malaria. Due to this dearth of 
PD information antimalarial treatment strategies have tended to rely on PK 
information with limited PD information provided by clinical data from curative 
therapy. Ideally detailed PD information in the form of graded dose-response 
data would input into treatment strategy design to produce an optimised 
strategy. This is the goal of establishing PK-PD relationships; to be able to 
design an optimal regimen which maximises the effect of the drug per unit dose 
or improves the convenience of treatment regimens [143]. Various PD models 
have been proposed, however the inability to examine subtherapeutic doses 
clinically limits the extent to which human PD information can be gathered [104, 
105, 177, 347].  
 
In vivo animal models can potentially provide relevant information that is 
otherwise very difficult to acquire clinically or in vitro. Any modelling approach 
should not be considered as a replacement to conducting clinical trials, but 
instead as a decision-making tool to improve the design of a clinical trial during 
drug development.  
3.1.2 Antimalarial pharmacodynamics 
Pharmacodynamics is the quantitative relationship between the observed drug 
concentration and the magnitude of the observed effect or the relationship 
between the drug and its receptors, its mechanism of action and therapeutic 
effect [360]. In disease chemotherapy, optimised PD is the goal and requires an 
understanding of the PK. 
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There are difficulties with PD evaluations in malaria. The most obvious difficulty 
is practical aspects of monitoring the PD effect in the clinical setting. The PD 
effect is typically the parasite bioburden, and parasitological recovery is 
conventionally assessed by parasite clearance from peripheral blood smears 
[425]. The relationship between parasitaemia and disease, particularly in P. 
falciparum infection, is arguably loose, as patients can present with coma, liver 
and renal dysfunction with low peripheral parasitaemia [126, 420]. There is also 
the complication of late stage sequestering of parasites in falciparum infections. 
This is less of a confounding issue for other forms of human and animal malaria 
where peripheral parasitaemia is a more accurate reflection of the disease state. 
 
Immune status is also an important consideration in clinical PD. It has been 
understood since early reports by Yorke and Macfie [420] in 1924 that 
antimalarial treatment responses in semi-immune or immune patients is better 
than those in non-immune patients. For this reason in endemic areas age is an 
important factor in therapeutic response. Additionally immunity is temporarily 
disrupted in pregnancy and in certain infections. 
 
3.1.3 Animal models of malaria 
Isolation of wild non-human strains of malaria parasites have enabled the 
establishment of animal models for malaria which have a long established 
history in malaria research complementing in vitro and clinical research. They 
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are useful due to the limitations in scope and interpretation of in vitro studies as 
well as practical and ethical constraints in clinical studies. Animal models 
facilitate the examination of disease progression [332], host-parasite interactions 
such as immune responses [8, 88, 352, 448], organ studies [7, 10] and parasite 
disease mediation studies [332, 366, 369] which can ultimately lead to 
explanations of observations in humans. This is the goal of disease models, to 
better understand the disease in order to provide explanations for clinical 
observations, without putting humans at risk. 
3.1.4 P. berghei malaria 
Unlike P. falciparum in which sequestration of late stage parasites occurs, all P. 
berghei blood stages are visible in the peripheral circulation. Vinke and Lips 
(1948) described the morphology of P. berghei as follows:  
“The ring stage is usually uninucleate and contains a large vacuole. 
Trophozoites are nonvacuolated, slightly amoeboid and contain fine granules of 
black pigment which are left behind at schizogony when from 6-20 merozoites 
with small nuclei are formed from each schizont. Parasitized erythrocytes 
hypertrophy but show no granulation. Polyparasitism is frequent, the cytoplasm 
of the parasites merging into confluent masses 10.6µ in diameter, which stain 
dark blue with Giemsa and which frequently contain no pigment. In heavy 
infections, erythroblasts are found in the circulation and are often invaded. 
Gametocytes are 7-8µ in diameter.” 
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P. berghei is virulent in mice of all ages [57, 350] and displays more severe 
pathological changes and higher mortality rates than other rodent malarias. The 
100% mortality of P. berghei infection in mice is normally due to severe 
anaemia, causing hypoxia and hypothermia [57]  and death occurs from 5-20 
days according to the number of inoculating parasites. The mortality rate is a 
major reason for P. berghei being the animal model of choice for 
chemotherapeutic studies [81, 82, 292]. 
 
The erythrocytic life cycle of P. berghei in vertebrate hosts is approximately 24 h 
and Mercado and Coatney [250] observed in 1951 that the number of 
merozoites produced per schizont varied during the course of the infection. Early 
in the infection the average number was 8 while on the third and seventh patent 
days it was 5.5 and 12.8 respectively. Fragility of erythrocytes, as determined by 
the number of extracellular parasites, increased towards the end of the infection. 
 
Preferential invasion of reticulocytes by P. berghei merozoites was first noted in 
mice by Ramakrishnan and Prakash [313], while gametocytes developed 
exclusively in mature erythrocytes. The relationship between the number of 
parasites and reticulocytes has been suggested as an explanation as to why 
young animals become more heavily infected with P. berghei [179]. 
 
Vinke and van den Bulche [317] noted splenic enlargement and anaemia in 
infected mice in 1949. An increase in numbers of reticulocytes and erythroblasts 
as well as the presence of pigment in the liver, bone marrow and phagocytic 
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leucocytes in the circulation; and necrotic lesions in the liver have also been 
observed. 
 
Passage of P. berghei parasites is usually achieved by diluting a small quantity 
of blood from an infected host with a suitable diluent and injecting infected 
erythrocytes into a new host either intra peritoneally (i.p.) or intravenously (i.v.) 
via a tail vein [57]. A standard inoculation dose of 107 parasitised erythrocytes in 
100-200μL is commonly used in in vivo studies with P. berghei [57, 433]. 
Parasites have been shown to penetrate the mouse peritoneal wall into the 
blood stream within one minute of inoculation [44]. After inoculation an 
exponential increase in parasitaemia is observed, until a peripheral parasitaemia 
of 10-50% is achieved [350]. Rapid rises in parasitaemia and subsequent 
erythrocyte destruction can cause anaemia and host death within 5 days post 
inoculation [57, 350]. 
3.1.5 P. berghei chemotherapy screening tests 
A number of standard P. berghei in vivo tests have developed since the 1950s 
when P. berghei models were first discovered, which are still in use today. 
These tests are commonly referred to the “Peters 4-day test” or simply the “4-
day test” and the “Rane test” and originally developed as antimalarial screening 
tests. In the 4-day test drug treatment commences only hours after P. berghei 
infection and is repeated over 4 days after which parasite bioburden is 
compared with that in untreated mice via counting thin films. The 4-day test is 
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often referred to as a suppression test since treatment commences soon after 
infection. 
 
The Rane test differs from the 4-day test in that drug treatment commences 72 h 
post inoculation with P. berghei. In this case the infection is established and so 
the test is more representative of treatment rather than infection suppression. 
After 72 h post infection, groups of animals are treated with different 
concentrations of the antimalarial candidate. An increase in animal survival past 
7 days is considered the minimum effective response for an active compound. 
Compounds which increase animal survival past 30 days are considered 
curative [278].  
3.1.6 P. berghei as a pharmacodynamic malaria model 
The 4-day and Rane tests have tended to be employed as relatively simple 
screening tests that provide very useful, but limited pharmacodynamic 
information. This information tends to be either the level of suppression or cure 
of infection by a compound relative to control mice, or relative to an established 
antimalarial such as chloroquine. 
 
There is the potential for a murine P. berghei model to be used to collect 
pharmacodynamic information on drug doses on the parasite population in the 
form of graded dose responses. This type of model could be based on the Rane 
test, with groups of mice infected and treatment starting 72 h later at an 
appropriate level of parasitaemia in an established infection. Much more regular 
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monitoring of parasitaemia through thin films than is seen in drug screening 
tests could provide detailed graded responses. The data from these P. berghei 
studies could potentially be scaled and used as input into clinical studies as a 
starting point to rational design of treatment regimens and multiple dose 
treatment timing. It also may provide a model to screen and assess effective 
combination therapies. 
 
Despite the development of other research models of malaria including 
humanised mouse models [18] and efficacy testing in human volunteers [119, 
244] there still exists a question about where detailed PD information can be 
reliably, cheaply and quickly obtained for antimalarial candidates in order to 
optimise treatment regimens [423]. Murine malaria is the only model that can 
realistically fill this gap. It would however, need to be part of a larger effort using 
for example, testing in a P. falciparum model in human volunteers and clinical 
studies. 
3.1.7 Artemisinin 
Early study of qinghaosu was carried out by the Qinghaosu Antimalaria 
Coordinating Research Group and results were published in English in 1979 
[152]. This reported chemical, pharmacological and clinical results for studies 
using artemisinin. Pharmacologic studies reported 138.8mg/kg as the ED50 in 
mice against P. berghei, which were treated with 50mg/kg daily for 3 days. 
Monkeys infected with P. cynomolgi were treated with 200mg/kg daily for 3 days 
however 5 of 7 of the monkeys showed recrudescence. The LD50 in mice was 
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reported to be 5105mg/kg orally, 2800mg/kg i.m. and 1558mg/kg i.p.. 2099 
human patients were effectively treated with Qinghaosu as either 2.5-3.2g 
tablets, 0.5-0.8g oil, 0.8-1.2g oil suspension or 1.2g water suspension, all given 
i.m. except for the tablets which were taken orally. The recrudescence rate was 
greater than 25%, and greater than 80% for the tablet treated group against P. 
falciparum infections [152]. The Qinghaosu Antimalaria Coordinating Research 
Group concluded that artemisinin could be given at a dose of 300mg daily for 3 
days, and recommended the intramuscular route for optimum clinical efficacy 
[152]. 
 
A series of reports was subsequently published by the China Cooperative 
Research Group on qinghaosu and its derivatives as antimalarials in 1982 
outlining pharmacokinetic and pharmacodynamic data of artemisinin and several 
semi-synthetic derivatives [1-4]. These findings were confirmed by Hien and 
White [171] a decade later and since that time the artemisinins have become 
front line treatment for malaria globally in the battle against malaria and drug 
resistant parasites. 
 
Artemisinin monotherapy was registered in Vietnam during the 1990s as a first-
line treatment. In vitro testing against P. falciparum led to clinical trials of various 
regimens which are shown in Table 3.1. Artemisinin monotherapy was required 
to continue for at least 5 days to reduce recrudescence, and a single dose of 
artemisinin and mefloquine was the most practical, effective, safe and 
inexpensive treatment for uncomplicated malaria [170]. 
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Table 3.1 – Summary of clinical trials of artesunate monotherapy in the treatment of 
patients with P. falciparum malaria taken from Barrell and Fitton 1995 [31]. 
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A major disadvantage of monotherapy with artemisinin and its family of 
antimalarials is the high recrudescence observed in clinical studies [106]. The 
short terminal half-life of artemisinins has been suggested as the reason for low 
monotherapeutic efficacy and as a result the artemisinins are best suited to use 
in artemisinin combination therapy (ACT) with longer half-life antimalarials with 
differing mechanisms of action [22, 242, 305]. ACTs are recommended for 
treatment of uncomplicated malaria throughout the world [430]. 
 
Artemisinin itself has not been used in ACTs because of its time dependent 
pharmacokinetics and low bioavailability. Artemisinin and artemether also have 
a marked ability for enzymatic auto induction when administered over several 
days [23, 145, 399]. 
 
It is believed that artemisinin resistance has emerged, which compromises the 
efficacy of the antimalarial combinations currently in use [207]. The impact of 
artemisinin resistance is therefore potentially large because hundreds of millions 
of doses of artemisinin combination treatments are dispensed every year [343]. 
Descriptions of artemisinin resistance do not always fulfil classical criteria for 
antimalarial resistance [14, 114, 298]. 
3.1.8 Artemisinin-based antimalarial monotherapies 
A comment by Looareesuwan et al [235] on the purpose of their 1997 report on 
monotherapy studies into artemisinins raises some questions about the rational 
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design and implementation of antimalarial therapy regimens in the clinical 
setting. 
 
“Although it is generally accepted that effective treatment with sodium 
artesunate monotherapy requires administration for 5-7 days, there is little 
evidence to support this.” 
 
Barradell and Fitton [31] succinctly reviewed artesunate monotherapy in 1995 
(Table 3.1). Clinical trials with artesunate demonstrate that artemisinin 
monotherapy is highly effective for the treatment of acute malaria and that 
recrudescence with artemisinins is a significant problem, especially for short 
treatment regimens. Results from artesunate monotherapeutic studies indicate 
that treatment regimen duration, rather than total dose seems to be more 
important in reducing recrudescence [60]; treatment duration of 5 days or 
greater is required to achieve acceptable cure rates [62] and there is no benefit 
to 12 h dosing over 24 h dosing [61].   
3.1.9 Dihydroartemisinin 
Dihydroartemisinin (DHA) is a sesquiterpene lactone, a semi synthetic derivative 
and active metabolite of artemisinin. DHA has a very short plasma half-life  in 
the order of 40-60 minutes [37]. Due to poor solubility and possible instability 
DHA has not been clinically utilised as much as other artemisinins [227]. This is 
despite the fact that DHA has been demonstrated to display greater in vitro and 
in vivo activity against P. berghei than either ART or QHS [186] with little 
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difference between their efficacy in clinical trials [171]. DHA has been combined 
with piperaquine as an efficacious combination treatment against P. falciparum 
[189, 359]. 
 
Dihydroartemisinin provides an interesting and clinically relevant antimalarial 
compound with which to examine the benefits of a pharmacodynamic model of 
murine malaria. The artemisinins will remain important in antimalarial therapy for 
many years to come and elucidation of their mechanisms of action and 
resistance, as well as optimising dosing regimens and combination antimalarials 
will be crucial in protecting this class from the emergence and spread of serious 
clinical resistance. 
3.1.10 Aims 
It is postulated that animal studies could be used as an appropriate intermediate 
stage of drug regimen development, between in vitro studies and clinical trials. A 
murine model was considered to be an established, convenient and cost-
effective choice, whilst the use of an artemisinin-based drug has contemporary 
clinical relevance in pharmacodynamic model development. 
 
The aims of the present series of studies were to develop an in vivo murine 
malaria model that could eventually be used to investigate both dose-response 
and regimen characteristics for antimalarial drugs, and ultimately to develop 
strategies for combination therapies. The initial aims were to: 
(i) Establish and characterise a murine model of malaria 
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(ii) Validate a parasite enumeration procedure 
(iii) Determine an infection regimen to allow examination of drug treatment 
(iv) Formulate DHA for injection 
(v) Determine approximate dose response range for DHA administration 
(vi) Validate the murine model by investigating pharmacodynamics of 
graded single-dose treatment using DHA. 
The hypotheses to be tested were: 
(i) A reproducible and stable P. berghei infection model can be estab-
lished to enable study of P. berghei infection and drug treatment. 
(ii) A P. berghei infection model can be used to obtain detailed pharma-
codynamic data on parasite population response to drug 
administration. 
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3.2 Methods 
3.2.1 Mice 
The studies were approved by the Animal Ethics Committee of Curtin University 
of Technology. All mice were obtained from the Animal Resources Centre 
(ARC), Murdoch, Western Australia. Male Swiss mice aged five-six weeks were 
used for experimental work. Male BALB/c mice aged 7-8 weeks were used to 
maintain the P. berghei infection. 
3.2.2 P. berghei infection 
Erythrocytic stages of P. berghei were maintained in 8-week-old male Balb/c 
mice and passaged weekly. The initial infection of ANKA P. berghei parasites 
was established from a suspension of cryopreserved P. berghei parasites 
(ANKA strain; originally obtained from the Australian Army Malaria Institute, 
Milpo, QLD, Australia) as described in 2.2.1. Blood harvested from infected 
BALB/c mice in citrate-phosphate-dextrose solution was administered by i.p. 
injection to infect the experimental mice. 
3.2.3 Hosts and dihydroartemisinin ranging studies 
A series of studies were undertaken to determine the age, weight and sex of 
animals to be used in further studies. A series of pilot studies were carried out 
which compared 6-8 week old male Swiss mice with 5-6 week old male Swiss 
mice and 5-6 week old female with male Swiss mice. All animals were infected 
with 107 parasitised erythrocytes i.p. and assigned into untreated control groups 
or into dose ranging groups to test the concentration of the lower therapeutic 
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limit of DHA. Doses of 0.1, 1, 10 and 25mg/kg DHA in 20% ethanol and 80% 
propylene glycol were administered approximately 72 h after infection and 
infection progression was monitored by once daily tail vein bleeds. The vehicle 
of 20% ethanol in propylene glycol was initially used as this was being used in 
parallel rat microsomal studies in the same laboratory. In further studies it was 
determined that ethanol in propylene glycol was an inappropriate vehicle for 
DHA in mice as increasing concentrations of DHA required vehicle 
concentrations approaching the LD50 of ethanol in mice. 
 
It was determined that male Swiss mice at 5-6 weeks provided animals of a 
suitable weight (~30g) and size for handling and blood sampling for a PD model 
of malaria. Female Swiss mice were deemed too small and light (~20g) and 
there were some indications in the literature that female oestrus can create 
variations in results in chemotherapeutic research [429, 453]. Five week male 
Swiss mice provided the youngest feasible animal subjects possible. This age 
was selected to provide animals with immature immune systems for the PD 
model for as long as possible for potential use in multiple dose studies in which 
mice may survive for many weeks. The age would reduce the influence and 
possible complications due to the immune system in more mature mice as much 
as possible. Subsequently for all experimental studies recipient male Swiss mice 
aged five weeks received an i.p. inoculation of parasitised erythrocytes.  
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3.2.4 Parasite enumeration and staging 
Parasitaemia was measured by microscopic quantitation from Giemsa-stained 
thin blood film smears made from tail vein bleeds as described in 2.2.5. A 
morphological chart (Figure 3.1) was constructed and used to classify parasites 
according to standard definitions of malaria morphological stages as rings, early 
and late trophozoites and schizonts [185]. 
 
Ring stage parasites (B) were defined as having a defined nucleus with a 
crescent shaped edge to the vacuole. Early stage trophozoites (C) have a larger 
and partly filled vacuole while late stage trophozoites were defined as those with 
half to completely filled vacuoles (D). Schizonts were characterised by the 
presence of multiple nuclei, and no clear separation between nucleus and 
vacuole (E). 
3.2.5 Parasite inoculation studies 
Parasite inoculation studies were conducted to determine the most appropriate 
number of P. berghei infected RBCs to inoculate experimental mice with, in 
order to provide a stable reproducible model with an appropriate parasitaemia 
for drug studies. Four groups of three, five week old Swiss male mice were 
infected with either 105, 106 or 107 parasitised erythrocytes. The infection was 
 
Figure 3.1 – P. berghei morphological classification chart showing uninfected RBC(A), 
ring stages(B), early trophozoites(C), late trophozoites(D), schzonts(E) and merozo-
ites(F). 
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followed and thin blood films taken daily to monitor the development of the 
infection with different infecting inocula sizes. Subsequently for all experimental 
studies, recipient male Swiss mice aged five weeks received an i.p. inoculation 
of 107 parasitised erythrocytes. 
3.2.6 Erythrocyte population and blood studies 
Erythrocyte population and blood studies were conducted in order to 
characterise blood changes and other pathophysiological aspects of the P. 
berghei infection in the Swiss mouse model.  Haematological changes are a 
common and obvious complication with malaria infections and include anaemia, 
white blood cell changes, thrombopathy and coagulopathies [246, 247, 362-
364]. Erythrocyte population studies were conducted on five week old Swiss 
mice infected with 107 parasites. Eight mice were euthanized (pentobarbitone 
sodium 100mg/kg i.p.) every 24 h for 7 days after inoculation. Heparinised blood 
was harvested by cardiac puncture and red cell blood count (mean of triplicate 
measurements) was determined using a Cell-Dyn 3500 automated 
Haematology Analyser (Diamond Diagnostics, Massachusetts, USA). Since 
mouse RBCs are smaller than human cells, the samples were run under the 
Veterinary mode using a Mouse parameter setting. As cell separation and 
counting occurs due to pre-calibrated mean corpuscular volume values, this 
ensured that red blood cells were counted as such, rather than being counted as 
large platelets in the human mode. Parasite density in the blood also was 
measured at each time point. 
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As well as erythrocyte and parasite density data, white blood cell population 
changes, haemoglobin concentration and platelet concentration data were 
collected over the course of infection using a Cell-Dyn 3500 automated 
Haematology Analyser (Diamond Diagnostics, Massachusetts, USA). Spleen, 
liver and whole body weight measurements were also taken. 
3.2.7 Formulation of dihydroartemisinin 
Ethanol and ethanol in propylene glycol was used as a vehicle for DHA in mice 
studies as it had been used in previous studies, involving Wistar rats in our 
laboratory, which do not make up part of this Thesis [40]. The solubility of DHA 
in ethanol however was not sufficient to allow injection of doses of DHA above 
50mg/kg or multiple doses within 24 h in Swiss mice without causing visible 
ethanol side effects and compromising the experiments. A series of solubility 
studies were conducted to obtain a suitable vehicle for DHA formulation to be 
administered i.p. 
3.2.8 Dihydroartemisinin treatment 
Dihydroartemisinin was formulated in 60% v/v DMSO in Polysorbate 80, with a 
final injection volume of 100μL. The vehicle dose was less than 25% of the LD50 
for both DMSO and Polysorbate 80 in mice [327]. Initial safety studies were 
conducted using the drug vehicle at doses up to 400μL (for 30 g mice), with no 
observed adverse effects. 
 
Five groups (n=8) of five week-old male Swiss mice received a single i.p. 
treatment 72 h after inoculation with 107 parasites, with either 0, 1, 3, 10, 30 or 
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100mg/kg DHA. Parasitaemia was monitored as described above until mice 
were euthanized according to pre-determined guidelines (parasitaemia >40% 
and/or body weight decline by >10% in a 24 hperiod, both of which were 
determined to be indicative of terminal deterioration in health of malaria-infected 
mice). 
3.2.9 Dihydroartemisinin pharmacokinetics 
3.2.9.1 Drug administration and blood sampling 
Pharmacokinetic data for DHA in the P. berghei murine malaria model were 
collected. While PK investigations were not the focus of these studies, detailed 
PK data for the artemisinins in mice had not been previously reported. Studies 
have been reported in healthy and malaria-infected rats [224, 225, 311, 330, 
444, 445] suggesting that the elimination half-life for DHA is approximately 15-25 
minutes or two to three fold shorter than in humans [102]. 
 
Five week-old male Swiss mice were divided into healthy-uninfected (n = 66) or 
malaria-infected (n = 35) groups and the malaria-infected group received an i.p. 
injection of 107 uninfected RBC or 107 RBC as described previously (2.2.2). 
Approximately 72 h later post inoculation groups were administered 100mg/kg 
DHA. This occurred at a parasitaemia of approximately 5% in the malaria-
infected group, which was confirmed by thin film examination. All mice received 
100mg/kg sodium pentobarbitone 5-10 minutes prior to blood collection. 
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Blood was collected from the healthy group by cardiac puncture from groups of 
3-6 mice at each time point of 2, 5, 7.5, 10, 15, 20, 25, 30, 40, 50, 60, 90 and 
120 minutes after dosing (1mL fluoride/oxalate Vacutainer; Becton-Dickinson, 
Franklin Lakes, NJ). Blood was collected from the malaria-infected group in a 
similar manner from groups of 3-5 mice at each time point of 2, 5, 10, 15, 30, 45, 
60, 90 and 120 minutes. Blood was centrifuged at 3,000g for 7 minutes 
immediately after collection, and the plasma was separated and stored at -80C 
until analysis. 
3.2.9.2 Pharmacokinetic analysis 
Stock solutions of 1mg/mL of DHA and the internal standard 1mg/mL artemisinin 
(QHS) in 45% acetonitrile in 0.1M Walpole’s acetate buffer, pH 4.8 (A2.11) were 
prepared and stored in the dark at 4C. Solutions were determined to be stable 
under these conditions for several weeks. 
 
 
High performance liquid chromatography (HPLC) analysis was performed using 
a Waters 1525 binary pump, Waters 2487 Dual  absorbance detectors with a 
484 tunable absorbance detector. Separations were achieved using a 
LiChrospher 100 RP18 (5m) LiChroCART 250-4 C18 column with a Waters 
Symmetry C18 (5m, 3.9×20mm) guard column. The mobile phase was 45-50% 
acetonitrile in Walpole’s acetate buffer, pH 4.8(A2.11) at a flow rate of 
0.7mLs/min and post column derivatization with a solvent injection system at 
60PSI using 1.2M KOH in 90% methanol at 0.4mL/min with a 69C mixing block. 
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DHA in plasma was analysed using a validated HPLC assay [38] with 
modification of the extraction procedure. 200L of plasma was mixed with 
internal standard (20L of 5mg/L artemisinin in methanol), 100L of 0.1M 
Walpole’s acetate buffer, pH 4.8 (A2.11) and 900L of 20% v/v ethyl acetate in 
butanol chloride. The mixture was gently agitated for 10-30 minutes at room 
temperature and the organic layer (typically 700-800L) was aspirated and dried 
under nitrogen for 10 minutes. The residue pellet was reconstituted in 100-
150L of mobile phase (45-50% acetonitrile in Walpole’s acetate buffer, pH 
4.8(A2.11)), and the injection volume was 80L and injected using a Waters 717 
Plus autosampler. For each analytical batch a 5 or 8-point linear calibration 
curve was prepared using stock 1mg/mL DHA. 
 
Analysis of pharmacokinetic data was performed by Professor Kevin Batty 
(School of Pharmacy, Curtin University). The mean plasma concentration for 
each sub-group in the healthy and malaria-infected groups was used to 
generate pharmacokinetic parameters. Noncompartmental PK analysis 
(Kinetica, version 4.2; Thermo Fisher Scientific, Inc., Waltham, MA) was used to 
estimate the area under the plasma concentration-time curve (AUC), terminal 
elimination half-life (t½), apparent clearance (CL/F) and apparent volume of 
distribution (V/F). 
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3.3 Results 
3.3.1 P. berghei malaria model in Swiss mice 
The original P. berghei infection was established from cryopreserved stock on 
the 26 May 2001 in male Balb/c mice.  
3.3.2 Parasite inoculation study 
It was decided that a 5% parasitaemia would be used as a starting parasitaemia 
in later drug treatment studies. Drug studies were to be conducted in an 
established infection, and 5% parasitaemia represents a high enough 
parasitaemia to count blood films easily while the infection has not caused 
significant and irreversible physiological effects that may compromise 
experimental results. 5% also provides a starting infection in which the 
parasitaemia can drop over two orders of magnitude before the limit of detection 
is reached (2.2.5) (Figure 3.2). 
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3.3.3 Erythrocyte population studies 
The percentage parasitaemia increased from 0.07±0.02% 24 h after infection 
with 1×107 infected erythrocytes up to 67±11% at 7 days after infection (Figure 
3.3). Animals were euthanized at this point after a decrease in body weight of 
10% over 24 h, which was used as an indicator that the infection was severe in 
order to minimise animal suffering (Figure 3.4).  
 
Quantification of parasitaemia in a murine model is traditionally measured as a 
proportion, or percentage, of infected erythrocytes as in Figure 3.3. However, to 
characterise an infection model, it was considered necessary to convert the 
proportion of infected erythrocytes to the number of parasitised erythrocytes  
Days after inoculation
0 1 2 3 4 5 6 7 8 9
P
a
ra
s
it
is
e
d
 e
ry
th
ro
c
y
te
s
 (
/
L
)
106
2x106
3x106
4x106
5x106
6x106
7x106
 
Figure 3.2 – P. berghei infection after inoculation with 10
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Figure 3.3 – Parasite density and SD measured in percentage of infected erythro-
cytes over the course of the P. berghei infection (n=8 for each data point). 
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Figure 3.4 – Animal average body weight and SD during the P. berghei infection  (n=8 
for each data point) 
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per μL of whole blood. This is dependent on the erythrocyte count, which 
declines as malaria infection progresses (Figure 3.5), mainly due to clearance of 
parasitised erythrocytes by the spleen [230, 231]. There was no significant 
change in the erythrocyte population until after 72 h post infection, when the 
population decreased linearly until animals were euthanized (Figure 3.5). 
 
Since the decline in erythrocyte count with increasing parasitaemia was 
considered an important variable to be incorporated into the murine model, the 
first step in model development was to define the relationship between the 
degree of parasitaemia and the erythrocyte count based on erythrocyte 
population studies. 
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Figure 3.5 – Average and SD of the number of erythrocytes per L over the course of 
a P. berghei infection after inoculation with 10
7
 parasitised erythrocytes at T0 (n=8 
for each data point).  represent period from 72 h during which erythrocyte popula-
tion decreases in a linear fashion. 
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These studies showed a significant inverse linear relationship between the 
parasitaemia and the number of erythrocytes (Figure 3.6; r2 = 0.99; n = 64; P = 
0.05). The mean erythrocyte count in healthy mice (n = 7) was 8.6 ± 0.7  
106/μL. The relationship between erythrocyte count and parasite density was 
used to convert the percentage of parasitised erythrocytes determined by 
microscopy to parasitised erythrocytes/μL using Equation 3.1 below. 
         6106.8%085.001.0%/  iii EELE   
Equation 3.1 
where: Ei is the number of infected erythrocytes and Ei(%) is the 
percentage of total erythrocytes in the thin blood film. The 
slope (-0.085) and intercept (8.6  106) values were derived 
from the erythrocyte count versus parasitaemia data shown in 
Figure 3.6. 
 
The resulting relationship between the number of parasitised erythrocytes per 
L as infection progresses is shown in Figure 3.7. 
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Figure 3.6 – Erythrocyte count (mean  SD; n=8; triplicate analysis of each sample) 
verus parasitaemia in Swiss mice inoculated with P. berghei. There was a significant 
linear correlation between erythrocyte count and parasitaemia (P=0.05; r
2
=0.99; n=64). 
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Figure 3.7 – Parasitaemia (mean  SD; n=56) measured as the number of parasitised 
erythrocytes per L of blood over the time course of infection. 
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3.3.4 Pathophysiological studies 
During the erythrocyte studies other physiological parameters were measured in 
order to further understand infection. It was considered that this may be useful 
information in constructing a model of infection and disease progression in 
Swiss mice. White blood cell counts, liver weight, spleen weight, haemoglobin 
and platelet concentrations were determined from 8 sacrificed mice every 24 h 
during the course of infection for 168 h. 
3.3.5 Haemoglobin concentration 
During the course of P. berghei infection the whole blood haemoglobin 
concentration did not significantly change prior to 72 h post infection. From 96 
hours post infection the haemoglobin concentration began to decrease to 
approximately 50% by 168 h post infection (Figure 3.8). As expected this 
corresponds to the fall in erythrocyte concentration which also decreases after 
72 h to less than 50% control values as erythrocytes are removed and 
destroyed. 
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3.3.6 Platelet concentration 
During the course of the P. berghei infection platelet count decreased by up to 
50% by day 6 post infection (Figure 3.9). 
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Figure 3.8 – Whole blood haemoglobin concentration (g/L; mean  SD; n=8; ; triplicate 
analysis of each sample) as P. berghei infection progresses untreated. 
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Figure 3.9 – Blood platelet concentration (K/L; mean  SD; n=8; ; triplicate analysis of 
each sample) as P. berghei infection progresses untreated. 
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3.3.7 Liver and spleen weight 
During the course of the infection the liver weight as a percentage of the total 
body weight did not significantly change (Figure 3.10). Actual liver weights (i.e. 
not normalised using body weight) of infected mice therefore change over the 
course of the infection at a rate similar to whole body weight loss. 
 
The spleen of infected animals underwent-significant weight increase relative to 
body weight from 72 h post infection (Figure 3.11A). Normalised spleen weights 
increased by 50% as the infection progressed. The spleens were visibly 
enlarged and had much darker and mottled colouring relative to healthy spleens 
(Figure 3.11B).  
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Figure 3.10 – Liver to body weight ratio expressed as a percentage over the course of 
untreated P. berghei infection (mean  SD; n=8). 
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3.3.8 White blood cell population changes 
During infection progression there was an almost exponential increase in total 
white blood cell counts (Figure 3.12). The white cell population changed during 
the course of the infection with an increase in the ratio of eosinophils to other 
white cells, and a decrease in neutrophils (Figure 3.13). 
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Figure 3.11 – (A) Spleen to body weight expressed as a percentage over the course of 
untreated P. berghei infection (mean  SD; n=8). (B) Comparison of spleens from a 
healthy control (left) and P. berghei infected mice at 96 (centre) and 168 h (right) post 
infection alongside a ruler showing mm and cm increments. 
  126 
 
 
Time After Infection (hours)
0 24 48 72 96 120 144 168
W
h
it
e
 B
lo
o
d
 C
e
lls
(K
/u
L
)
0
5
10
15
20
25
30
 
Figure 3.12 – Change in white blood cell counts over the course of P. berghei infection 
(mean  SD; n=8). 
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Figure 3.13 – Change in white blood cell population counts over the course of P. 
berghei infection (mean  SD; n=8). 
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3.3.9 Dihydroartemisinin single dose treatment 
P. berghei showed a graded dose response to DHA treatment (Figure 3.14). For 
1, 3, 10, 30 and 100mg/kg doses nadir occurred approximately 18-24 h after 
administration and all doses were sub-therapeutic and leading to parasite 
recrudescence. 
3.3.10 Dihydroartemisinin treatment staging 
A series of blood films from a single mouse treated with 100mg/kg DHA at 72 h 
after inoculation were staged in order to examine changes in parasite population 
stages with DHA treatment and determine the usefulness of parasite staging 
data. Early stages (Rings) were least affected by DHA treatment while late 
stages (Schizonts) showed the greatest decrease (Figure 3.15). 
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Figure 3.14 – Graded dose response of P. berghei infection to 0, 1, 3, 10, 30 and 
100mg/kg DHA doses in Swiss mice (mean  SD; n=8 for each data point). 
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3.3.11 Dihydroartemisinin pharmacokinetics 
Pharmacokinetic data are shown in Figure 3.16. Analysis of pharmacokinetic 
data was performed by Professor Kevin Batty (School of Pharmacy, Curtin 
University). Pharmacokinetic parameters are shown in Table 3.2. The AUC in 
malaria-infected mice (1.630.11mg.h/L) was significantly lower than in healthy 
mice (1.960.10mg.h/L; P<0.05). The terminal elimination t½ values for DHA for 
healthy and malaria-infected mice were similar (Table 3.2, Figure 3.16). Data 
from this study were consistent with previous investigations in rats. 
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Figure 3.15 – Staging of P. berghei infection in a Swiss mouse treated with 100mg/kg 
DHA at 72 h post inoculation. 
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Table 3.2 – Pharmacokinetic parameters for IV DHA in mice 
 t½ (min) CL/F(L/h/kg) V/F (L/kg) 
Healthy Mice 18.8 50.9 23.0 
Malaria-infected Mice 24.6 61.3 36.3 
 
 
Minutes
0 20 40 60 80 100 120
D
ih
y
d
ro
a
rt
e
m
is
in
in
 (

g
/L
)
10
100
1000
10000
 
Figure 3.16 – Plasma concentration-time profile for DHA in P. berghei malaria-infected 
() and uninfected () Swiss mice. Data are mean  SD for 3-6 mice. 
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3.4 Discussion 
A murine model of malaria infection has been established. 107 infected 
erythrocytes administered i.p. were used to infect 5 week old male Swiss mice. 
Treatment commenced 72 h after infection when parasitaemia reached 
approximately 5% to allow treatment to be monitored in an established infection. 
Thin blood films were prepared regularly after drug administration and the mice 
can be carefully monitored as the infection progresses.  
 
An important consideration in establishing a model of antimalarial treatment was 
to characterise the level of parasitaemia at which treatment should begin. 
Starting treatment at a parasitaemia of 5% did not cause any visible distress to 
the mice, nor was it related to any significant changes in body weight, 
erythrocyte count or liver and spleen weights. Furthermore, the infection-time 
profile after DHA treatment could be followed until pre-determined experimental 
endpoints were reached (parasitaemia >40% and/or body weight decline by 
>10% in 24 h period), which was usually at least 3–5 days longer than controls, 
depending on the DHA dose. At starting parasitaemias of 0.5–1%, DHA was 
also effective, but due to low post-treatment parasitaemias it was only possible 
to characterise a partial infection-time profile across the full range of DHA doses. 
Hence it was concluded that the optimum starting parasitaemia for 
pharmacodynamic studies was 5%. 
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Ishih et al [182] reported that a complex relationship exists between parasite 
load and efficacy, and parasite levels influenced the outcome of CQ treatment in 
a P. berghei NK-65 model. It is therefore important that any in vivo malaria 
model should have a well defined treatment parasitaemia and be able to 
produce consistent and reproducible starting parasitaemia. For this reason 5% 
parasitaemia, rather than 72 h post inoculation, should be the trigger for 
commencement of treatment in the model.  
 
Characterising the time-dependent change in parasitaemia in the model 
described here depends on being able to accurately and efficiently determine 
parasite counts by light microscopy. In this regard, valid parasite densities at a 
parasitaemia of 0.5% can be determined by counting up to 30 fields of view 
(normally >6000 erythrocytes). By comparison, if 100 fields of view are counted, 
the limit of detection is a parasitaemia of about 0.004%. Hence, regular thin 
blood film monitoring of the malaria infection in this model can provide graded 
dose–response data over at least three orders of magnitude below the starting 
parasitaemia of 5%. In addition, if the decline and recrudescence phases of the 
infection are well characterised, it is possible to estimate a nadir at a 
parasitaemia of <0.0001% (<10 parasites/L) by logarithmic extrapolation. The 
level of PD evaluation that is possible with the model presented here is a 
substantial advance on conventional animal methods of measuring antimalarial 
efficacy. The ‘Peters 4-day test’ in which parasite inoculation is followed by four, 
once-daily doses of drug, commencing at the time of inoculation  [293], 
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demonstrates suppression of parasite growth/multiplication and is a well 
established rodent test for screening antimalarial drugs. By contrast, the Rane 
test [293] evaluates the effect of a drug on parasite elimination in an established 
infection, as has been demonstrated in efficacy studies of trioxolane antimalarial 
drugs [402]. Recent studies in rat models also show some features of the Rane 
test, but detailed dose–response relationships were not reported [226, 285, 
443]. 
 
The model development work described here is based on the principles of the 
Rane test, but there has been allowance made for both variation in parasite 
multiplication rate and changes in the erythrocyte count in describing 
progression of the infection. Characterisation of changes to the erythrocyte 
population during infection, allow for a more accurate and decoupled estimation 
of parasite population changes, which is particularly relevant as parasite 
densities exceed 10%. 
 
Hence the model presented in these studies provides a more flexible and 
pathophysiologically appropriate experimental framework for investigation of 
drug action and study of dosing regimens. The basic protocol for the 
experimental in vivo PD P. berghei murine model is summarised in Figure 3.17.  
 
The method was validated using graded single doses of DHA which provided 
detailed PD data of the P. berghei infection during drug treatment. Parasitaemia 
decreased quickly after DHA administration to nadir at between 18 and 24 h. 
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Interestingly the peak in parasite decline is approximately 24 h post 
administration while DHA has a very short plasma half-life of ~25 minutes in 
Swiss mice [39]. This would suggest that there is either a delay in the DHA 
induced killing of parasites and/or a delay in erythrocyte removal. Determination 
of the PK parameters for DHA in mice has not been previously reported, and 
while DHA pharmacokinetics were not the focus of these studies, it was 
demonstrated that detailed PK-PD data and relationships can be studied in this 
model. 
 
DHA studies show that a murine model of malaria treatment can provide an 
array of sub-therapeutic dose-response data that is not possible in clinical 
 
Figure 3.17 – Schematic representation of the study protocol used for antimalarial pharma-
codynamic efficacy studies. A 5% parasitaemia rather than a specific time should be used as 
the start of sub-therapeutic drug treatment. 
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studies. The model appears to be reproducible and stable and has provided 
robust dose-response data. 
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CHAPTER FOUR 
 
4. Establishing a mathematical model of murine P. berghei 
infection and single dose monotherapy with dihydroartemisinin 
4.1 Introduction 
Animal models of human disease can provide valuable information leading to 
insights into the human disease state. Investigations using animals to examine 
detailed pharmacodynamic (and PK) relationships between a drug, host and the 
disease (or parasites) require a large number of animals and a significant time 
investment. Pharmacokinetic and pharmacodynamic studies in the previous 
chapter utilised 40 mice to provide PD and 101 mice to provide PK data. While 
40 mice per graded single dose PD study may not seem large, when collecting 
detailed PD data as reported, the 81 data points represented in Figure 3.14 
comprise some 648 thin films. Considering future work in  multiple and 
combination dosing studies in the in vivo P. berghei model, and the aim of 
regimen optimisation, use of the model becomes questionable due to the time 
required without guarantee that optimisation will be truly demonstrable, or the 
results clinically relevant. 
 
Subsequent to the development of a robust in vivo murine model of malaria 
infection reported in Chapter 3, and embarking upon further PD studies, the 
question arose as to whether a mathematical model of murine malaria infection 
and specific drug treatment, could be developed to allow a large portion of 
experimental work to be carried out in-silico, with the results verified by animal 
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studies. In this way much of the drug treatment regimen design and optimisation 
could be mathematically simulated and then experimentally verified, saving both 
time and animals. 
4.1.1 Mathematical models – limitations and pitfalls 
The use of models is central to the scientific method. However, acceptance and 
application in the field of physiology and medicine often lags behind that of other 
disciplines. This is often due to the mismatch between the complexity of the 
processes in question and the limited data available from in vivo studies. The 
limitations in data collection are basically problems of measurement and are 
summed up by Cobelli et al [91] to include 
 restrictions on the number of variables and parameters – some 
physiological parameters cannot be measured and the frequency 
of sampling is often restricted; 
 many measurements are corrupted by noise due to experimental 
error or unwanted physiological disturbances; and 
 clinically there are some variables (e.g. patient discomfort) for 
which scales of measurement are not clearly defined and only 
qualitative concepts exist. 
 
Technological progress in medical imaging including PET (positron emission 
tomography) and MR (magnetic resonance) imaging are allowing collection of 
more detailed functional information less intrusively, and is beginning to 
overcome some of the traditional measurement problems associated with 
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physiology and medicine. This will likely enhance the scope to construct more 
accurate models of physiological processes and lead to a greater use of 
mathematical modelling techniques in the field. 
 
Mathematical modelling or “simulation” is a way of creating an artificial biological 
system in vitro for which properties can be changed. By externally controlling the 
model, new datasets can be created to explore aspects of the simulated model. 
In modelling, sets of differential equations and logic clauses are used to create a 
dynamic systems environment that can be tested. A model is an optimal mix of 
hypotheses, evidence, and abstraction to explain a phenomenon. Barh and 
colleagues made the following comment on in silico modelling [29]  
 
“in silico modelling in the life sciences is far from straightforward, and suffers 
from a number of potential pitfalls. Thus, mathematically sophisticated but 
biologically useless models often arise because of a lack of biological input, 
leading to models that are biologically unrealistic, or that address a question of 
little biological importance. On the other hand, models may be biologically 
realistic but mathematically intractable. This problem usually arises because 
biologists unfamiliar with the limitations of mathematical analysis want to include 
every known biological effect in the model. Even if it were possible to produce 
such models, they would be of little use since their behavior would be as 
complex to investigate as the experimental situation. These problems can be 
avoided by formulating clear explicit biological goals before attempting to con-
struct a model. This will ensure that the resulting model is biologically sound, 
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can be experimentally verified, and will generate biological insight or new 
biological hypotheses. The aim of a model should not simply be to reproduce 
biological data. Indeed, often the most useful models are those that exhibit 
discrepancies from experiment. Such deviations will typically stimulate new 
experiments or hypotheses. An iterative approach has been proposed, starting 
with a biological problem, developing a mathematical model, and then feeding 
back into the biology. Once established, this collaborative loop can be traversed 
many times, leading to ever increasing understanding.” 
 
There are two basic approaches to developing mathematical models. These are 
the data-driven approach or “modelling the data”, which is based upon 
experimental data, or the “modelling the system” approach, which is based upon 
a fundamental understanding of the physical and chemical process. These could 
be considered top down, or bottom up modelling approaches. The modelling 
discussed in this Chapter is based on data from Chapter 3 and may be regarded 
as a “modelling the data” approach. There are however inputs from assumptions 
about malaria in order to ensure the model is physiologically based, which fall 
under a “system modelling” approach. It can be argued that these assumptions 
are based on observation of malaria, rather than fundamentally understanding 
the system, so the model presented in the studies here was largely based on 
modelling the data.  
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4.1.2 Data modelling methodology 
Data driven or “black box” models seek quantitative descriptions of physiological 
systems based on input and output descriptions derived from experimental data 
collected on the system. The methodological framework is shown in Figure 4.1 
[90]. These types of models are appropriate where there are gaps in the 
understanding of the underlying physiology or when an overall representation of 
the systems dynamic inputs and outputs is required without specifying how the 
physiological mechanisms give rise to this behaviour [90]. 
 
Once data have been collected a data driven model can be constructed based 
on representations of input and outputs and initial parameters which are 
estimated from the data. The model then requires validation, which is an 
examination of whether the model is sufficient relative to its intended purpose. Is 
the model credible? Is the model output plausible? The basic methodological 
process of model construction and model validation is represented in Figure 4.2 
[90] and similarly to Barh and colleagues comments [29] highlights that 
modelling is an iterative approach; from biology, to model development and back 
 
Figure 4.1 – data driven modelling methodological framework, reproduced from 
Cobelli and Carson 2001 [90] 
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again. There are a number of salient points made by Cobelli and Carson [90] 
with respect to models 
 All models are approximations and should be flexible to include new data 
and observations. 
 A good model is clearly falsifiable. 
 Successful modelling is dependent upon quality data, and quality 
modelling. 
 
 
4.1.3 Mathematical models of infection 
There exists a multitude of mathematical models of human infection, from 
epidemiological models through to individual host-parasite models [15, 69, 76, 
92, 181, 202, 283, 310, 385, 392, 396]. The discipline of mathematical modelling 
of disease grew from the success of this approach in understanding the 
epidemiology of directly transmitted viral and bacterial infections (e.g. measles, 
 
Figure 4.2 – overview of modelling methodological framework, reproduced from 
Cobelli and Carson 2001 [90] 
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mumps and rubella), and the impact of mass vaccinations on transmission rates 
[92]. Anderson in 1994 commented [16] 
 
“distrust of mathematics is easy to understand as it often centres not so much 
on an unfamiliarity with the language but more on the simplicity of the 
assumptions embedded in models in the face of known biological complexity.” 
 
Similarly to animal models of disease, results from mathematical models should 
be considered in the context of the assumptions upon which a model is based 
and a thorough validation of the results against data. The mathematical 
modelling approach is consistent with the philosophy of experimental science. It 
is reductionist and should ultimately lead to greater understanding of biological 
processes which can feedback into more accurate modelling.  
4.1.4 Mathematical models of malaria infection 
The study of dynamic processes in malaria with the use of mathematical models 
has its origins in the work of Ross and Macdonald [236, 324], as discussed 
previously. Malaria models have tended to focus on epidemiological models with 
little input into the dynamics within individual people, which play a large role in 
the transmission and spread of malaria. In 1997 McKenzie and Bossert  [246] 
commented that 
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 “Among the hundreds of mathematical models of malaria published since Ross’ 
pioneering work, remarkably few address any aspect of dynamics within an 
individual host. We have located ten such models ...” 
 
In these models limited clinical PD data [50, 203, 325] has been used to 
mathematically model aspects of P. falciparum infection in humans to examine 
hypotheses about connections between fluctuations in asexual parasitaemia, 
gametocytemia and host immune response [17, 103, 148, 209, 246, 400, 424]. 
Since malaria pathogenesis is related to asexual blood stages of malaria, and 
prognosis is largely dependent on the level of asexual parasitaemia [41, 150, 
163, 269, 356], it is interesting that more epidemiological models do not address 
individual host dynamics. This is likely due to the difficulty of modelling human P. 
falciparum. 
 
Human mathematical models of malaria infection are, of necessity, complex. 
Such models, according to Molineaux et al [256] require 5 factors to produce the 
level of realism in simulated versus observed parasitaemia. They are 
1. Intra-clonal antigenic variation 
2. Large variation of the variants baseline growth rate 
3. Innate autoregulation of the asexual parasite density 
4. Acquired variant specific immunity 
5. Acquired variant-transcending immunity 
This form of modelling in humans relies on use of limited historical data, as 
discussed in 1.2.11. In the clinical setting there are the added complications of  
  143 
 Reinfection 
 Multiple strain and poly-clonal infections 
 Drug Resistance 
 Co-infections or dietary disorders 
 Non-compliance to drug regimens 
 Host immune responses 
 Sequestration of parasites 
 
In 2002 Gravenor et al [147] presented an age-structured compartmental model 
for estimating total parasite load in falciparum malaria patients. This model 
employed clinical observations of peripheral parasitaemia to estimate population 
dynamics of sequestered parasites, which cannot be observed by the clinical 
investigator. They concluded that the model could not be used to make robust 
estimates of sequestered parasite dynamics due to insufficient data to construct 
the model and refine variable parameters [147]. 
 
Relative to clinically observed P. falciparum parasite population dynamics, P. 
berghei parasite dynamics in laboratory mice, are significantly less complex. 
4.1.5 Compartmental modelling 
Compartmental models, which form the basis underlying the research presented 
in this Chapter, are mathematical models used to describe the behaviour of 
materials or energies in a defined system. A compartment is a defined partition 
in which the study “material” is assumed to be homogeneously distributed. As 
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such a compartment is a mathematical concept that does not necessarily 
correspond to a physiological space or easily defined physical volume. A 
compartmental system is a finite number of compartments that interact by 
exchanging the “material” under study.  A compartmental model is a 
mathematical model with equations to describe the transfer or flux of material 
between compartments. System variables define the amounts of material in 
each compartment and the changes in these compartments are represented by 
differential equations. Fractional transfer coefficients are represented by arrows 
indicating inputs and outputs from compartments. Compartmental analysis is a 
geometric representation of a system of differential equations. Some key 
concepts in compartmental modelling are [36]: 
 Compartmental models should provide a plausible description of the 
system being studied in order to justify use of a given model. 
 Aspects of a model that are observable or known experimentally can be 
fitted using a forcing function, which forces contents of a specific 
compartment to equal a known function and can be used to decouple 
complex systems. 
 Selection of the sampling protocol can have a significant effect on the 
precision with which parameters are estimated. Data points are especially 
important in regions where changes in the slope of curves are important 
so data sampling should be increased in these regions if possible. 
 Data weighting is used to fit models to data using a weighted least-
squares approach so both the value and the weight of the data are taken 
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into account in the calculations. When at least two data sets are used, 
relative data weighting (as opposed to absolute data weighting) allows 
automated optimisation of each data set weight. When an error structure 
is not known exactly relative error weighting should be employed.   
4.1.6 Aims 
The aim of the series of studies presented here was to investigate the feasibility 
of using P. berghei infection and single dose PD treatment data, to design and 
develop a suitably simplistic and experimentally functional mathematical model 
of P. berghei malaria in Swiss mice. The initial aims were to: 
i. Determine a mathematical relationship to describe time and parasite 
bioburden in Swiss mice infected with P. berghei parasites. 
ii. Develop a simple and biologically plausible mathematical model of P. 
berghei growth in a Swiss model. 
iii. Determine a mathematical relationship to describe time and parasite 
death and removal after administration of DHA. 
iv. Determine if it is possible to introduce a drug-dependent parasite removal 
term to simultaneously model death, removal and baseline population 
growth of the parasite.  
The hypotheses to be tested were: 
i. A mathematical model of P. berghei infection progression in Swiss mice 
can be developed that reflects experimental observations. 
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ii. A mathematical model of P. berghei death and removal in Swiss mice 
treated with DHA can be developed that reflects experimental 
observations. 
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4.2 Methods 
4.2.1 Relationship between time and parasite burden 
Data presented in Chapter 3 (Figure 3.2 and Figure 3.7) were analysed using 
the regression function in SigmaPlot to the fit of various functions and 
approximate the relationship between infection time and parasite bioburden. 
This was to serve as a starting point for construction of an untreated infection 
model. In determining the most appropriate fitting function the physiological 
relevance of the function as well as the r2 values were considered, particularly 
as time approached zero (i.e. very early in infection).  At t = 0 (time of infection) 
the parasitaemia should be greater than zero. 
 
The parasitaemia at this time is not a real value but a theoretic value or effective 
starting parasitaemia. If 1107 infected erythrocytes are injected into the host 
intra peritoneal cavity, a certain proportion will migrate to the blood stream, while 
older, fragile and more rigid erythrocytes are more likely to be removed by host 
mechanisms prior to reaching the peripheral circulation. The actual observed 
parasitaemia at t = 0 will be zero, but is effectively some number less than 1107 
for the purposes of modelling. The Leiden Malaria Research Group have 
reported that approximately 10% of P. berghei parasites survive i.p. injection 
[185]. Late in the infection, the parasitaemia will approach a maximum which 
cannot exceed 8.6x106 infected RBC/l. Healthy Swiss mice have approximately 
8.60.7x106 RBC/l (3.3.3). An infection of 8.6x106 RBC/l would represent a 
theoretically maximum parasitaemia of 100%. This is significantly higher than 
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the actual maximum achievable level of infection since animals will not survive 
with such a high level of infection. Additionally RBC destruction associated with 
infection progression above 10%, results in the total number of RBC being 
significantly less than 8.6 x 106 RBC/l. 
 
Based on the need to meet these criteria, the equations tested to approximate 
infection progression were required to have two horizontal asymptotes and a bell 
shaped derivative. The bell shaped derivative represents an initial increase in 
the rate of infection dependent only upon the parasite multiplication, which 
reaches a maximum, and then the rate of infection begins to fall. This occurs as 
the available number of uninfected RBC falls and the infection reduces the total 
number of RBC. 
 
P. berghei parasite growth in a Swiss mouse model which is free of immune 
interference should approximate a logistic function with a carrying capacity that 
is no greater than the maximum number of RBC in a Swiss mouse. Logistics 
functions, which are a type of sigmoid, are commonly used for approximating 
resource limited population growth. They combine an exponential growth 
equation with a bounded exponential equation (or exponential growth to a 
maximum) to produce a curve that meets the requirements for P. berghei growth 
outlined below (Figure 4.3). 
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4.2.2 Conceptual model of P. berghei infection 
The aim of these studies was to develop a model with biologically plausible 
assumptions and parameter ranges which produced a simulated parasite 
population that is statistically similar to the P. berghei parasite populations 
observed in Swiss mice. The raw data therefore needed to be reduced to as 
short a list of variables as possible, without compromising the biological 
relevance of the model, whose distributions can be used as quantified simulation 
targets. The following features are apparent on inspection of the data in Chapter 
3 so were considered as initial simulation targets for a conceptual model. 
 An initial period of possibly exponential increase in parasite population 
growth (Figure 3.7). 
 This is followed by a peak and gradual decline in the rate of parasite 
population growth to a plateau (Figure 3.7). 
 A model should include terms for parasite growth rate (equivalent to 
number merozoites per schizont, at least in early infection stages) and 
parasite removal. It is assumed however that in unchallenged infections 
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Figure 4.3 – Plots of (A) exponential growth and (B) exponential growth to a maximum 
which should approximate early and late population growth in a Swiss mouse model. 
(C) A logistic function should theoretically model both growth phases. 
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parasite removal is minimal due to minimal immunological interference in 
parasite population development [338-340]. 
 
Based on these features a basic conceptual compartmental model of parasite 
population growth was constructed (Figure 4.4). Initially compartments 
represented the four main life cycle stages of P. berghei being rings, early and 
late trophozoites and schizonts as categorised previously and shown in Figure 
3.1 (Figure 4.4A). 
 
These four lifecycle-stage-compartments were replaced with twenty four 
compartments representing parasites of hourly ages (Figure 4.4B). This 
removed the dependence of the model on definitions of parasite stages. 
 
Figure 4.4 – Conceptual compartmental models of P. berghei infection. Model (A) 
differentiates parasite stages of the life cycle based on morphological classification. 
Model (B) was a modification to characterise the lifecycle into 24 compartments of 
equal time. This model still allows examination of stages based on a grouping of 
compartments but removes the dependency of the model on specific stage definitions. 
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Additionally rather than having four rates, representing progression of parasites 
from rings to early trophozoites, early trophozoites to late trophozoites and 
etcetera, there were two rates representing one twenty fourth of the parasites 
life cycle and parasite multiplication. 
4.2.3 Mathematical model of P. berghei infection in SAAM II 
Once a conceptual model was established it was constructed in SAAM II 
Simulation, Analysis and Modelling Software for Kinetic Analysis (University of 
Washington, Seattle, USA). SAAM II is a compartmental and numerical 
modelling program that was readily available and is commonly used in the 
pharmaceutical industry for kinetic modelling. The program can create systems 
of ordinary differential equations from a compartmental model structure and 
provided a convenient and powerful platform for constructing a mathematical 
model of malaria that was understood. 
 
Aspects of compartmental modelling to be considered in constructing the model 
included: 
 Model structure and compartmentalisation 
 Initial estimates of the parameters 
 Use of forcing functions to decouple the model and represent schizont 
rupture and RBC invasion 
 Data weighting 
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The basis of the SAAM II compartmental model (Figure 4.4) was that the 24 h 
life cycle of P. berghei was divided into compartments, each representing 
approximately one hour of parasite growth. Twenty four one hour compartments 
were selected to construct a model independent of life cycle stages while still 
allowing stages to be examined if required by grouping compartments into 
domains representing life cycle stages. This also allows the time of life cycle 
stages to be altered without changes to the operation of the model. 
 
Parameters required in the model of parasite growth and development included 
parasite progression through compartments, parasite multiplication and parasite 
elimination rates. The parasite multiplication rate is the only one of these 
parameters that can be approximated based upon observed experimental 
results for inclusion into the SAAM II model. Parasite progression through 
compartments is a number of parasitised erythrocytes per L of blood moving or 
aging at one twenty fourth of the parasite life cycle, which is close to 24 h, while 
parasite elimination should be close to zero assuming minimal immune 
interference due to immune suppression by P. berghei [338]. 
4.2.4 Validation of mathematical model of P. berghei infection 
Once a mathematical model of infection was constructed the model needed to 
be validated to determine whether or not it was adequate for modelling infection. 
While this validation step may be presented as a seemingly distinct and 
separate entity, validation was continually carried out as the modelling process 
was undertaken. Carson et al  presented the basic outline of the modelling 
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process (Figure 4.5) in which the processes, including validation, are highly 
interrelated and essentially iterative [73]. 
 
The validation process followed in these studies was based on methodology 
presented by Cobelli et al [91]. Validity criteria can be separated into internal 
and external criteria. Internal criteria (e.g. consistency and algorithmic validity) 
enable the model to be assessed without reference to external criteria 
(empirical, theoretical, heuristic and practical validity) which refers to aspects 
external to the model including purpose, theory and data. Each of the validity 
criteria as discussed by Cobelli et al (1984) are defined below  
 Consistency requires that the model contains no logical, mathematical, 
or conceptual contradiction. 
 Algorithmic validity requires the simulation algorithm produces accurate 
solutions. 
 
Figure 4.5 – Representation of the basic iterative modelling process reproduced from 
Carson et al 1983 [73] 
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 Empirical validity requires that the model solutions should correspond to 
available experimental data with adequate accuracy. 
 Theoretical validity requires that the model should be consistent with 
accepted theories. 
 Heuristic validity refers to the potential of the model to be used for 
scientific explanation. For example the model may provide information on 
an unmeasured variable that may indicate that additional experiments 
should be carried out. 
 Practical validity refers to the practical usefulness of the information 
provided by the model, and is over and above the theoretical and 
empirical validity. 
 
Model validation was considered at all stages in the modelling process from 
concept to completion. Both internal and external criteria were applied during 
model formation as it was a requirement that the postulated compartmental 
system must be in agreement with known physiology. The final stages of 
validation are primarily concerned with satisfying conditions of empirical validity, 
which are of necessity, more stringent for a predictive model than for a 
descriptive model. In the case of the predictive model presented in this Chapter, 
the model must not only match available experimental data but also interpolated 
and extrapolated data. Parameter values need to reflect the underlying physical 
phenomena occurring in the system under study. 
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4.3 Results 
4.3.1 Relationship between time and parasite bioburden 
In the in vivo model presented in Chapter 3, infection progression was controlled 
by the size of the inoculation (i.e. 1x107 infected erythrocytes). Visual inspection 
of the infection curves (Figure 3.7) suggests that in Swiss mice, P. berghei 
population dynamics are limited only by the available pool of uninfected red 
cells. All infected RBC can be assumed to be visible in peripheral smears, as 
opposed to P. falciparum infections where sequestration reduces the visible 
parasite population. The parasite bioburden time relationship visually appeared 
similar to a sigmoid function. The list of potential functions available to meet the 
required criteria was narrowed to sigmoidal functions which are summarised in 
Table 4.1. Three and Four parameter sigmoid functions provided the best fit 
while providing consistency with in vivo observations. A 5 parameter sigmoid 
function provided the best r2 (Table 4.1), however proved physiologically 
implausible as time approached 0, or inoculation. 
4.3.2 Constructing a compartmental model of P. berghei infection 
A compartmental model was constructed in SAAM II based upon 24 
compartments representing the life of infected erythrocytes from infection 
(compartment 1) to rupture (compartment 24). A screen shot of the compartment 
model is shown in Figure 4.6. 
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Table 4.1 – Equations used to fit untreated P. berghei infection data. A 5 parameter 
sigmoid had the highest r
2
 but was an unrealistic fit as t approached 0*. This was similar 
to the 5 parameter Weibull and 3 parameter Hill, logistic, Chapman and Gompertz func-
tions which have not been included in the table. Three and four parameter sigmoids were 
the best and most realistic fits. 
Function Equation r
2 
Sigmoid 
(3 parameter) 




 



b
xx
e
a
y
0
1
 
0.988 
Sigmoid 
(4 parameter) 




 



b
xx
e
a
yy
0
1
0  0.988 
Sigmoid 
(5 parameter) 
c
b
xx
e
a
yy















 
 0
1
0  
0.994* 
Logistic 
(4 parameter) 
b
x
x
a
yy








0
0
1
 
0.984 
Gompertz 
(4 parameter) 





 

b
xx
eaeyy
0
0  
0.981 
Hill 
(4 parameter) bb
b
xc
ax
yy

 0  0.984 
Chapman 
(4 parameter) 
cbxeayy )1(0
  0.981 
 
The model was created as a non-cyclic catenery compartmental model, 
meaning each compartment flows into the next (catenery) and the last 
compartment does not feedback into the first (non-cyclic). Rather than being 
cyclic, the model terminates with the red cell death and a forcing function is used 
to then “inject” newly infected erythrocytes into the model, representing 
merozoite release and invasion. The first step in characterising the model was 
determining the infection function, hence forth referred to as the effective 
parasite multiplication factor (EPMF). The function was referred to using 
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“effective” and “factor” as it is a simplified function based on physiological data 
that incorporates several biological functions such as the number of merozoites 
per schizont, the reduction in uninfected erythrocytes and possibly innate 
immune removal of parasites, rather than a clearly delineated process. 
 
As well as the EPMF the effective parasite inoculation (EPI) was defined as the 
theoretic infection at inoculation (t=0). This was assumed from literature and 
observations to consist predominantly of rings and early to mid trophozoites, 
since older parasitised erythrocytes are unlikely to survive i.p. injection. The 
compartments in the model were divided roughly into rings (q1-q2 = 
approximately 2 h), early trophozoites (q3-q9 = approximately 7 h), late 
trophozoites (q10-q23 = approximately 14 h) and schizonts (q24 = 
approximately 1 h). Each of these was entered as a sample region in SAAM II 
so that it is possible in later experiments to examine parasite stages. Changing 
parasite stage designations simply requires adjusting of compartments in each 
sample. For example Sample 1 was designated as ring stages which were 
defined as q1 and q2. If it was deemed that the P. berghei rings stages lasted 
for 3 h instead of 2, sample 1 could be modified to include q1, q2 and q3. 
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4.3.3 Effective parasite multiplication factor (EPMF) 
The parasite multiplication rate largely comprises the rate of schizont rupture 
and subsequent successful merozoite invasion of erythrocytes. An important 
consideration in describing the EPMF as infection progresses is the number of 
available erythrocytes decreases (refer to Figure 3.5 and Figure 3.6). This 
reduces the carrying capacity of the system, and limits the total resources 
available for parasites and so reduces parasite multiplication. The EPMF should 
be described relative to the level of infection, rather than time. The intention is to 
 
Figure 4.6 – SAAM II compartmental model of P. berghei infection in mice based upon 
conceptual model. Ei represents distribution of infected erythrocytes at inoculation 
(EPI). k(0,23) and k(0,24) represent drug dependent parasite elimination and schizont 
rupture. E invasion represents rate of merozoite infection of erythrocytes or the 
effective parasite multiplication factor (EPMF). 
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eventually model drug treatment, so time will not be a good indication of 
infection depending on the time of drug administration. 
 
Accordingly in the pharmacodynamic model, an effective parasite multiplication 
factor (EPMF) was determined experimentally as a function of the proportion of 
parasitised erythrocytes in whole blood. The effective parasite multiplication 
factor is a function of the parasite population dynamics (i.e. change in parasite 
population) relative to the parasite population or ratio of infected to uninfected 
erythrocytes. This decouples the parasite multiplication from the time after 
infection, enabling modelling of infection with different initial parasitaemia and 
infections that are treated, thus altering the parasite population dynamics over 
time. 
 
To determine the effective parasite multiplication rate (EPMR or change in 
parasitaemia over time as distinct to EPMF) the change in parasite density every 
24 h was determined over the course of infection for individual mouse data 
(Figure 3.2 – P. berghei untreated infection with 105, 106 and 107 infected 
erythrocytes). The EPMR over the time course of an infection with 107 PRBC 
given i.p. is presented in (Figure 4.7A). The effective parasite multiplication rate 
was then plotted against parasitaemia (/l) in order to determine how the 
infection progresses as the parasite density increases (Figure 4.7B). 
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An approximation function for the EPMF was determined by fitting functions to 
the EPMR versus parasitaemia data as plotted in Figure 4.7B. Requirements of 
the fitting function were that at low parasitaemia the EPMF should approach a 
biologically plausible maximal multiplication rate close to the number of 
merozoites produced per infected erythrocyte. From the literature and 
observations this should be approximately 6-18 merozoites [135, 185, 212]. 
Additionally as infection progresses the EPMF should approach zero. 
 
The EPMF was approximated by fitting a 3-parameter power function to 
experimental data for the difference in parasite density over one life cycle (24 h), 
in mice inoculated with 105, 106 or 107 parasitised erythrocytes, versus the 
number of parasitised erythrocytes (Equation 4.1; Figure 4.8A). Initial parameter 
estimates of y0, a and b were obtained by fitting Equation 4.1 in SigmaPlot. 
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Figure 4.7 (A) – Effective parasite multiplication rate per 24 h life cycle for infection 
with 10
7
 parasitised erythrocytes as a function of time. Data is mean  SD (n=8) 
(B) – Effective parasite multiplication rate per 24 h life cycle as a function of the 
parasite density in untreated inoculations with 10
5
(), 106() and 107 () parasitised 
erythrocytes i.p. Data is mean  SD. 
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Other functions were tested using the SigmaPlot regression wizard. However, 
none provided biologically plausible results at both low and high levels of 
infection. An example of such biological implausibility is that physiologically the 
parasitaemia cannot exceed the total number of available erythrocytes. Since 
erythrocyte numbers per μL decline as infection progresses, the number of 
infected erythrocytes should never exceed the average healthy number of 
erythrocytes per μL. Any function used to determine the EPMF should cross the 
x axis prior to reaching a level of 1107 infected erythrocytes per μL in order to 
be considered biologically valid. Similarly, the EPMF can never exceed the 
maximum number of merozoites per schizont. This implies that at x = 0 the 
EPMF function should not exceed a value of 20. 
 
The parasite EPMF was added to the SAAM II compartmental model which was 
used to fit the power function to experimental data. Computational settings used 
relative error specification, with a Rosenbrock integrator function, and data-
based optimization with a convergence criterion of 0.001. Fitting was weighted 
to higher parasitised erythrocyte values as these data points have smaller 
inherent error. 
)(0
b
iEayEPMF   
Equation 4.1 
where: Ei is the number of infected erythrocytes; y0 is the theoretical 
maximum EPMF (the practical maximum of y0 occurs when Ei 
= 1); a is the coefficient and b is the exponent for the equation. 
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Model estimates for y0, a and b were 9.7, 0.73 and 0.16 
respectively. 
 
At low levels of infection (e.g. 103-104 parasitised erythrocytes), EPMF was 
shown to be of the order of 6.5-7.5, thus representing a biologically plausible 7-
fold increase in parasitaemia every 24 h [135, 185, 402]. At higher levels of 
parasitaemia (e.g. 106 parasitised erythrocytes or 10-12% parasitaemia), the 
EPMF was of the order of 3, reflecting a lower rate of parasite growth, mainly 
due to the diminishing pool of uninfected erythrocytes.  
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Figure 4.8 – (A) Fitting and optimisation of EMPF for 10
7
 inoculation mean data () 
using SAAM II with Equation 4.1 (). Values from experimental data fit in SigmaPlot 
were used as initial modelling parameters in SAMM II ().  
(B) The EPMF as determined by SAAM II () with data from untreated individual 
mouse data () following inoculations with 105, 106 or 107 parasitised erythrocytes. 
The log/log scale allows better visualisation of the function properties as it approach-
es low infection and high infection. These end points are significant to model validity 
and biological consistency. 
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4.3.4 P. berghei pharmacodynamic model 
As the factors that were most likely to be influential in the pharmacodynamics of 
P. berghei infection had been characterised, the next step was to establish and 
parameterize the model. The P. berghei model of infection contained 24 
compartments (Figure 4.6) each representing 1 h of the parasite life cycle. 
Variable parameters for the model included the parasitaemia at inoculation (EPI, 
an estimate of viable parasites) and the flux (a rate constant), representing 
parasite population progression through compartments (kp). Since the 
compartments represent a common residence time, the progression through all 
compartments is equal to kp and should be in the order of 1 (which represents 
compartments of approximately 1 h duration or a 24 h life cycle). Immediately 
following inoculation, the parasite population can be considered as being 
distributed between all 24 compartments, thus approximating a mixed infection. 
The results of preliminary modelling indicated however that the immediate post-
inoculation parasite population was comprised predominantly of early to mid 
stage parasites distributed across compartments 1 to 16. This was consistent 
with observations that erythrocytes with early stage parasites predominate in the 
thin film examinations, indicating that rings and trophozoites comprise most of 
the viable parasites in the inoculum and are more resilient to the passage 
process. The effect of this adjustment of the initial parasite age distribution was 
that some synchronicity is observed in modelling results at low parasite densities 
(Figure 4.9). This is what would theoretically be expected. Synchronicity was 
quickly lost which is also consistent with observations. 
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The forcing function input of parasites into compartment 1 approximates 
infection of erythrocytes by released merozoites and multiplication of the 
infection. The equation for the parasite multiplication was determined to be: 
 
Parasite Multiplication = (q24  kp)  EPMF 
Equation 4.2 
where: q24 is the number of parasites in the 24th compartment (model 
starts with q24 = 0 because all parasites were initially distribut-
ed across compartments 1 to 16); kp is the rate of schizont 
rupture and merozoite release (model commenced with kp = 
1). Initial values for EPMF (from Equation 4.1) and parasite 
progression (kp = 1; represents a parasite life cycle length of 
24 h) were determined by modelling untreated infection data. 
 
The P. berghei model of infection in mice inoculated with 105, 106 or 107 
parasitised erythrocytes is shown in Figure 4.9. From the model, the EPI (the 
viable parasite biomass) was estimated to be 47  25% of the inoculum. 
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4.3.5 Dihydroartemisinin administration and the P. berghei model 
The final stage in the development of the overall model was to incorporate the 
effects of drug treatment using DHA. Parasite clearance after drug 
administration was incorporated into the model, using an elimination function 
applied to compartment 23. A Gaussian function was used to approximate the 
parasite clearance in a Swiss mouse model due to DHA treatment. A Gaussian 
function was selected, as a bell shaped curve was logically appropriate to model 
parasite elimination, which would increase after drug administration from zero to 
 
Figure 4.9 – Parasite density-time profile (mean ± SD) of P. berghei infection and 
model fitting results for inoculations of 10
5
 ( ---), 106 ( ─ · ─) and 107 ( ──) parasi-
tised erythrocytes (n = 3 per inoculation). In the first 2 days after inoculation the model 
shows a partially synchronous infection. Synchronicity is lost by day 3. 
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a maximal parasite elimination, and then decline back to zero as drug is cleared. 
Hence, the simplest equation that represented the data was: 
BAeD
Tttk
DHA
inj 
 )((
 
Equation 4.3 
where: DDHA is the drug-dependent parasite elimination as a function 
of time (t) after inoculation; coefficient A is a function of the 
drug dose and defines the magnitude of maximum parasite 
elimination; k is the drug-dependent rate of parasite elimina-
tion; tinj is the time of drug administration, T is the time from 
administration to the peak parasite elimination (according to 
model estimates) and B represents a time independent in-
crease in parasite elimination. 
 
No improvement in fit was achieved by placing the elimination function in other 
compartments or in multiple compartments. Elimination from each of the 
compartmental stage domains (e.g. rings, early trophozoites, late trophozoites 
and schizont domains) significantly increased the complexity of the model 
without improvement. 
 
Initial parameter estimates were obtained from graphical data fitting and were 
inputted into SAAM II. Parameters were assigned upper and lower limits where 
these were biologically relevant to ensure the model did not produce biologically 
implausible results. For other parameters, limits were assigned based on 
observed biological standard deviation. 
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The final model describes the rise in parasitaemia following infection, its nadir 
following DHA administration, and the subsequent resurgence of parasitaemia 
(analogous to ‘recrudescence’). The modelling process involved solving 
Equation 4.2 (parasite multiplication) and Equation 4.3 (drug-dependent parasite 
elimination) sequentially in SAAM II. In this sequential fitting, Equation 4.2 starts 
at the time of inoculation (t = 0), while Equation 4.3 becomes active at the time 
of drug administration (t = 72 h). A switch term (z) was applied to the front of the 
drug dependent elimination equation which was switched from zero to 1 at 72 h 
post inoculation. 
 
Assumptions made in the modelling process were that drug treatment did not 
alter the EPMF (that is, the number of uninfected erythrocytes invaded by viable 
merozoites) and that the rate of parasite removal was independent of drug dose 
(parasite removal is host dependent and dead parasites can continue to 
circulate until removed). Figure 4.10 (n = 8 per group) shows that there was a 
graded dose-response relationship with increasing single doses of DHA. The 
time of nadir in parasite density was independent of dose and occurred 
approximately 24 h after treatment, with a maximum 12-fold reduction in parasite 
density following 100mg/kg DHA. Estimates of the parameters for the model are 
summarised in Table 4.2 and Table 4.3. 
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Figure 4.10 – Parasite density-time profiles (mean ± SD; n = 8 per group) and model fits 
of data in mice treated with DHA, three days after inoculation with 10
7
 parasitised 
erythrocytes. Single doses of DHA were given by intraperitoneal injection at Day 3: 
Control (DMSO:Polysorbate 80;  ──), 1mg/kg ( ─ ─), 3mg/kg ( ──), 10mg/kg ( ─ 
─), 30mg/kg ( ──) and 100mg/kg ( ─ ─). 
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Table 4.2 – Pharmacodynamic drug treatment model Bayesian parameters derived from untreated P. berghei infection modelling results. 
y0 is the maximum EPMF, kp is one 24
th
 of the parasites life cycle, kDHA is the rate of drug dependent parasite removal and T (Tinj+TDHA) is 
the time after administration to maximal drug dependent parasite removal. Other model parameters (Ei – initial parasitaemia, A – func-
tion of drug dose and B – drug independent increase in parasite removal) were entered into the model as adjustable variables (see Table 
4.3). 
Drug Treatment Model Parameters Population Mean Standard Deviation Lower/Upper Limits 
y0 9.7 0.5 9 14 
a 0.7 0.5 0.1 2 
b 0.15 0.1 0.01 0.8 
kp 1 0.05 0.9 1.1 
kDHA 0.6 0.1 0.5 1 
tinj + TDHA 85 6 72 100 
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Table 4.3 – Pharmacodynamic model parameters (mean ± SD) determined from Equation 4.3: DDHA = Ae
-k(t-T)
 + B, where DDHA is the drug-
dependent parasite elimination as a function of time (t) after inoculation; coefficient A is a function of the drug dose; kDHA is the rate of 
parasite elimination (/hr); T is the time from inoculation to the peak parasite elimination and BDHA represents a time independent increase 
in parasite elimination. 
Parameter Dihydroartemisinin dose (mg/kg) 
(Data from pharmacodynamic model) 100 30 10 3 1 
ADHA 12535 ± 2592 3377 ± 1969 932 ± 695 487 ± 180 14 ± 11 
BDHA 0.9 ± 0.4 0.6 ± 0.3 0.9 ± 0.5 0.3 ± 0.2 0.1 ± 0.3 
T (tinj + TDHA) (h) 84 ± 1.5 84 ± 1.4 83 ± 1.4 85 ± 1.2 84 ± 1.6 
kDHA (/h) 0.57 ± 0.04 0.57 ± 0.13 0.57 ± 0.01 0.58 ± 0.02 0.58 ± 0.01 
Fold-decrease in parasite density 
(from time of drug administration to nadir) 
12 ± 4 5 ± 1 2.5 ± 1 2 ± 0.2 N/A 
Time of maximum parasite elimination, after 
drug administration (h) 
12 ± 1.5 12 ± 1.4 11 ± 1.4 13 ± 1.2 12 ± 1.6 
Time of nadir parasite density, after drug 
administration (h) 
26.6 ± 1.8 24.6 ± 1.0 20.9 ± 2.3 21.7 ± 2.0 N/A 
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4.3.6 Dihydroartemisinin treatment on parasite stages 
Staged thin films from a mouse treated with 100mg/kg (Figure 3.15) were used 
to investigate the ablity of the in silico model to simulate parasite life cycle 
stages. Results are shown in Figure 4.11. In silico modelling indicated that the 
time for rings, early trophozoites, late trophozoites and schizonts (Figure 2.1) 
were approximately 1, 7, 14 and 2 h respectively. For this reason the elimination 
compartment for DHA was moved from compartment 23 to 22, so that 
elimination was occurring during the late trophozoite phase. Modifying the 
parasite stage definitions and drug dependent parasite elimination compartment 
did not alter in silico modelling results. 
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Figure 4.11– Mathematical model simulated pharmacodynamics and staged microsco-
py counting for total parasitaemia ( ), and populations of rings ( ), early 
trophozoites ( ), late trophozoites ( ), and schizonts ( ) for a 30mg/kg DHA 
treatment at 72 h post inoculation. 
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4.4 Discussion 
The studies reported here describe the development of a robust in silico 
pharmacodynamic model of murine malaria that incorporates parasite 
multiplication and changes in the erythrocyte population as a function of 
parasitaemia. Models of this type can be valuable tools for understanding how 
drugs, alone or in combination, and their dosing schedules alter the time course 
and level of infection and the practical application of this model to those ends 
will be investigated in subsequent chapters. 
 
The studies have shown that an in vivo murine model of antimalarial treatment 
as described in Chapter 3, can provide an array of sub-therapeutic dose-
response data that would not be possible in clinical studies. Hence, application 
of a murine model in the pre-clinical drug development process could assist in 
selection of candidate antimalarial agents and dosage regimens for drug 
combination studies during subsequent clinical trials. 
 
Development of an in silico model incorporating a simple drug-dependent 
parasite elimination function as described in this Chapter enables the generation 
of data characterising the time and level of nadir, as well as peak effect of the 
drug. The test antimalarial drug, DHA (1 - 100mg/kg), produced a nadir in 
parasitaemia approximately 24 h after dosing, and the in silico PD model 
revealed a time to peak parasite elimination of only 12 h. This finding suggests 
that for maximal therapeutic effect in the murine model, DHA should be given at 
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12-hourly intervals (half of the parasite lifecycle). Delaying drug administration to 
correspond with the nadir may allow a significant proportion of parasites to 
recover between each dose. Notably, the data from doses of 10, 30 and 
100mg/kg (0.5 log increases) showed a progressive two-fold lower nadir (Table 
4.3). Based on this observation, it could be predicted that three appropriately 
timed 30mg/kg doses of DHA should produce a nadir at least 15-fold lower than 
the starting parasitaemia (compared to the 12-fold lower nadir with 100mg/kg as 
a single dose; Figure 4.10). 
 
One of the limitations of murine studies as a conceptual model of therapeutic 
strategies for clinical trials is the 24 h lifecycle of P. berghei compared to the 48 
h lifecycle of P. falciparum. Hypotheses related to duration of drug 
administration [420] or comparisons of single-dose and multi-dose regimens of 
antimalarial drugs could be tested in a murine model, with due regard to the 
differences in lifecycle duration and the need for allometric scaling of doses, 
prior to clinical trials. A further potential limitation relates to the pathophysiology 
of P. berghei infection, specifically the starting parasitaemia of ~5% in this 
model. However, Swiss mice are tolerant of P. berghei infection at a low-
moderate level of parasite density (<5%), with organ failure and death occurring 
only at high parasitaemia [97, 213, 293]. Hence, the features of the P. berghei 
model infection are beneficial for PD studies because tolerance to the infection 
allows the mice to reach a parasite density of up to 5% before drug treatment 
strategies are commenced and the parasitaemia can be monitored down to a 
level of approximately 0.005%. In addition, in vivo evaluation of stage-specificity 
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is feasible if parasites are differentially counted as rings, trophozoites and 
schizonts. Furthermore, sequestration is not a factor in P. berghei infection of 
Swiss and Balb/c mice, hence the total parasitaemia should equate to the total 
parasite burden. 
 
In addition to recognising differences between murine and human malaria, the 
studies have been designed to develop an in silico PD model that is biologically 
plausible and adaptable to a variety of general modelling software packages. 
Preliminary studies showed that the rate of increase in parasitaemia was similar 
in the first 3-4 days after inoculation with 105 to 107 parasitised erythrocytes 
(Figure 4.9), as was recrudescence for approximately two days after the post-
treatment nadir (Figure 4.10). At a high parasitaemia, the rate of increase in 
parasitaemia was substantially reduced but the parasites harvested from these 
mice show a typical growth pattern when passaged to naïve recipients (data not 
published). Hence, by quantifying the rise in parasitaemia and incorporating the 
change in erythrocyte population into the model, a realistic multiplication factor 
(EPMF) was established as a continuous variable. The simple equations for 
parasite multiplication (Equation 4.2) and elimination (Equation 4.3) provided a 
close fit to the experimental data and generated parameters (e.g. time to peak 
parasite elimination) that should be useful in developing dosage regimens for 
antimalarial drugs in the murine model. 
 
The model constructed to this point has been demonstrated to be consistent 
with experimental observations, as well as being algorithmically, empirically and 
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theoretically valid. These validations will be continued in subsequent studies, 
which will also examine heuristic and practical validity. It is intended that the 
model be used to predict the outcomes of multiple-dose treatments and to 
examine the effects of combination treatment regimens. Such studies should 
demonstrate the potential value of the murine model for conceptual development 
of dosage regimens in pre-clinical and clinical studies. 
 
A summary of the SAAM II based mathematical model of P. berghei infection in 
Swiss mice is provided below in Figure 4.12. While individual aspects of the 
model such as the compartmentalisation, parasite multiplication and drug 
elimination are in isolation rather simple and straight forward, the final model 
provides an ability to simulate infection and treatment with DHA based upon the 
level of infection or parasite density that is complex and novel. A working 
protocol for development of the model based on Chapters 3 and 4 has also been 
included. 
4.4.1 Protocol for the development of a murine model of infection and 
drug treatment 
 Dose Ranging Studies 
o Preliminary study to determine doses to be used in graded dose 
response treatment studies. Doses need to be selected to avoid 
immune responses. 
 ~6 week old male Swiss mice infected with 107 infected 
erythrocytes i.p. at time 0. 
 Use cohorts of ~3 mice. 
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 24 h sampling from 4 h post treatment. 
 Monitor mice until 10% drop in body weight over 24 h period 
or end of experiment. 
 
 Graded Dose Response Studies 
o Select at least 4 sub therapeutic doses to test based on dose 
ranging study on a log scale (e.g. 1, 3, 10, 30mg/kg). 
o Select a sampling schedule for adequate data samples (e.g. 8 to 
12 h from 24 h post inoculation) 
o A control cohort should be included of ~4-8 mice on which to base 
in silico modelling. 
 
 In silico Model Construction 
o Fit mean  SD control untreated infection data and determine 
EPMF equation in SAAM II. 
o Fit mean  SD for graded dose response data with untreated 
EPMF variables fixed. 
o Examine graded dose response data to determine the drug 
dependent parasite elimination function. 
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s1 = Rings Stage Simulation Sample* 
s2 = Early Trophozoite Simulation Sample 
s3 = Late Trophozoite Simulation Sample 
s4 = Schizonts Simulation Sample 
s5 = Total Parasite Simulation Sample 
 k(0,24) = k(2,1) =……= k(24,23) =kp 
ex1 = initial inoculation at t=0 or EPI 
ex5 = (q24  kp)  EPMF 
      = (q24  kp)  (y0 - (a × Ei
b
)) 
k(0,23)= DDHA = Ae
-k(t-T)
 + B* 
Figure 4.12 – Screenshot of SAAM II compartmental model in experiment mode with 
definitions of variables and equations. Black circles and lines represent compartments and 
compartmental fluxes. Blue represents inputs red represents model sample points or data 
outputs. *The model was subsequently modified so that S1 was represented by  q1, 
early trophozoites by q2-q8, late trophozoites by q9-q22 and schizonts by q23 and 24. 
The k(0,23) drug elimination was move to compartment 22. These changes affected 
only the model definitions of parasite life cycle stages, and did not alter modelling 
and modelling results otherwise. 
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CHAPTER FIVE 
 
5. Using a mathematical model of murine P. berghei and single 
dose monotherapy to predict multiple dose outcomes. 
5.1 Introduction 
Studies in Chapter 4 demonstrated that it was possible to mathematically model 
a P. berghei infection model in Swiss mice after single dose treatment with DHA. 
This in silico model requires further validation. It is capable of modelling and 
simulating single dose DHA data. However, its validity depends on it being able 
to simulate or predict multiple dose therapy based on single dose modelling 
alone. This is in essence a practical and empirical validity test. Can the model 
predict and facilitate optimisation of multiple dose monotherapy based on single 
dose data? What criteria are suitable for judging the success or accuracy of 
itspredictions? The validity of the model must be demonstrated if the model is to 
be used to optimise drug treatment and potentially, combination treatment. 
 
While the aim of the series of studies presented here may be considered an 
intermediate step in moving towards combination treatment optimisation, the 
importance of monotherapeutic treatment should not be overlooked. Even 
though current clinical guidelines logically aim for combination treatments, 
understanding optimum drug monotherapy is critical to successful deployment in 
combination. Potentially, the model under construction has the ability to examine 
aspects of monotherapy, dosages and dose intervals and to aid in 
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understanding and explaining aspects of infection and treatment that are difficult 
to examine in vivo. This will form part of the heuristic validation of the model. 
5.1.1 Removing monotherapies from the clinical setting 
In 2007 the World Health Assembly passed a mandate calling on the removal of 
all artemisinin based monotherapies from pharmacies and health clinics around 
the world [24]. Antimalarial monotherapies are not recommended except in the 
treatment of severe complicated malaria, and only until patients are able to 
move to locally effective oral artemisinin-based combination medicines. There 
are however a significant number of companies still marketing artemisinin 
monotherapies and regulatory action is required to stop the supply of artemisinin 
based monotherapies [337]. Despite this active move to stop the supply and use 
of monotherapies, rational design of combination treatment regimens requires 
understanding of monotherapy of the individual components. 
5.1.2 The importance of antimalarial monotherapies 
The Medicines for Malaria Venture (MMV) in its 2010 report on the 
“Development of combination therapies for treatment of uncomplicated 
Plasmodium falciparum malaria” outlined recommendations to clarify changes in 
antimalarial therapy development strategies towards combination treatment for 
2020 [403]. According to MMV, dose selection “has often been rather empirical”. 
It was also commented that PK evaluation in patients is problematic due to drug 
sequestration in erythrocytes and tissues, and that the lack of a good basis for 
PK/PD evaluation for antimalarials makes dose-finding studies difficult. These 
issues make it hard to provide regulatory authorities with robust rationale for the 
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dose regimen evaluated in confirmatory studies. MMV concluded that new 
approaches for dose finding need to be developed for antimalarial combination 
therapy [403].  
 
With a clinical shift from monotherapy there is also a greater problem for the 
rational design of future regimens. Demonstrating the contribution of each agent 
to the combination requires monotherapy studies [403]. In the 2009 approval of 
Coartem® as a fixed dose combination of artemether-lumefantrine, the FDA 
emphasised the importance of studies comparing the combination with each 
component of the combination [6, 403]. 
5.1.3 New approaches for optimum dose selection 
Determining PK-PD relationships for the individual drugs in a combination in vivo 
is critical to enable selection of optimum doses [423]. This should then form the 
basis for evidence-based dose regimen in phase 3 trials. White [423] argued 
that failure to achieve this led to deployment of suboptimal antimalarial drugs as 
monotherapies and combination partners, eventually leading to poor treatment 
outcomes and the emergence and spread of resistance [423]. 
 
An alternative PK-PD approach is suggested by White [423] for dose finding, 
which could improve and accelerate dose finding and potentially avoid 
systematic under prescribing and under dosing. The objective is determination 
of the in vivo mean inhibitory concentration (MIC), or dose at which the parasite 
multiplication factor per asexual cycle is one [423]. This is a concept that has 
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been successful in the field of antimicrobials. Improved PK-PD approaches to 
different human populations are required when developing rational antimalarial 
treatment strategies, particularly for new antimalarials [423]. There are several 
examples such as pyrimethamine and sulfadoxine and piperaquine doses for 
children, which were determined from experience with adult populations without 
sufficient PK-PD analysis in children. PK drug differences between children and 
adults now suggest that doses in children were (and are in the case of 
piperaquine) suboptimal [30, 377]. 
 
There are implications for the future development of antimalarial combination 
therapies. How should the individual components be evaluated when they will 
never be deployed as monotherapies? White [423] suggests the MIC as a 
potential approach to improve dose regimen design. In vitro susceptibility tests 
and estimation of the MIC in human volunteers receiving subtherapeutic doses, 
could enable improvement of optimal dose finding and development of treatment 
regimens. They could enable greater understanding of the relationship between 
in vitro susceptibility data and in vivo human data [423]. Some potential 
problems with this method are discussed by White [423] and include: 
 Variation of the MIC between compounds is unknown and so may not 
provide a useful measure to inform dose finding and optimisation; 
 MIC determination in certain compounds (e.g. those with short biological 
half-lives or pharmacodynamic effects) may be very difficult or not 
possible; 
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 Monitoring of parasite bioburden for volunteer human in vivo studies 
would require the use of quantitative real-time polymerase chain reaction 
(qPCR) since parasitaemia will fall below the microscopy limit of 
detection. It is possible the MIC may fall below the qPCR limit of 
detection, or that qPCR results will not be sufficient to accurately 
determine the MIC. 
 
Improved strategies for developing rational treatments against malaria are 
necessary to prevent resistance and optimise use of current and future 
antimalarial treatment. It will however take a significant amount of time and 
clinical research, which may not in isolation be able to provide the necessary 
information to rationally develop treatments. There is potential for the use of 
intermediate animal in vivo models to provide useful PK-PD data to improve 
understanding and plug the gaps between in vitro susceptibility data and human 
PK-PD data. In vivo treatment optimisation in an animal model, such as that 
present here, could provide information to direct clinical trials and develop new 
approaches for selection of optimum doses, saving time and money. It may also 
provide an indication of the uses and problems of measures such as MIC in 
rational design of antimalarial regimens. 
5.1.4 Aims 
The aim of the present series of studies was to investigate the feasibility of 
using the established mathematical in silico model of P. berghei infection 
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and single dose treatment to predict multiple dose DHA monotherapeutic 
outcomes in Swiss mice. The initial aims were to: 
i. Develop the existing model of P. berghei infection and 
treatment with DHA to incorporate multiple treatment doses. 
ii. Investigate multiple dosing regimens using the model to de-
termine the optimum dose interval for DHA. 
iii. Use the model to determine the best regimen and develop 
criteria for evaluating regimens. 
iv. Experimentally test selected regimens to assess the value 
of the mathematical model in predicting multiple dose 
monotherapeutic outcomes.  
The hypothesis to be tested was: 
A mathematical model of P. berghei infection and drug 
treatment in Swiss mice can be developed from single 
dose, graded pharmacodynamic data and used to pre-
dict multiple dose outcomes, thus enabling 
optimisation of the treatment strategy. 
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5.2 Methods 
5.2.1 Incorporating multiple dose treatment into the compartmental model 
To modify the compartmental model developed in Chapter 4 to incorporate 
multiple drug doses, multiple drug dependent parasite elimination equations 
were added based on Equation 4.3 and could take one of two forms shown 
below. 
            ....2)((21)((1   dTttkddTttkdDHA BeABeAD injinj  
Equation 5.1 
            BeAeAD TttkdTttkdDHA injinj   ....)((2)((1  
Equation 5.2 
where: DDHA is the DHA dependent parasite elimination as a function 
of time (t) after inoculation; coefficient A is a function of each  
DHA dose and defines the magnitude of maximum parasite 
elimination for dose 1, 2, etc (d1, d2….); kDHA is the DHA-
dependent rate of parasite elimination; tinj is the time of injec-
tion or administration of each dose and TDHA is the time from 
inoculation to the peak parasite elimination (according to 
model estimates) and B represents a time independent in-
crease in parasite elimination. 
 
To model monotherapy, the terms kDHA and TDHA were entered as fixed variables 
since their values depend on the drug administered and are independent of 
dose (Table 4.3). kDHA was estimated as 0.57 and TDHA as 12 h after DHA 
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administration (Table 4.3). The variability in A depends on the dosing regimen 
being investigated and was entered as an adjustable parameter. The term B, 
which represents change in the parasite growth rate after drug administration, 
was included as either individual dose related variables (Equation 5.1) or as a 
single variable (Equation 5.2). The term is intended to allow for immunological 
interference by the host, which was considered negligible for an untreated short 
duration infection, but may be influential if drug treatment sufficiently prolongs 
host survival. It was anticipated that in the case of DHA multiple dose modelling, 
immune interference will be negligible relative to each dose due to short dosage 
intervals and so Equation 5.2 should be a suitable approximation. However, for 
future modelling of drugs with longer half-lives (e.g. chloroquine) it is possible 
that Equation 5.1 may be a more appropriate approximation. 
 
To ensure effective modelling of multiple doses each drug term had a “switch” 
term (z) added to the front to allow it to be switched on or off. For example, a 
dose administered at 72 h would have a switch term of 0 prior to 72 h, which 
was changed to a 1 at 72 h using the change condition function in SAAM II. The 
switching term was left as 1 from the administration time till the end of the 
experiment, so drug elimination terms were not artificially switched off by SAAM 
II once initiated. This meant that a drug elimination term could not inadvertently 
influence modelling before it had actually been administered or simulated to 
have been administered. Thus Equation 5.2 becomes Equation 5.3 below. 
            BeAzeAzD TttkdTttkdDHA injinj   ....)((22)((11  
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Equation 5.3 
Due to the construction of the model, all drug related parasite removal occurs 
through compartment 22. The biological accuracy of this is arguable, since 
parasitised RBC are unlikely to be removed at approximately 22 h in their life 
cycle. The model was not improved by spreading the parasite removal over 
multiple compartments and single compartment elimination provided a simplified 
model. The actual time during the life cycle that individual parasites are removed 
is less important than the influence this has on parasite multiplication. 
Irrespective of when parasites are removed, the effect of reducing the size of the 
next generation of parasitised RBC is unchanged. The model parasite 
elimination function is a model of drug dependent infected RBC removal and 
models this satisfactorily with single compartment elimination. The individual 
drug dependent elimination functions are in effect combined in the model into an 
overall drug dependent parasite elimination term as Equation 5.3. 
5.2.2 Predicting outcomes of multiple dose dihydroartemisinin 
monotherapy 
For prediction of DHA multiple dose monotherapy the values in Table 4.2 and 
Table 4.3 were used with the modified multiple dose model. A value of 1500 was 
used for EPI (number of infecting erythrocytes) as this provided a simulated 
parasitaemia of approximately 5% at 72 h. The drug elimination equation used 
for constructing predicted dynamic curves was Equation 5.3 and B values were 
taken from Table 4.3. ADHA values were calculated using Equation 5.4 which 
was determined by a linear fit of model derived ADHA values against the dose 
administered (DoseDHA) in mg/kg as shown in Table 4.3. The relationship had an 
  187 
r2 value of 0.9979 and was used to estimate the ADHA values for different doses 
during modelling. 
ADHA = 124.03  DoseDHA 
Equation 5.4 
Two sub-therapeutic DHA dosing regimens were selected to test the ability of 
the model to optimise and predict treatment regimen outcomes. Both regimens 
were designed to deliver the same total dose in a different number of doses 
using the most optimal dose interval as determined by the in silico model. For 
example, the first regimen delivered a total of 50mg/kg DHA in five equal 
10mg/kg doses while the second delivered 50mg/kg as an initial 30mg/kg dose 
followed by two 10mg/kg doses. These dose regimens were selected as they 
reflect clinical P. falciparum artemisinin based monotherapy studies from which 
it has been observed that longer courses of daily treatment are more effective 
than short courses and an initial loading dose is often administered [60-62, 196, 
223, 297]. 
5.2.3 Determining the optimum dose interval for dihydroartemisinin 
The optimum DHA dose interval was assumed to be approximately 12 h based 
on single dose modelling results showing maximum parasite drug dependent 
elimination at approximately 12 h post administration (Table 4.3). For each of 
the two test regimens described above, dose intervals of 0, 6, 10, 12, 14, 16, 18, 
20 and 24 h were modelled to determine the optimum interval to reduce the 
parasitaemia as quickly and for as long as possible (i.e. to determine the best 
sub-therapeutic regimen). For each treatment regimen a dose interval of 0 h 
  188 
should be equivalent to a single dose of 50mg/kg unless the model is internally 
invalid. 
5.2.4 Criteria for comparing treatment regimens 
Predetermined criteria were developed to compare the efficacy of treatment 
regimen. These were based upon measuring the parasitaemia at the start of 
regimen administration (PINJ), the minimum parasitaemia reached after drug 
administration (Pnadir) and the time after the commencement of drug 
administration for parasite population recrudescence (Trecrud) to return to the 
level at drug administration. From these values the parasite reduction ratio can 
be determined. 
5.2.5 Internal validation of the multiple dose model of dihydroartemisinin 
treatment 
Internal model validation was assessed (i.e. consistency, algorithmic and 
theoretical validity) using the following criteria : 
 Multiple doses with a dose interval of zero should provide equivalent 
results as a single dose of equal concentration. This can be tested using 
existing single dose data (i.e. 310mg/kg doses with zero dose interval 
should be equivalent to a single dose of 30mg/kg) and extrapolating to 
modelled data (i.e. 510mg/kg doses with zero dose interval should be 
equivalent to a single dose of 50mg/kg). 
 To be theoretically valid the model should demonstrate that (at the 
optimum dose interval) split dosing is more effective than single dosing 
(with the same amount of drug delivered) and that a longer dosing 
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regimen is more effective than a shorter one using the same dose 
interval. 
5.2.6 External validation of the multiple dose model of dihydroartemisinin 
treatment 
The empirical validity of the multiple dosing model was assessed by studying the 
two dosage regimen experimentally in the in vivo model. Infected Swiss mice 
were randomly divided into controls (n=5) and two treatment regimen groups 
(n=8) receiving either 510mg/kg doses of DHA every 12 h starting from 72 h 
post inoculation or receiving 30mg/kg DHA at 72 h post inoculation followed by 
210mg/kg doses every 12 h. Parasitaemia was monitored as previously 
described and experimental multiple dose in vivo PD results were compared 
with in silico model predictions to judge practical validity of the model in 
predicting the most effective treatment regimen. Subsequently the model was 
used to fit data to determine the accuracy of the model construction and 
empirical results. 
 
Model validation and “accuracy” in the context of the series of studies presented 
here requires definition. Model “accuracy” in predicting the optimal treatment 
regimen was the aim of the studies, which was to enable regimen optimisation, 
not perfectly simulate a P. berghei infection. The measure of model validation 
and accuracy that was important was relative. Which regimen is most effective? 
Is regimen A better than regimen B and do the model and experimental results 
agree? The model presented here was in development, and based upon a 
limited number of experimental results. It was expected that there could be 
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significant discrepancies between the absolute parasite dose response 
simulations and experimental studies. The following studies did however provide 
additional experimental data which was used to improve the precision of the 
model in simulating P. berghei infection and treatment. 
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5.3 Results 
5.3.1 Determining the optimum dose interval for dihydroartemisinin 
Model simulations for 510mg/kg doses at 0, 6, 10, 12, 14, 16, 18, 20, 24 h dose 
intervals are shown in Figure 5.1. Values used to compare each regimen such 
as time until nadir and recrudescence and fold decrease in parasitaemia are 
shown in Table 5.1. Additional dose intervals of 15 and 17 h were also 
examined. From a comparison of these values (Figure 5.2) it was concluded that 
a dose interval between 12-18 h was most effective. Results demonstrate that  
 Split dosing of DHA is much more effective than a single bolus as 
demonstrated by 510mg/kg doses with a 0 h dose interval (single 
50mg/kg dose) compared with 510mg/kg doses at any dose interval 
between 6-24 h. 
 Dose intervals greater than 20 h are less effective as parasite removal is 
slower and the nadir parasitaemia is higher. This is despite similar 
recrudescence times. 
 Dose intervals shorter than 10 h are less effective since the parasite nadir 
is higher and recrudescence times are shorter. The rate of parasite 
removal is however slightly faster. 
 Nadir parasitaemias for the most effective regimens drop below the limit 
of detection. With a 12 h dose interval the parasitaemia drops to 0.002%. 
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Figure 5.1 – Mathematical model simulated DHA multidose treatment of P. berghei 
infection in Swiss mice. The model simulates 510mg/kg multiple dose DHA regimens 
at varying dosage intervals between 0 and 24 h. An interval of 0 approximates single 
dose DHA treatment of 50mg/kg. 
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Table 5.1 – Mathematical model simulated parameter values for 510mg/kg multiple dose 
DHA treated P. berghei infection in Swiss mice at varying dosage intervals. An interval of 
0 approximates single dose treatment with 50mg/kg. 
 DHA Dose Interval (h) 
Model Simu-
lated 
Parameter 
Values 
0 6 10 12 14 15 16 17 18 20 24 
Nadir Parasi-
taemia (parasitised 
erythrocytes/L) 
66011 1412 288 198 186 176 171 205 280 917 21642 
Fold Decrease in 
Parasitaemia 
6 291 1427 2069 2204 2335 2404 2006 1465 448 19 
Time of Nadir (hrs 
after start of 
treatment) 
26 46 62 70 78 82 86 90 94 102 118 
Time of Recru-
descence (hrs after 
start of treatment) 
68 156 198 212 220 220 230 230 230 218 180 
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5.3.2 Predicting multiple dose dihydroartemisinin treatment outcomes 
Similar to the analysis of a simulated 510mg/kg DHA treatment regimen a 
30mg/kg followed by two 10mg/kg DHA dose regimen was simulated (Figure 
5.3). Results on selection of an optimum dose interval were similar to that 
observed with the 510mg/kg regimen in that an interval of between 12-18 h 
was optimal (Table 5.2 and Figure 5.4). Results support those found examining 
the 510mg/kg regimen. Split dosing is more effective than a single bolus of 
DHA. Dose intervals below 10 h and above 20 h were less effective. Doses 
between 12-18 h were most effective with fast parasite elimination, lowest nadirs 
and longest time to recrudescence. 
 
Figure 5.2 – Graphical representation of model simulated parameters from Table 
5.1.  () represents the change in the fold changes in parasitaemia over time 
while   () and  (--) represent time of recrudescence and time of nadir respec-
tively. The shaded area shows the dose intervals resulting in the most efficient 
regimen. 
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Table 5.2 – Mathematical model simulated parameter values for 30+210mg/kg multiple 
dose DHA treated P. berghei infection in Swiss mice at varying dosage intervals. An 
interval of 0 is equivalent to a single dose treatment with 50mg/kg. 
 DHA Dose Interval (h) 
Model Simulated 
Parameter Values 
0 6 12 14 16 18 20 24 
Nadir Parasitaemia (parasi-
tised erythrocytes/L) 
66011 7615 3171 2644 2312 2942 6102 26749 
Fold Decrease in Parasi-
taemia 
6 54 129 155 178 139 67 15 
Time of Nadir (hrs after start 
of treatment) 
26 34 46 50 54 58 62 70 
Time of Recrudescence (hrs 
after start of treatment) 
68 118 142 150 156 156 146 128 
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Figure 5.3 – Mathematical model simulated DHA multidose treatment of P. berghei 
infection in Swiss mice. The model simulates a 30+210mg/kg dose DHA regimens at 
varying dosage intervals between 0 and 24 h. An interval of 0 approximates single 
dose DHA treatment of 50mg/kg. 
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Comparison of Table 5.1 and Table 5.2 indicate that for 50mg/kg total dose of 
DHA a 510mg/kg dose regimen is much more effective than a 30+210mg/kg 
regimen with equal dose intervals. The two regimens with 12 h dosage intervals 
were selected to be validated experimentally, based on 12 h being considered 
within the optimal dose interval range. This schedule is also more comparable to 
clinical treatment of P. falciparum where treatment occurs twice per parasite life 
cycle (i.e. daily). Comparison of the simulation of these two dose regimens 
(Figure 5.5) show that the 5-dose regimen is predicted to be significantly more 
effective than the 3-dose regimen with the same total dose (50mg/kg) and dose 
intervals. The 5-dose regimen reduces parasitaemia by approximately 16 times 
that of the 3-dose regimen, extends the time to nadir by 24 h and extends the 
recrudescence time by 70 h. The benefits of the 5-dose regimen are provided 
 
Figure 5.4 – Graphical representation of model simulated parameters from Table 5.2.  
() represents the change in the fold changes in parasitaemia over time while   () 
and  (--) represent time of recrudescence and time of nadir respectively. The shaded 
area shows the dose intervals resulting in the most efficient regimen for 510mg/kg 
doses, which overlaps that of the 30+210mg/kg regimen. 
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without sacrificing the speed at which the initial parasite reduction occurs after 
DHA administration (Figure 5.5).  
 
5.3.3 Dihydroartemisinin in vivo multiple dose treatment 
Parasite density time profiles with standard errors are shown in Figure 5.6 with 
respective model predictions. Model predictions for both regimens satisfy 
relative accuracy with experimental data as shown in Table 5.3. Model precision 
generally falls within standard errors for experimental data. There was a 
significant difference between the level (precision) of parasitaemia at nadir 
between the 510mg/kg model and data. This was likely due to the nadir 
approaching the limit of microscopic detection. This was supported by the data 
presented in Table 5.3 with close agreement between model and experimental 
data estimates of fold decrease in parasitaemia and time to recrudescence in 
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Figure 5.5 – Mathematical model simulated DHA multidose treatment of a 
30+210mg/kg DHA regimen () and a 510mg/kg DHA regimen (---) both at 12 h dose 
intervals. A 50mg/kg single dose of DHA is modelled for comparison (). The graph 
represents model simulations of two selected dosage regimens to be tested and 
validated experimentally. 
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the 30+210mg/kg regimen and time to recrudescence in the 510mg/kg 
regimen. 
 
It should be noted that the model predictions were not altered to fit experimental 
data. The modelling was conducted with a starting parasitaemia at 72 h of 5%. 
The model curves were not normalised to match the experimental data mean 
parasitaemia at the time of treatment (Figure 5.6). The mean parasitaemia of the 
510mg/kg and 30+210mg/kg cohorts were 6.8  2.0% and 6.1  1.0% 
respectively. 
 
The experimental parasitaemia for both regimens appears to show a region of 
slow growth immediately after nadir followed by a faster rate of increase in the 
parasite population. This is lacking or much less pronounced in modelling 
predictions.   
Table 5.3 – Comparison of mathematical model simulated parameter values for 
510mg/kg and 30+210mg/kg multiple dose DHA treated P. berghei infection in Swiss 
mice compared to experimental results obtained using the same two regimens. 
 Model and Data Regimens 
Model/Data 
Estimated Values 
510mg/kg 
Model 
510mg/kg 
Data 
30+210mg/kg 
Model 
30+210mg/kg 
Data 
Nadir Parasitaemia 
(parasitised 
erythrocytes/L) 
198 850 3171 3917 
Fold Decrease in 
Parasitaemia 
2069 689 129 136 
Time of Nadir (hrs after 
start of treatment) 
70 75 46 52 
Time of Recrudescence 
(hrs after start of 
treatment) 
212 212 142 153 
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Figure 5.6 (A) – Experimental data (mean and SD; n=8) for mice infected with P. 
berghei and treated with five 10mg/kg doses of DHA every 12 h commencing 72 h after 
inoculation ( ). The dotted line shows the mathematical model prediction of the 
parasite dynamics during DHA treatment which was not normalised for starting 
parasitmemia.  
(B) – Experimental data (mean and SD; n=8) for mice infected with P. berghei and 
treated with three doses of DHA every 12 h of 30, 10 and 10mg/kg commencing 72 h 
after inoculation ( ). The dotted line shows the mathematical model prediction of 
the parasite dynamics during DHA treatment which was not normalised for starting 
parasitmemia. 
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5.4 Discussion 
The research presented in this Chapter demonstrates that data collected from 
single dose graded dose response data of DHA treatment of P. berghei infection 
in Swiss mice can be used to accurately predict DHA multiple dose treatment 
outcomes. The significance is that prediction of multiple dose treatment allows 
the optimum dose regimen to be determined taking into account different dose 
intervals and different dose sizes. Importantly it also enables this optimisation to 
be accomplished more accurately and with significantly fewer in vivo studies 
than could be achieved experimentally (refer to Figure 5.1 and Figure 5.3). 
 
The regimens used to demonstrate this were of equal total dose (50mg/kg) split 
over 5 and 3 doses. The results show that five doses is much more effective 
than 3 using the same dosage interval. This is expected from clinical studies 
which have shown that for artemisinins treatment efficacy is highly related to the 
duration of treatment and split dosing is much more effective than single dosing 
[32, 268]. 
 
A dose interval of 12-18 h was determined to be optimal for DHA treatment. This 
is consistent with clinical theory that administration of short half-life antimalarials 
is optimised at two doses per parasite life cycle (~12 h in P. berghei and 24 h in 
P. falciparum). Clinical studies have reported little benefit from administration of 
artesunate at 12 h intervals compared with 24 h intervals [61]. This supports the 
model prediction that 12 h intervals are optimal. Additionally modelling 
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comparing 510mg/kg doses at 12 h intervals and 95mg/kg dose at 6 h 
intervals can be simulated and compared as in Figure 5.7.   
 
The simulations in Figure 5.7 have been normalised to the mean parasitaemia at 
time of treatment of the 510mg/kg experimental data. The model predicts that 
the split 95mg/kg model is slightly more effective (with slightly lower total dose 
of 45mg/kg. In this way simulated treatment duration is comparable). However, it 
would be unlikely that there would be significant difference between the two 
regimens in an in vivo model. This result is consistent with clinical observations 
[61]. 
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Figure 5.7 - Experimental data ( mean and SD; n=8) and model simulation () for 
mice infected with P. berghei and treated with 5x10mg/kg DHA at 12 h dose intervals 
from 72 h post inoculation and model simulation ()  of treatment with 9x5mg/kg DHA 
at 6 h dose intervals from 72 h post inoculation. Models have been normalised so that 
the parasitaemia at 72 h is the mean of the experimental data at 72 h. 
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Another aspect of the in silico model that can be examined using SAAMII is the 
rate of parasite elimination. The rates of parasite elimination for the two 
regimens examined in this chapter are plotted in Figure 5.8. The significance or 
usefulness of this information is unclear. There does not appear to be a 
relationship between the area under the parasite elimination curves that can be 
used to determine optimal dosing or intervals. This however may be different for 
long half-life antimalarials. It is clear however that the regimen duration is longer 
in Figure 5.8A than B. The usefulness of the drug dependent parasite 
elimination rate may become clearer with comparison between several 
antimalarials. 
 
It is theoretically possible that the mathematical in silico model could be used to 
determine the MIC. This has not been investigated in the present study as MIC 
is primarily useful in comparison, and DHA would be an inappropriate 
antimalarial to explore MIC due to a lack of robust MIC data and its short 
biological half-life. However, it is possible that the model could be used to 
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Figure 5.8 – Model derived parasite elimination rate plots for (A) 5x10mg/kg doses of 
DHA at 12 h intervals from day 3 post inoculation and (B) 30+2x10mg/kg doses of DHA  
at 12 h intervals from day 3 post inoculation. 
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determine a drug concentration and dose interval over which parasite 
multiplication is maintained at one. If examined across a wide range of 
antimalarials this could provide evidence for the usefulness of the MIC 
parameter in comparing antimalarials.  
 
The in silico model has been shown to be both internally valid and externally 
valid. It is consistent within itself as demonstrated since five multiple doses 
(510mg/kg) all applied at the same time is equivalent to one single dose of 
equivalent concentration (e.g. 50mg/kg). The model is externally valid in that it is 
able to accurately predict multiple dose outcomes based only upon graded 
pharmacodynamic data and is physiologically plausible. 
 
An aim of the current experiments was to determine a set of criteria for 
determining the optimum of two or more sub therapeutic treatment regimens. 
Regimens were compared on the time to nadir, level of parasite reduction, and 
the recrudescence time, which was defined as the time for the infection to return 
to levels when treatment was initiated. These parameters seem adequate in the 
case of DHA for determining the most effective regimen. The nadir parasitaemia, 
parasite reduction ratio or time to recrudescence all appear to be consistent with 
in the frame work of a modelled infection commencing at the same 
parasitaemia. 
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An animal model such as that described in this thesis is not going to remove the 
need to conduct human PK-PD trials. These studies can provide useful insights 
into PK-PD relationships using a simplified in vivo model that may be possible to 
scale to the clinical setting to provide insights and starting points that may well 
never be possible from clinical data. It also may be possible to help answer 
questions such as whether MIC is a useful measure in assisting dose finding 
and optimisation. As White comments [423] “The MIC is a useful theoretical 
concept, but its utility in dose finding and other aspects of therapeutic 
assessment remains to be defined. It is not known how variable it is.”  The ability 
to experimentally and mathematically model the P. berghei infection and 
treatment also allows in depth examination of theoretical concepts such as MIC, 
and confirmation of these concepts experimentally in vivo.  
 
The significance of these findings are that through use of detailed single dose 
graded PD data to produce a mathematical model of P. berghei infection and 
treatment with DHA, it is possible to accurately and precisely simulate and 
predict single and multiple dose monotherapeutic outcomes. This process 
facilitates optimisation of monotherapy with significantly less time and cost than 
if optimisation was determined solely through experiments in the in vivo system. 
The mathematical model also allows heuristic in silico investigation of aspects of 
infection and treatment that would be difficult with only in vivo data. This has the 
potential to allow development and assessment of methods to aid 
monotherapeutic and combination treatment optimisation through examination of 
concepts such as MIC and parasite elimination functions. 
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Using the methods described here it is possible to optimise and understand 
monotherapy treatment, which is a critical component of optimising combination 
treatment regimens. 
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CHAPTER SIX 
 
6. Using a mathematical model of murine P. berghei single dose 
monotherapy to predict multiple dose combination outcomes. 
6.1 Introduction 
In Chapters four and five, it was demonstrated that it was possible to 
mathematically model a P. berghei infection and single dose treatment with 
DHA. This model was partially validated in that it was capable of accurately 
modelling the pharmacodynamic response to single dose DHA data and 
predicting parasite density-time profiles following multiple dose DHA 
monotherapy. The next stage of the validation for the model was testing the 
ability to predict multiple dose combination therapy based on single dose 
modelling. This was a prerequisite if the model is to be used to optimise 
combination treatment. 
 
Prior to assessing the ability to predict combination outcomes, the ability to 
model single dose monotherapy of antimalarials other than DHA required 
attention. Other antimalarials have longer biological half-lives and may require a 
different parasite elimination equation than previously used to model DHA. 
 
In this Chapter, data collected and analysed by another researcher in our 
laboratories, using the techniques developed in this thesis, were used to 
address model validity with chloroquine treatment. The availability of these data 
provided a valuable, independent practical validation of the mathematical model. 
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Model development in Chapters 3, 4 and 5 was an iterative process based upon 
data collected and analysed by one person, the author. It is possible that during 
this process, idiosyncratic anomalies could have been introduced into the model, 
based for example upon microscopy techniques or other experimental bias. 
Modelling data collected and counted by another researcher may indicate if such 
idiosyncrasy exists, and provide useful practical validation for the model. 
6.1.1 History of chloroquine use 
Chloroquine, a 4-aminoquinoline was first used as an antimalarial in 1947 [355]. 
It was synthesised in 1934 at Bayer but was not used as an antimalarial due to 
toxicity concerns [355]. Its action and toxicity was re-evaluated by the U.S. 
military in 1946 and Loeb et al recommended that CQ be made available for the 
prophylaxis and treatment of all blood stage malaria infections [229]. CQ quickly 
became the most widely used antimalarial for several decades due to its 
effectiveness, tolerability, safety and low cost [164].  
 
CQ treatment was a central pillar of the World Health Organization’s global 
malaria eradication program after World War II with approximately 300 million 
tablets distributed by the U.S. International Cooperation Administration (the 
predecessor to U.S.A.I.D.) between 1960 and 1962 [89]. Parasite populations 
worldwide were subject to an intense selection pressure for CQ resistance. 
Resistance was first detected in South America in 1959 and independently in 
South East Asia in 1960 [290]. By the 1970s CQ was no longer effective in the 
majority of South-East Asia and by 1978 the first cases of resistance in east 
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Africa were reported. By the early 1980s, 75% and 82% of infections in Kenya 
and Malawi respectively were found to be CQ resistant [47]. As resistance 
spread, morbidity and mortality due to malaria increased [391, 452]. 
 
Nevertheless, CQ is still widely used, particularly in the treatment of P. vivax and 
in special patient groups such as children and pregnant women [197, 221, 264, 
274, 432]. Studies have indicated that clinical efficacy of CQ may return a 
decade after it has been withdrawn from first line treatment, highlighting its 
potential re-emergence as an important therapeutic option for malaria, most 
likely in combination with artemisinin or chemosensitizing agents [141, 162, 218, 
241, 262, 263, 383, 414]. 
 
The antimalarial mechanism of action of CQ has not been fully elucidated, 
although the most accepted theory is that CQ interferes with haemoglobin 
digestion by the parasite [54, 355]. There is also increasing evidence indicating 
that CQ exerts several modulatory effects on the immune system [241, 383]. 
Chloroquine resistance is reported to be dependent on direct transport via 
mutated CQ resistance transporters (PfCRT) [241].  
6.1.2 Artemisinin based combinations 
The WHO recommends artemisinin-based combination therapy (ACT) for all P. 
falciparum confirmed cases [433]. ACTs are recommended for enhancement of 
efficacy [305, 418, 426], lowering malaria transmission and the potential to lower 
the rate at which resistance emerges and spreads [272, 421]. Convincing 
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evidence for the effectiveness of artemisinin based combination therapy in 
improving cure rates and decreasing malaria transmission were first 
systematically collected on the western border of Thailand [272]. This 
investigation also demonstrated a reversal in mefloquine resistance. Despite the 
success of the artemisinin-mefloquine combination it is difficult to generalise 
these results to other ACTs. While combination with an artemisinin does provide 
advantages such as improved parasite clearance and reduced gametocyte 
carriage [306, 376, 406], the International Artemisinin Study Group meta-
analysis of almost 6000 patients found that for ACTs to lead to high cure rates, 
reduce transmission and provide protection against resistance, the partner drug 
needs to be highly effective [9]. This seems to counter the experience with 
mefloquine. Mefloquine monotherapy had a declining treatment success rate, 
due to parasite resistance, of approximately 70% prior to the introduction of the 
combination with artesunate in 1994, which increased treatment success rates 
to almost 100% [272]. 
6.1.3 Chloroquine and artemisinin based combinations 
Clinical trials have indicated that ACT with artesunate and CQ are superior to 
CQ monotherapy [139, 354, 374]. The ACT improved 14 and 28 day cure rates 
as well as faster parasite clearance; however the reported treatment success 
rates for the ACTs were significantly below the 95% that is desirable. In Sao 
Tome and Principe, the 14 day failure rate for CQ versus the ACT were 80.1% 
and 16.6%; however, the 28 day failure rates were 81.1% and 32.4% [139]. 
Similarly in Burkina Faso for CQ versus artesunate-CQ the 14 day failure rates 
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were 64% and 20% while the 28 day failure rates were 81% and 51% 
respectively [354]. In Ivory Coast the 14 day failure rate for CQ versus the ACT 
were 85% and 77%, and the 28 day failure rates were 96% and 92% 
respectively [9]. While it is clear that ACTs are a significant improvement on CQ 
monotherapy, it has not been demonstrated that a CQ-based ACT will be 
effective clinically. 
6.1.4 Chloroquine studies in murine models 
As well as its clinical importance, CQ is important as a comparator for in vitro 
and in vivo preclinical testing of antimalarial agents [276, 293, 402, 446]. In vitro 
and in vivo efficacy studies have produced paradoxical results for CQ and 
artemisinin based combinations. CQ and artesunate are reported to be 
antagonistic [83, 367] and additive [127, 160] in vitro and additive in in vivo 
preclinical studies with artemisinin and DHA [82, 261]. Recent chemical studies 
by Haynes et al [166] comparing the action of methylene blue and artemisinins, 
explain the antagonism between CQ and artemisinins in vitro and are also 
reconcilable with the antimalarial mode of action of CQ perturbing intraparasitic 
redox homeostasis.  
 
The pharmacokinetics [12, 70, 261, 384, 407] and pharmacodynamics [261, 
286, 291, 294, 295] of CQ have been studied in murine malaria models. Detailed 
pharmacodynamic data of CQ treatment collected by Moore et al (using the in 
vivo model described in Chapter 3) have indicated that CQ shows a dose related 
reduction in parasitaemia with a 5-to >500-fold reduction in parasitaemia for 
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doses between 10 to 50mg/kg and a parasite nadir 2 days after treatment [261]. 
These studies also found that CQ has a weak additive efficacy combined with 
DHA. Pharmacokinetic investigation of CQ in mice showed a biphasic profile 
similar to that for CQ pharmacokinetics in other mammalian species (humans, 
rats, rabbits, monkeys and dogs) including long elimination half-life, moderate 
clearance and large volume of distribution, indicating scaling of specific 
parameters may be plausible for preclinical investigations [261]. Chloroquine 
efficacy studies by Ishih et al in ICR mice using P. berghei NK65 based on a 
Peters 4-day test indicated that a complex relationship exists between the 
parasite load and the efficacy of the drug [182]. Ishih et al also highlighted the 
requirement to identify the ideal time to initiate treatment in mice models [182]. 
6.1.5 Aims 
The aim of the present series of studies was to investigate the feasibility of using 
the established mathematical model of P. berghei infection and DHA treatment 
to predict multiple dose combination therapeutic outcomes in Swiss mice. The 
initial aims were to: 
i. Validate that the existing model of P. berghei infection and treatment with 
DHA can be used to model drugs with longer biological half-lives. 
ii. Investigate combination therapy dosing regimens using the model to 
determine the ability to predict parasite dynamics with combination 
therapy. 
iii. Use the model to determine an optimised combination treatment regimen. 
iv. Demonstrate practical validity of the in silico model. 
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The hypothesis to be tested was: 
 A mathematical model of P. berghei infection and treatment in 
Swiss mice can be developed from single dose graded 
pharmacodynamic data and can be used to predict combination 
therapy outcomes. 
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6.2 Methods 
6.2.1 Selection of a dihydroartemisinin combination partner 
In order to examine the ability to predict combination therapy outcomes using 
the mathematical model of malaria it was first necessary to develop a single 
dose model of another antimalarial as a combination partner with DHA. CQ was 
chosen for study due to the availability of preclinical pharmacodynamic data in 
our laboratory and because there is growing interest in the reintroduction of CQ 
clinically as parasites regain sensitivity to CQ in many endemic areas. There are 
also questions over the efficacy of artemisinin-CQ combinations with ambiguous 
or paradoxical results from in vitro and in vivo preclinical and clinical studies [83, 
367] [127, 160] [82, 261]. 
6.2.2 Chloroquine pharmacodynamic data 
Chloroquine pharmacodynamic data were kindly provided by Jillian Stoney from 
studies conducted in our laboratory (Jillian Stoney, BPharm (Hons) thesis [370]) 
and subsequently reported as part of a larger study [261]. Experimental animals, 
parasites and experimental protocols were based upon those described in 
Chapter 2 and 3. CQ diphosphate in water at 30mg/ml was diluted to the 
required concentrations in a standard 100µL injection volume. The solution was 
filtered (Millex-HV 0.45µm filter unit, Millipore, Molsheim, France) prior to i.p. 
injection [261]. 
 
Pharmacodynamic data for single dose CQ treatment of P. berghei infection in 
Swiss mice at 0 (n=4), 10 (n=9), 20 (n=7), 30 (n=9) and 50mg/kg (n=7) 
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administered 65 h after inoculation at an approximate starting parasitaemia of 
5%, are presented in Figure 6.1A. Pharmacodynamic data for multiple dose CQ 
treatment and combination treatment with CQ plus DHA are presented in Figure 
6.1B.  Data were collected for two multiple dose treatment regimens of 
510mg/kg and 220+10mg/kg of CQ administered at 12 h dose intervals 
beginning 65 h post inoculation. Pharmacodynamic data for combination 
treatment of 30mg/kg CQ plus 30mg/kg DHA administered separately at 65 h 
post inoculation are also presented (Figure 6.1B). The raw mean percentage 
parasitaemia data were converted to parasitaemia per L for each time point as 
described in Equation 3.1. 
 
The CQ pharmacodynamic experiments were performed as pilot studies and 
were conducted by a relatively inexperienced researcher, trained in our 
laboratory in murine handling and malaria microscopy techniques. The data 
collected were less comprehensive than earlier validation studies and show 
greater variation than those for DHA presented in Chapter 3. Data were not 
collected to be modelled, nor to provide detailed and robust pharmacodynamic 
data for CQ, but to provide baseline data to direct future experimental work. The 
data provided a valuable test for exploring the use of the mathematical model of 
malaria in a smaller and sparser data set.  
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Figure 6.1 – (A) Single dose pharmacodynamic data for untreated ( n=4) Swiss mice 
infected with P. berghei and CQ treatment at 65 h post inoculation with 10mg/kg (), 
20mg/kg (), 30mg/kg () and 50mg/kg () chloroquine. Data are mean  SD and were 
collected and provided by Jillian Stoney. 
(B) Pharmacodynamic data from P. berghei infected Swiss mice treated with either 
5x10mg/kg CQ at 12h intervals ( n=4), 2x20+10mg/kg CQ at 12h intervals ( n=4) or a 
combination of 30mg/kg CQ and 30mg/kg DHA ( n=4)  at 65 h post inoculation. The limit of 
microscopic detection was approximately 0.005% (---). Data are mean  SD and were 
collected and provided by Jillian Stoney [370]. 
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6.2.3 Chloroquine pharmacodynamic model construction 
The pharmacodynamic model of CQ was constructed to be conceptually 
identical to that developed for DHA. An uncoupled 24-compartment model with 
drug dependent parasite removal occurring from compartment 22 was used. The 
average parasitised erythrocytes per µL data was used to construct a model of 
CQ treatment. The first step involved using the model of P. berghei infection in 
Swiss mice developed in Chapter 4 to model untreated data and confirm that 
parameters were within expected and acceptable biological variation. Figure 6.2 
shows the in silico model of P. berghei infection and the untreated control 
infection data from four mice. The unfitted model has been shown (solid line), 
and confirms that untreated P. berghei infections in our laboratory using 6 week 
old male Swiss mice and ANKA P. berghei parasites produced a reproducible 
infection that can be accurately modelled. Model parameters determined in 
Chapter 4 (Equation 4.1) were used as initial model estimates and were entered 
as Bayesian terms into SAAM II with standard deviations and lower and upper 
limits as determined in Chapter 4 and shown in Table 6.1. A starting 
parasitaemia of 1500 parasites per L was used which represents 
approximately 30% of the 107 i.p. inoculation being viable. This was used as a 
starting point based on results from Chapter 4. While the model fell within the 
standard deviation of the data, SAAM II was used to fit the untreated data and 
the results are shown in Figure 6.2 and Table 6.1. 
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Table 6.1 – Untreated model initial estimates based on model development experiments in 
Chapter 4. The terms were fitted in SAAM II to provide the fitting estimates. 
 Data from Chapter 4  
Untreated Model 
Parameters 
Initial 
Estimate 
Standard 
Deviation 
Lower/Upper Limits 
Fitting 
Estimate 
y0 9.7 0.5 9 0.5 9.75 
a 0.7 0.5 0.1 0.5 0.55 
b 0.16 0.1 0.01 0.8 0.182 
kp 1 0.05 0.9 0.05 1.01 
EPI (PRBC/L) 1500 - - - 1678 
 
With confirmation that the underlying infection model adequately represented 
the infection in this data set the next step was to add drug dependent parasite 
removal functions as described in Chapter 4, with Equation 4.3 becoming 
Equation 6.1 below.  
CQ
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Figure 6.2 - Untreated P. berghei 
pharmacodynamic data ( n=4) in 
Swiss mice. The untreated model of P. 
berghei infection () developed in 
Chapter 4 falls within data standard 
deviations without adjustment or 
fitting. The fitted model is also shown 
(). Data are mean  SD and were 
collected and provided by Jillian 
Stoney [370]. 
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time (t) after inoculation; coefficient ACQ is a function of the 
drug dose; kCQ is the rate of parasite elimination; tinj is the time 
of injection post inoculation; TCQ is the time from injection to 
the peak parasite elimination and BCQ represents a time 
independent increase in parasite elimination. 
 
The only modification to Equation 6.1 from Equation 4.3 was that initial 
modelling was conducted with a B value fixed at zero to determine if this term 
was necessary for fitting CQ data. Model fitting was only significantly improved 
by adding a B value in the 10mg/kg treatment group.  
 
Mean data with standard deviation were modelled for CQ rather than modelling 
of individual mouse data as in Chapter 4 for DHA. This was due to the large 
variation in the parasitaemia at the time of treatment within and between groups. 
Single dose data points greater than 240 h post inoculation (Figure 6.1A) were 
excluded from modelling as they were from a small group of surviving mice after 
euthanasia of the majority of the group. Data points in Figure 6.1B which were 
near the limit of microscopic detection were also excluded as they do not 
represent the actual parasitaemia. The LOD for these experiments was 0.005% 
or ~430 PRBC/L. 
6.2.4 Dihydroartemisinin and chloroquine treatment model 
A pharmacodynamic model of DHA and CQ combination treatment was 
constructed as previously described for multiple dose models so that the drug 
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dependent parasite elimination function from compartment 22 represented 
elimination by both DHA and CQ. The elimination equations are additive 
implying that modelling results represent perfectly additive parasite effects 
between DHA and CQ. Model parameters for DHA determined in Chapter 4 
were used due to the absence of single dose DHA data. 
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6.3 Results 
6.3.1 Chloroquine single dose treatment modelling 
Modelling results for CQ single doses and the CQ data (mean  SD) are 
presented in Figure 6.3A and Table 6.2. There was a large variation in the 
parasitaemia at the time of treatment, which was intended to correspond to a 5% 
parasitaemia or 4.3105 parasitised erythrocytes per L (represented by the 
dashed line in Figure 6.3A). Several of the groups fell significantly below this 5% 
target, with the 20 and 30mg/kg groups having a starting treatment parasitaemia 
of 2%. Due to this large variation in parasitaemia at the time of treatment, 
normalised models are presented in Figure 6.3B.  
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Figure 6.3 – (A) Single dose pharmacodynamic data (mean  SD) and model fitting 
results for untreated (  n=4) Swiss mice infected with P. berghei and CQ treatment 
at 65 h post inoculation with 10mg/kg ( ), 20mg/kg ( ), 30mg/kg ( ) and 
50mg/kg ( ) CQ. 5% parasitaemia is indicated by the horizontal dashed line (----
).Data were provided by Jillian Stoney [370]. 
(B) Pharmacodynamic modelling results for untreated () and CQ treated groups with 
10mg/kg (), 20mg/kg (), 30mg/kg () and 50mg/kg () normalised at a starting 
inoculation of 1678 parasitised erythrocytes per L. 
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Models were normalised by modifying the EPI (number of parasitised 
erythrocytes at inoculation) to equal to 1678 PRBC/L without modification of 
any other model parameters. This value was chosen as it was the estimated 
number of parasitised erythrocytes at inoculation in the untreated control group 
from the CQ data set. 
Table 6.2 - Pharmacodynamic model parameters for CQ graded single dose pharmacody-
namics data determined from model fitting of Equation 6.1 
PD Model Parameters Chloroquine dose (mg/kg) 
 50 30 20 10 
ACQ 1568 802 643 211 
BCQ 0 0 0 0.35 
tinj + TCQ (h) 95.9 92.5 78.0 92.0 
kCQ (/h) 0.22 0.20 0.18 0.27 
Fold-decrease in parasite density (from time 
of drug administration to nadir) 
278 120 36 6 
Time of maximum parasite elimination, after 
drug administration (h) 
30.7 27.5 13 27 
Time of nadir parasite density, after drug 
administration (h) 
56.5 52 40.5 44.5 
 
6.3.2 Chloroquine single dose model 
To produce a model of CQ single dose treatment, the modelling results in Table 
6.2 were used to produce averaged ACQ, TCQ and kCQ values. As B values were 
not required for fitting except for the 10mg/kg doses, for predictive modelling it 
was assumed that B was zero in all cases. Values for (tinj + TCQ) and kCQ were 
89.6 h and 0.22 h-1 respectively determined by averaging values in Table 6.2. 
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Values for A were estimated as 29.19 multiplied by the CQ dose in mg/kg by use 
of an origin intercepting linear fit of ACQ values from Models were normalised by 
modifying the EPI (number of parasitised erythrocytes at inoculation) to equal to 
1678 PRBC/L without modification of any other model parameters. This value 
was chosen as it was the estimated number of parasitised erythrocytes at 
inoculation in the untreated control group from the CQ data set. 
Table 6.2. Model results for 10, 20, 30 and 50mg/kg simulated treatment are 
presented in Figure 6.4 and can be compared to modelled data in Figure 6.3B. 
Figure 6.4 includes a simulated dose of 90mg/kg to demonstrate extrapolation 
outside the experimental data provided to create the model. Interpretation of 
extrapolated results without experimental validation should be undertaken with 
caution, but could direct further experimental studies.  
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Figure 6.4 – Single dose pharmacodynamic model simulations for untreated () Swiss 
mice infected with P. berghei and CQ treatment at 65 h post inoculation with 10mg/kg 
(), 20mg/kg (), 30mg/kg (), 50mg/kg () and 90mg/kg () CQ. 
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6.3.3 Chloroquine multiple dose modelling 
Single dose CQ results used to construct the CQ mathematical model were 
used to predict the multiple dose pharmacodynamics for the two CQ multiple 
dose regimens presented in Figure 6.1B. Drug dependent parasite elimination 
equations from compartment 22 for each regimen are shown below as Equation 
6.2 and Equation 6.3, which were based upon those developed in Chapter 5 for 
DHA. 
Equation 6.2 for 20+20+10mg/kg CQ Regimen 
        )24(102)12((201)(20)23,0(   CQinjCQCQinjCQCQinjCQ TttkTttkTttk eAzeAzeAzk  
Equation 6.2 
Equation 6.3 for 510mg/kg CQ Regimen 
        )48(104)12(101)(10 ...)23,0(   CQinjCQCQinjCQCQinjCQ TttkTttkTttk eAzeAzeAzk   
Equation 6.3 
where: k(0,23) is the SAAM II parameter representing DCQ which is 
the  CQ dependent parasite elimination as a function of time 
(t) after inoculation; z is a switching function to allow activation 
of each drug function at the time of its administration; 
coefficient A10/20 is a function of the drug dose representing 10 
and 20mg/kg CQ; kCQ is the rate of parasite elimination; tinj is 
the time of injection post inoculation and TCQ is the time from 
injection to the peak parasite elimination of CQ. 
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Model predictions are shown with experimental data (mean  SD) in Figure 6.5A 
and B.  
 
SAAM II was used to adjust or fit model predictions to determine where there 
could be an improvement to the model predictions and if there were potential 
errors in model parameters for CQ treatment. Figure 6.6 shows the 510mg/kg 
CQ regimen data () and model prediction (----) as well as the model fitting (). 
SAAM II achieved a more accurate fit for the data by modifying the peak 
parasite removal (TCQ) from 24.6 to 15 h. The other CQ model parameters such 
as ACQ or kCQ were not modified by SAAM II to improve the fit. 
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Figure 6.5 – (A) Multiple dose pharmacodynamic data (mean  SD) and model predic-
tion based on single dose modelling results for a 2x20+10mg/kg CQ regimen 
commencing at 65 h and with 12 h dose intervals. Data were provided by Jillian Stoney 
[370].  
(B) Multiple dose pharmacodynamic data (mean  SD) and model prediction based on 
single dose modelling results for a 5x10mg/kg CQ regimen commencing at 65 h and 
with 12 h dose intervals. Data were provided by Jillian Stoney [370]. 
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6.3.4 Determination of the optimum dose interval for chloroquine 
The multiple dose models of CQ treatment were used to examine the impact of  
changing the dose interval of CQ treatment. Similar to DHA modelling presented 
in Chapter 5, this was expected to provide an optimised dose interval for CQ 
treatment. Model predictions for various dose intervals of the three doses of the 
220+10mg/kg regimen are presented in Figure 6.7 and Table 6.3. The 12 h 
dose interval used in experimental work was, as expected, much more effective 
than a single equivalent dose of 50mg/kg (or zero h interval). Dose intervals of 
24 and 48 h were more effective, although the optimum dose interval according 
to the in silico model was approximately 42 h. Only a small increase in 
recrudescence time was achieved by increasing the dose interval above 42 h, 
and this occurred with a higher parasite nadir (Figure 6.7). Recrudescence time 
was defined as the time from drug treatment for the parasitaemia to return to the 
level at which treatment began. 
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Figure 6.6 – Multiple dose pharmacodynamic data (mean  SD ) with model predic-
tion (----) and model fitting () by SAAM II for a 5x10mg/kg CQ regimen commencing 
at 65 h and with 12 h dose intervals. Data were provided by Jillian Stoney [370]. 
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Table 6.3 – Mathematical model simulated parameter values for 220+10mg/kg multiple 
dose CQ treated P. berghei infection in Swiss mice at varying dosage intervals.  
 CQ Dose Interval (h) 
Model Simulated 
Parameter Values 
0 12 24 30 36 42 48 54 
Nadir Parasitaemia 
(parasitised 
erythrocytes/L) 
1173 193.0 45.8 26.6 15.9 15.5 22.3 41.5 
Fold Decrease in 
Parasitaemia 
214 1299 5481 9420 15735 16155 11263 6045 
Time of Nadir (hrs 
after start of 
treatment) 
48.5 67 89 101 113 125 137 150 
Time of Recrudes-
cence (hrs after 
start of treatment) 
125 217 255 273 291 303 311 317 
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Figure 6.7 – Mathematical model simulated CQ multidose treatment of P. berghei 
infection in Swiss mice. The model simulates 2×20+10mg/kg multiple dose CQ regi-
mens at varying dosage intervals between 0 and 54 h. An interval of 0 approximates 
single dose CQ treatment of 50mg/kg. 
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Model predictions for various dose intervals of the five doses of the 510mg/kg 
regimen are presented in Figure 6.8 and Table 6.4. Similar to the 3-dose 
regimen, the 5-dose regimen with 12 h dose interval (used in experimental work) 
was much more effective than a single equivalent dose of 50mg/kg (or zero hour 
interval). The 36 h dose interval regimen was the most effective modelled result 
and the parasite nadir occurred at a parasitaemia below one parasite per L 
(Figure 6.8).  
 
Comparing the two multiple dose regimens delivering a total 50mg/kg of CQ 
over either 3 or 5 doses, as anticipated 5 split doses of 10mg/kg was more 
effective than 3 doses of 20+20+10mg/kg over any dose interval (greater than 
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Figure 6.8 – Mathematical model simulated CQ multidose treatment of P. berghei 
infection in Swiss mice. The model simulates 5×10mg/kg multiple dose CQ regimens at 
varying dosage intervals between 0 and 54 h. An interval of 0 approximates single 
dose CQ treatment of 50mg/kg. 
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zero). However, the rate of reduction in parasite density was greater with the 
higher doses of CQ (Figure 6.7 and Figure 6.8). 
Table 6.4 – Mathematical model simulated parameter values for 510mg/kg multiple dose 
CQ treated P. berghei infection in Swiss mice at varying dosage intervals.  
 CQ Dose Interval (h) 
Model Simulated 
Parameter Values 
0 12 24 30 36 42 48 
Nadir Parasitaemia 
(parasitised 
erythrocytes/L) 
1178 23.6 3.2 1.6 0.97 1.5 4.6 
Fold Decrease in 
Parasitaemia 
213 10651 78928 159711 260669 162812 54600 
Time of Nadir (hrs 
after start of 
treatment) 
48.5 89.5 137 161 185 208 233 
Time of Recrudes-
cence (hrs after 
start of treatment) 
125 207 276 308 335 355 367 
 
6.3.5 Dihydroartemisinin and chloroquine combination modelling 
The equation for the combination parasite elimination for DHA and CQ was 
constructed similarly to that used in multiple dose treatments and took the form 
shown in Equation 6.4 for elimination in a DHA and CQ combination regimen. 
     CQinjCQDHAinjDHA TttkCQCQTttkDHADHA eAzeAzk   (()23,0(  
Equation 6.4 
The equation parameters to model a 30mg/kg combination dose of both DHA 
and CQ are shown in Table 6.5. TDHA and kDHA parameters were determined 
from Table 4.3 and the ADHA for 30mg/kg by using Equation 5.3. TCQ, kCQ, and 
ACQ for 30mg/kg CQ were determined as described in 6.3.3. Model prediction for 
a combination treatment of 30mg/kg DHA and 30mg/kg CQ administration at 65 
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h is presented in Figure 6.9A. Model single doses of 30mg/kg DHA and 30mg/kg 
CQ are added in Figure 6.9B for comparison with the combination prediction. 
Table 6.5 - Mathematical model parameter values for P. berghei infection and combination 
treatment with 30mg/kg CQ and 30mg/kg DHA. 
Drug Treatment Model Parameters Value 
y0 9.75 
a 0.55 
b 0.182 
kp 1.01 
ADHA / ACQ 3720.9 / 875.7 
kDHA / kCQ (h
-1) 0.57 / 0.22 
TDHA / TCQ (h) 12 / 24.6 
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Figure 6.9 (A) – Mathematical model simulated combination treatment () of 30mg/kg 
DHA and 30mg/kg CQ treatment of P. berghei infection in Swiss mice with experi-
mental data ( mean  SD).  
(B) – Mathematical model simulated combination treatment () of 30mg/kg DHA and 
30mg/kg CQ treatment of P. berghei infection in Swiss mice with simulated single dose 
treatment of 30mg/kg DHA () and 30mg/kg CQ (). 
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6.3.6 Optimum dose interval for a dihydroartemisinin and chloroquine 
combination 
The model of DHA and CQ combination treatment was used to determine the 
optimum dose interval for a single 30mg/kg dose of DHA and CQ. The tinj term in 
Equation 6.3 was modified to simulate differing injection times. Results of 
modification of the dose interval are presented in Figure 6.10 and Table 6.6. For 
a combination of 30mg/kg single doses of DHA and CQ the optimum treatment 
outcome in the Swiss murine model was obtained by administering DHA 42 to 
48 h after CQ (Figure 6.10B ). The rationale for choosing this dose interval 
rather than administering CQ 24 h after DHA was the much more rapid parasite 
reduction which was delayed in the 24 h interval (Figure 6.10A ). 
 
Table 6.6 - Mathematical model simulated parameter values for 30mg/kg DHA and CQ 
combination regimens in a P. berghei infection in Swiss mice at varying dosage intervals.  
(A)                                                             (B) 
Time Post Infection (hours)
0 24 48 72 96 120 144 168 192 216 240 264 288
P
a
ra
s
it
is
e
d
 E
ry
th
ro
c
y
te
s
 (
/
l)
102
103
104
105
106
107
0hr Interval
6hr Interval
12hr Interval
18hr Interval
24hr Interval
36hr Interval
Time Post Infection (hours)
0 24 48 72 96 120 144 168 192 216 240 264 288
P
a
ra
s
it
is
e
d
 E
ry
th
ro
c
y
te
s
 (
/
l)
102
103
104
105
106
107
0hr Interval
24hr Interval
36hr Interval
42hr Interval
48hr Interval
54hr Interval
 
Figure 6.10 – (A) Mathematical model simulated combination treatment of 30mg/kg 
DHA at 65 h and 30mg/kg CQ at 0 (----), 6 (), 12 (), 18 (), 24 ()  and 36 ()  h after 
the DHA dose.  
(B) Mathematical model simulated combination treatment of 30mg/kg CQ at 65 h and 
30mg/kg DHA at 0 (----),24(), 36 (), 42 (), 48 () and 54 ()  h after the CQ dose. 
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Combo 
Dose 
CQ Dose Interval 
after DHA (h) 
DHA Dose Interval 
after CQ (h) 
Model Simulated 
Parameter Values 
0 18 24 36 42 48 54 
Nadir Parasitaemia 
(parasitised 
erythrocytes/L) 
1123 713 649 1403 571 563 2598 
Fold Decrease in 
Parasitaemia 
212 334 367 170 417 423 92 
Time of Nadir (hrs 
after start of 
treatment) 
46.5 64.5 70.5 82.5 66 72 78 
Time of Recrudes-
cence (hrs after 
start of treatment) 
121 143.5 151 155 140 148 149 
 
6.3.7 Parasite elimination functions for single, multiple and combination 
regimens 
Using the models of DHA and CQ single, multiple and combination treatments it 
was possible to simulate PD data as shown in Chapters 4, 5 and 6. Using the 
models it was also possible to examine other functions such as the number of 
parasitised erythrocytes eliminated over time due to drug administration or the 
parasite elimination rate function. This was discussed in 5.4. These parameters 
may provide an explanation of the observed PD effects by simulation of data 
that is difficult or impossible to measure in vivo. The parameters may also 
identify a parameter whose measure can be used to indicate which of multiple 
regimens is optimal similar to measures such as the parasite reduction ratio or 
mean inhibitory concentration often used in in vitro studies to compare efficacy. 
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Such parameters may provide a more simple method for determining the most 
optimal regimen than using nadir, time of nadir and time to recrudescence.  
 
The parasite elimination rates for single 30mg/kg doses of DHA and CQ are 
presented in Figure 6.11A. As expected CQ has a much broader elimination 
profile than DHA. Figure 6.11B shows combination treatment PRBC elimination 
for 30mg/kg of DHA and CQ at 65 h. This demonstrates that the combination 
model predicts an additive outcome, combining the elimination functions for the 
individual components. Figure 6.11C shows combination treatment with 
30mg/kg CQ followed by administration of 30mg/kg DHA 48 h later. Similarly 
Figure 6.12A and B show parasite elimination  during the course of treatment 
with a single dose of 50mg/kg CQ or 20+20+10mg/kg regimen of CQ at a dose 
interval of 12 h (Figure 6.11A) or 42 h (Figure 6.11B). Both of the split dose 
regimens provide significantly better treatment than the single dose, and the 42 
h multiple dose interval is significantly better than the 24 h interval.  
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Figure 6.11 - (A) – Mathematical model 
simulated parasite elimination for a single 
30mg/kg dose of DHA () and 30mg/kg dose 
of CQ () at 65 h post inoculation.  
 
(B) – Mathematical model simulated parasite 
elimination for a combination regimen of 
30mg/kg DHA and 30mg/kg CQ at 65 h post 
inoculation.  
 
 
(C) – Mathematical model simulated parasite 
elimination for a combination regimen of 
30mg/kg CQ administered at 65 h post 
inoculation followed by a 30mg/kg dose of 
DHA administered 48 h after the CQ. 
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Figure 6.12 – (A) Mathematical model simulated parasite elimination for two multiple 
dose regimens of 20+20+10mg/kg at dose intervals of 0 h ( or a single 50mg/kg dose 
) and 12 h ()  commencing at 65 h post inoculation.  
(B) Mathematical model simulated parasite elimination for two multiple dose regimens 
of 20+20+10mg/kg at dose intervals of 0 h ( or a single 50mg/kg dose ) and 42 h ()  
commencing at 65 h post inoculation.  
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6.3.8 Staging of parasites following treatment with chloroquine 
It was demonstrated previously (4.3.6) that it is possible to examine changes in 
parasite population stages using the in silico P. berghei model and DHA 
treatment. The model was used to produce a simulated staged model of 
30mg/kg CQ treatment (Figure 6.12A) with total CQ parasitaemia data. No 
staged data were available for CQ. DHA staged data is provided in Figure 6.12B 
for comparison (copy of Figure 4.11). An equivalent dose of CQ had a greater 
effect on the parasite density than DHA, but there did not appear to be a 
significant difference in the distribution of the parasite population stages after 
treatment.
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Figure 6.13 - (A) – Mathematical 
model simulated pharmacodynam-
ics for total parasitaemia (), and 
populations of rings (), early 
trophozoites (), late trophozoites 
(), and schizonts ()  for a 
30mg/kg CQ treatment at 65 h post 
inoculation.  
 (B) – Mathematical model simulated 
pharmacodynamics and staged 
microscopy counting for total 
parasitaemia ( ), and popula-
tions of rings ( ), early 
trophozoites ( ), late trophozo-
ites ( ), and schizonts ( ) for 
a 30mg/kg DHA treatment at 72 h 
post inoculation. Scaling is the 
same as Figure 6.13B to compare 
DHA and CQ staging. 
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6.3.9 Effects of parasitaemia at the time of drug treatment 
Ishih et al [182] have reported that a complex relationship exists between the 
parasite load and the efficacy of the drug for CQ treatment of P. berghei NK65 
infections. Due to the large variation in the level of parasitaemia at treatment of 
some of the data in the present study, the in silico model was used to simulate 
modifying the parasitaemia at which treatment starts, to examine the effect on 
drug efficacy. Results for a single dose of 100mg/kg DHA and 50mg/kg CQ at 
treatment parasitaemia varying between approximately 1-12% are summarised 
in Table 6.7. 
Table 6.7– Mathematical model simulated parameter values for single dose treatment with 
100mg/kg DHA and 50mg/kg CQ in a P. berghei infection in Swiss mice with treatment 
beginning at different parasite bioburdens.  
 100mg/kg DHA 50mg/kg CQ 
Parasi-
taemia at Inj. 
 % 
Parasi-
taemia at 
Injection 
 /L 
Parasi-
taemia at 
Nadir 
/L 
Fold 
Decrease in 
Parasi-
taemia 
Parasi-
taemia at 
Injection 
 /L 
Parasi-
taemia at 
Nadir 
/L 
Fold 
Decrease in 
Parasi-
taemia 
1% 85018 9287 9.2 85467 286 221.4 
2% 168642 17250 9.8 168142 666 252.5 
3% 250318 24508 10.2 250592 910 275.4 
5% 406267 37401 10.9 408551 1314 310.9 
8% 624029 53936 11.6 633875 1801 352.0 
10% 775102 64645 12.0 775752 2070 374.8 
12% 909657 73751 12.3 909969 2305 394.8 
 
  236 
6.4 Discussion 
In this chapter it has been demonstrated that the model of P. berghei infection 
and DHA treatment developed in Chapters 4 and 5 was capable of modelling the 
pharmacodynamics of CQ treatment. By combining an infection model with two 
models of drug treatment it was possible to predict combination therapy 
outcomes (Figure 6.9) in Swiss mice from graded single dose pharmacodynamic 
data (Figure 3.14 and Figure 6.1). This is a novel form of modelling that has 
several potential benefits. The model is capable of reducing in vivo experimental 
work therefore saving time, money and large numbers of animals through 
simulation of infection and treatment. The model allows examination and 
exploration of P. berghei treatment pharmacodynamics in ways that would be 
impractical experimentally, such as exploring the effect of starting parasitaemia 
at the time of treatment. It also allows in vivo results to be explained through 
examination of parasite multiplication and elimination functions and examination 
of parasite staging and parasite densities below the limit of detection of 
experimental techniques. In this way the model can add value to in vivo results 
through greater certainty of results, or in explaining results such as determining 
if a combination is more effective, or if the in vivo results are additive, 
antagonistic or synergistic. These demonstrate both the practical and heuristic 
validity and potential of the in silico model of P. berghei malaria.  
6.4.1 Treatment parasite density and efficacy studies 
Chloroquine data were collected by an inexperienced researcher and 
microscopist which contributed to large variation in parasitaemia at time of 
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treatment resulting in two distinct infection cohorts. In Figure 6.1A the control, 
10mg/kg and 50mg/kg groups have a treatment parasitaemia of approximately 
417180 parasites per L, or 5.1%, while the 20mg/kg and 30mg/kg groups have 
a treatment parasitaemia of 168052 parasites per L, or 2.0%. This could be a 
significant difference for a drug treatment study as literature [182] and results in 
Table 6.7 indicate that parasite density at the time of treatment does have a 
significant influence on the apparent efficacy of the drug treatment.  
 
Modelling results in Table 6.7 also provide a plausible explanation for the 
influence of parasite density on treatment outcomes. As the parasite density 
increases the parasite effective multiplication rate declines. This explains the 
model prediction that there is a greater fold decrease in parasitaemia for the 
same dose of either DHA or CQ as the level of infection increases. This provides 
a warning for in vivo malaria experiments. Care should be taken in making 
conclusions where there is a discrepancy in the level of infection at treatment. 
Normalising data should also be avoided as this will artificially increase or 
reduce the apparent efficacy of treatments relative to each other and potentially 
produce conclusions that are incorrect. Results in Table 6.7 indicate that a 
discrepancy in treatment parasitaemia of 3%, as is the case in CQ single dose 
data in Figure 6.1A, could lead to an 11% discrepancy in treatment outcome or 
fold decrease in parasitaemia for 100mg/kg DHA or a 23% discrepancy for CQ. 
Comparing treatments with a significant difference in treatment parasitaemia 
should be avoided or undertaken with caution. 
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6.4.2 Modelling chloroquine treatment 
Chloroquine treatment was successfully modelled and internally and externally 
validated. A single dose model of 50mg/kg was shown to be equivalent to 5 
10mg/kg doses administered simultaneously. It was also shown that the model 
could accurately and precisely simulate multiple dose treatments of CQ on 
parasite dynamics. Results in Figure 6.5 show that model simulations are 
accurate as they fall within biological variation of the in vivo data. The model 
accurately indicated that split dosing of CQ is more effective than single dosing 
and that split dosing over 5 days is significantly more effective than a 3 day 
regimen (Figure 6.7 and Figure 6.8). Results indicate that a CQ dose interval of 
36 to 48 h in the P. berghei malaria model provides theoretical optimal treatment 
outcome in the two regimens examined. This equates to a dose interval of 1.5-
2.0 erythrocytic life cycles, which has practical limitations and may not provide 
overall benefits compared to a dose interval of about 0.5 erythrocytic life cycles. 
 
Figure 6.5 demonstrates that the CQ model can simulate multiple dose 
treatment accurately to determine which of two treatment regimens will be most 
effective. The model indicates that a 510mg/kg regimen with 12 h dose 
intervals is significantly more effective when considering the three factors of 
parasite reduction rate, the parasite density at nadir and the time to 
recrudescence. This regimen was more effective than a 20+20+10mg/kg 
regimen with 12 h dose intervals and more practical than other dose intervals. 
Nevertheless, a dose interval of 1.0 erythrocytic life cycles provides an 
impressive parasite reduction rate (Figure 6.8) and a nadir almost one order of 
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magnitude lower (Figure 6.8, Table 6.4) and might be considered implausible 
only because of the contemporary dogma of two doses per erythrocytic lifecycle. 
Both of these split regimens are significantly more effective than a single 
50mg/kg dose of CQ. 
6.4.3 Modelling dihydroartemisinin and chloroquine combination 
treatment 
A further outcome was to demonstrate the use of the models of CQ and DHA 
treatment to simulate combination treatment. The mathematical model provides 
an additive simulation. This is shown in Figure 6.11 which demonstrates that the 
parasite elimination functions for DHA and CQ single dose treatment are 
combined in the combination model. The significance of this is that the 
combination model provides a tool to determine whether a combination in the in 
vivo malaria model is antagonistic, additive or synergistic by comparing it to in 
vivo data as described below. 
 
Figure 6.9A shows the predicted combination model with in vivo data for a 
combination of 30mg/kg DHA and CQ. The (additive) model predicts a larger PD 
effect of the combination than observed in vivo, which suggests that the DHA-
CQ combination is antagonistic in the Swiss P. berghei model. This result is 
supported by in vitro findings [83, 166, 367]; however some in vivo findings have 
indicated an additive effect [82, 261].  Clinical results of a study comparing CQ 
combined with artesunate versus CQ monotherapy in uncomplicated falciparum 
infections in children in Gambia concluded that CQ plus artesunate is not 
sufficiently efficacious to justify its introduction as a replacement for chloroquine 
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monotherapy [374]. The 28 day treatment failure was not improved in the 
combination regimen of 25mg base/kg of CQ given over three days with 4mg/kg 
artesunate given each of the three days. These results however may have been 
influenced by CQ resistance in Gambia. Another similar study in Malawi also 
comparing CQ monotherapy and in combination with artesunate failed to show 
significant benefit of the combination over CQ alone, in an area of CQ sensitivity 
[217]. Caution should be taken in comparing preclinical findings to clinical 
findings, however available clinical data does seem to suggest that 
combinations of artemisinins and CQ are not synergistic and there is little 
evidence to support introduction of CQ ACT. 
 
The combination model was further used to examine optimal dose intervals for 
CQ and DHA. Treatment improvement can be marginally achieved by splitting 
doses of CQ and DHA so that CQ treatment occurs approximately 24 h after 
DHA treatment or DHA treatment occurs approximately 48 h after CQ treatment 
(Figure 6.10 and Table 6.6). It should be noted that splitting DHA and CQ doses 
reduces the rate of fall in parasite density, but extends the recrudescence time 
and lowers the parasite nadir. Chloroquine followed by a DHA dose at 48 h is a 
more effective regimen than the DHA followed by CQ regimen but is contrary to 
ACT dogma. Both regimens have similar nadirs and recrudescence times, 
however CQ followed by DHA at 48 h provides a much faster parasite clearance 
(Figure 6.10 and Table 6.6). These results were not intended for comparison 
with clinical CQ ACTs. The combination of a single dose of DHA and CQ is not a 
clinically relevant regimen and even if it was, model simulations in Figure 6.10 
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would indicate that splitting a single dose of DHA and CQ would be unlikely to 
provide a significant or observable in vivo result. The exercise was performed to 
validate the ability to simulate combination treatment and examine optimisation 
in a P. berghei murine model which has been shown to be possible.  
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7. Conclusion 
The series of studies presented in this thesis demonstrate establishment of a 
novel in vivo-in silico model of P. berghei malaria for investigation of antimalarial 
pharmacodynamics and pharmacokinetics based upon the established Rane 
and Peters 4-day tests. The studies have demonstrated that the in vivo murine 
malaria model was suitable to generate detailed PD data that is impossible to 
obtain clinically. The subsequent development and validation of this unique 
mathematical model of a rodent malaria infection, capable of simulating and 
predicting parasite population changes during multiple dose in vivo treatment in 
Swiss mice, demonstrates the power of an in vivo preclinical malaria model. 
 
The applications for the in vivo and in silico model of malaria developed in this 
thesis are several fold. They provide a validated, standard platform for collection 
and comparison of detailed PD-PK data. Coupled with a robust mathematical 
model, the possibility exists to complement preclinical research with in silico 
investigation of optimum doses, dose intervals and combinations, to direct in 
vivo experimental outcomes, and reduce the number of studies required. The 
ability to perform three preclinical studies using two antimalarials and elucidate 
their PK-PD parameters and determine if they display antagonism or synergy 
and to what extent, is also significant. The in silico model enables the in vivo P. 
berghei model to be useful practically (by reducing the time, cost and 
experimental studies required) for exploring detailed pharmacodynamics and as 
a tool for dose and combination optimisation. 
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Another application for the in silico malaria model is the ability for it to be used 
for scientific explanation. Two examples from the work presented here 
demonstrate this heuristic potential of the model. Firstly, indication that the peak 
parasite elimination occurs 12 h after DHA administration provided an objective 
explanation as to why 12 h dose intervals (half erythrocytic life cycle) were most 
effective for multiple dose DHA treatment in the murine model. Secondly, in 
silico prediction that DHA and CQ efficacy is dependent upon parasite density at 
the time of treatment is due, at least in part, to changes in the parasite 
multiplication dynamics, provides an explanation for the experimental 
observations. The ability to explore infection and treatment to improve 
conceptual understanding is significant. These explanations can then be 
accurately and precisely tested using the in vivo model. The data can then be 
used iteratively to improve the in silico model of malaria.   
 
The in silico model has been developed so that it can be easily used and 
manipulated by biological scientists, who may make use of the in vivo model of 
murine malaria. Its use is not dependent on difficult or complex mathematical 
equations that may deter use by scientists unfamiliar with sophisticated PK-PD 
modelling. More complex models can be designed, as has been demonstrated 
by Patel et al [281] using concepts, methods and data collected as described in 
this thesis and previously reported [138]. 
 
The series of studies presented in this thesis established that the in vivo–in silico 
model of P. berghei malaria is suitable for detailed preclinical investigations of 
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antimalarial compounds. These investigations were the first known to describe 
detailed characterisation of P. berghei infection and PK-PD data for DHA in a 
murine model. They were the first to mathematically model parasite dynamics of 
P. berghei infection and treatment with DHA and CQ. The in silico P. berghei 
model was a novel, viable and practically achievable solution to the question of 
how to optimise antimalarial treatment in vivo. It is therefore concluded that the 
work described in this thesis is a valuable contribution to the preclinical 
investigation of antimalarial drugs. 
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APPENDIX 1 – Development of a pharmacodynamic model of 
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APPENDIX 2 – Reagents and Buffers 
 
A2.1 1M Acetic Acid 
Acetic Acid Glacial………………………………….. 
Water ………………………………………………... 
 
57.4mL 
to 1 Litre 
A2.2 Alsever’s Solution 
 Dextrose (anhydrous)…………………………….... 
 Trisodium Citrate (Na3C6H5O7.2H2O)…………….. 
Sodium Chloride…………………………………..... 
 Citric Acid (monohydrate)………………………….. 
Water……………………………………………….... 
 
20.5g 
8.0g 
4.2g 
0.5g 
to 1 Litre 
A2.3 Citrate Phosphate Dextrose Solution (pH 6.9) 
Trisodium Citrate (Na3C6H5O7.2H2O).................... 
Sodium Dihydrogen Phosphate(NaH2PO4.2H2O). 
Dextrose (anhydrous)........................................... 
Water..................................................................... 
Note: Sterilised by filtration (0.22m Millex OR 
filter unit; Millipore Bedford, MA, USA) 
 
30.0g 
0.16g 
2.0g 
to 1 Litre 
A2.4 Formaldehyde-Citrate Solution 
 Formaldehyde Solution (40% w/w CH2O)……….. 
 Trisodium citrate Solution (109mM)……………… 
 
10mL 
to 1 Litre 
A2.5 Glycerol in Alsever’s Solution 
 Glycerol……………………………………………… 
 
10mL 
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Alsever’s Solution…………………………………... 
Note: Sterilised by filtration (0.45m Millex HA 
filter unit; Millipore Bedford, MA, USA) 
to 1 Litre 
A2.6 Phosphate Buffer 0.1M pH 7.4 
Potassium dihydrogen phosphate (KH2PO4)……. 
Disodium hydrogen phosphate (Na2HPO4)……… 
Alsever’s Solution…………………………………... 
 
2.72g 
11.36g 
 to 1 Litre 
A2.7 Potassium Chloride – Phosphate Buffer 
Potassium Chloride………………………………… 
Phosphate Buffer 0.1M pH 7.4……………………. 
Water………………………………………………… 
 
11.5g 
100mL 
to 1 Litre 
A2.8 Sodium Acetate Solution 
Sodium acetate (CH3COONa)……………………. 
Water………………………………………………… 
 
82.04g 
to 1 Litre 
A2.9 Sorenson’s Phosphate Buffer pH 7.0 
Potassium dihydrogen phosphate (KH2PO4)……. 
Disodium hydrogen phosphate (Na2HPO4)……… 
Alsever’s Solution…………………………………... 
 
3.75g 
5.56g 
to 1 Litre 
A2.10 Trisodium Citrate Solution 109mM 
Trisodium citrate (Na3C6H5O7.2H2O).................... 
Water………………………………………………... 
 
32g 
to 1 Litre 
A2.11 Walpole’s Acetate Buffer 0.1M pH 4.8 
Acetic acid 1M………………………………………. 
 
40mL 
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Sodium acetate solution 1M………………………. 
Water………………………………………………… 
60mL 
to 1 Litre 
A2.12 Walpole’s Acetate Buffer 0.1M pH 5.0 
Acetic acid 1M………………………………………. 
Sodium acetate solution 1M………………………. 
Water………………………………………………… 
 
29.6mL 
70.4mL 
to 1 Litre 
  
 
